TW457246B - Dimeric small molecule selectin inhibitors comprising of (mannopyranosyloxy)biphenyl-substituted carboxylic acid - Google Patents
Dimeric small molecule selectin inhibitors comprising of (mannopyranosyloxy)biphenyl-substituted carboxylic acid Download PDFInfo
- Publication number
- TW457246B TW457246B TW85115658A TW85115658A TW457246B TW 457246 B TW457246 B TW 457246B TW 85115658 A TW85115658 A TW 85115658A TW 85115658 A TW85115658 A TW 85115658A TW 457246 B TW457246 B TW 457246B
- Authority
- TW
- Taiwan
- Prior art keywords
- selectin
- mmol
- bis
- compound
- cns
- Prior art date
Links
- -1 (mannopyranosyloxy)biphenyl-substituted carboxylic acid Chemical class 0.000 title claims abstract description 75
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 title claims description 27
- 102000003800 Selectins Human genes 0.000 title claims description 19
- 108090000184 Selectins Proteins 0.000 title claims description 19
- 239000003112 inhibitor Substances 0.000 title claims description 9
- 150000003384 small molecules Chemical class 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 99
- 108010024212 E-Selectin Proteins 0.000 claims abstract description 26
- 238000009739 binding Methods 0.000 claims abstract description 22
- 230000027455 binding Effects 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
- 108010035766 P-Selectin Proteins 0.000 claims abstract description 14
- 102100023472 P-selectin Human genes 0.000 claims abstract description 14
- 108010092694 L-Selectin Proteins 0.000 claims abstract description 12
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 239000000651 prodrug Substances 0.000 claims abstract description 7
- 229940002612 prodrug Drugs 0.000 claims abstract description 7
- 239000004305 biphenyl Substances 0.000 claims abstract description 5
- 235000010290 biphenyl Nutrition 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 102100023471 E-selectin Human genes 0.000 claims abstract 9
- 102100033467 L-selectin Human genes 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 91
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 78
- 239000000243 solution Substances 0.000 claims description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 62
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 50
- 230000002829 reductive effect Effects 0.000 claims description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 238000011049 filling Methods 0.000 claims description 30
- 238000005481 NMR spectroscopy Methods 0.000 claims description 29
- 210000000265 leukocyte Anatomy 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 25
- 239000005457 ice water Substances 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
- 230000002079 cooperative effect Effects 0.000 claims description 20
- 239000005416 organic matter Substances 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 17
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 16
- 210000004088 microvessel Anatomy 0.000 claims description 16
- 239000000123 paper Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 238000003818 flash chromatography Methods 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 11
- 239000011368 organic material Substances 0.000 claims description 11
- 229910052782 aluminium Inorganic materials 0.000 claims description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052681 coesite Inorganic materials 0.000 claims description 10
- 229910052906 cristobalite Inorganic materials 0.000 claims description 10
- 229910052682 stishovite Inorganic materials 0.000 claims description 10
- 229910052905 tridymite Inorganic materials 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000018044 dehydration Effects 0.000 claims description 8
- 238000006297 dehydration reaction Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 150000003385 sodium Chemical class 0.000 claims description 7
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 6
- 239000001273 butane Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 230000003511 endothelial effect Effects 0.000 claims description 6
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 6
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 239000002655 kraft paper Substances 0.000 claims description 5
- 238000004007 reversed phase HPLC Methods 0.000 claims description 5
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000034486 Multi-organ failure Diseases 0.000 claims description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 230000028709 inflammatory response Effects 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 238000007639 printing Methods 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 125000003944 tolyl group Chemical group 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- PWAXUOGZOSVGBO-UHFFFAOYSA-N adipoyl chloride Chemical compound ClC(=O)CCCCC(Cl)=O PWAXUOGZOSVGBO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 150000007857 hydrazones Chemical class 0.000 claims description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 claims description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 239000012925 reference material Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 claims description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- VHHWAUKXFGPSRM-UHFFFAOYSA-N 1-bromo-9h-fluorene Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2Br VHHWAUKXFGPSRM-UHFFFAOYSA-N 0.000 claims description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 229920000057 Mannan Polymers 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 229940022663 acetate Drugs 0.000 claims description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- PPQNMKIMOCEJIR-UHFFFAOYSA-N benzene-1,2,3-trithiol Chemical compound SC1=CC=CC(S)=C1S PPQNMKIMOCEJIR-UHFFFAOYSA-N 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 230000008033 biological extinction Effects 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 claims description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 claims description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229940114081 cinnamate Drugs 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229940039748 oxalate Drugs 0.000 claims description 2
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 claims description 2
- 229940049953 phenylacetate Drugs 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 150000003109 potassium Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 229910052704 radon Inorganic materials 0.000 claims description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940014800 succinic anhydride Drugs 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 claims description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 238000012549 training Methods 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims 10
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 6
- 125000006267 biphenyl group Chemical group 0.000 claims 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- GZQBGAMLHSVJRT-UHFFFAOYSA-N n-(9h-fluoren-1-yl)-9h-fluoren-1-amine Chemical compound C1C2=CC=CC=C2C2=C1C(NC=1C=CC=C3C4=CC=CC=C4CC=13)=CC=C2 GZQBGAMLHSVJRT-UHFFFAOYSA-N 0.000 claims 2
- UUNIOFWUJYBVGQ-UHFFFAOYSA-N 2-amino-4-(3,4-dimethoxyphenyl)-10-fluoro-4,5,6,7-tetrahydrobenzo[1,2]cyclohepta[6,7-d]pyran-3-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1C(C#N)=C(N)OC2=C1CCCC1=CC=C(F)C=C12 UUNIOFWUJYBVGQ-UHFFFAOYSA-N 0.000 claims 1
- 241000723347 Cinnamomum Species 0.000 claims 1
- 241000252233 Cyprinus carpio Species 0.000 claims 1
- 101000595196 Mus musculus Podocalyxin Proteins 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000012937 correction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 18
- 239000001257 hydrogen Substances 0.000 abstract description 8
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract description 3
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 abstract description 2
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 abstract description 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 abstract description 2
- 150000001408 amides Chemical class 0.000 abstract description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 103
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- 102000015689 E-Selectin Human genes 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 101150041968 CDC13 gene Proteins 0.000 description 15
- 239000007789 gas Substances 0.000 description 15
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 14
- 239000010410 layer Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102000016551 L-selectin Human genes 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 150000001409 amidines Chemical class 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 235000015170 shellfish Nutrition 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 6
- 235000011089 carbon dioxide Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229910015900 BF3 Inorganic materials 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000002309 gasification Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JLIDRDJNLAWIKT-UHFFFAOYSA-N 1,2-dimethyl-3h-benzo[e]indole Chemical compound C1=CC=CC2=C(C(=C(C)N3)C)C3=CC=C21 JLIDRDJNLAWIKT-UHFFFAOYSA-N 0.000 description 2
- YFKBXYGUSOXJGS-UHFFFAOYSA-N 1,3-Diphenyl-2-propanone Chemical compound C=1C=CC=CC=1CC(=O)CC1=CC=CC=C1 YFKBXYGUSOXJGS-UHFFFAOYSA-N 0.000 description 2
- BPIUIOXAFBGMNB-UHFFFAOYSA-N 1-hexoxyhexane Chemical compound CCCCCCOCCCCCC BPIUIOXAFBGMNB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 description 2
- LZHMNCJMXQKSBY-UHFFFAOYSA-N 4-(4-methoxyphenyl)butanoic acid Chemical compound COC1=CC=C(CCCC(O)=O)C=C1 LZHMNCJMXQKSBY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 101150046236 CNR1 gene Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- SHIYKHFFMRDJJC-UHFFFAOYSA-L [Na+].[Na+].[O-]O[O-] Chemical compound [Na+].[Na+].[O-]O[O-] SHIYKHFFMRDJJC-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- DULCUDSUACXJJC-UHFFFAOYSA-N benzeneacetic acid ethyl ester Natural products CCOC(=O)CC1=CC=CC=C1 DULCUDSUACXJJC-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 229940007550 benzyl acetate Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyloxyacetoaldehyde Natural products CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000003947 ethylamines Chemical class 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000003051 glycosyloxy group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- CDLTWXBTYNNYLN-UHFFFAOYSA-N (3-bromophenyl) acetate Chemical compound CC(=O)OC1=CC=CC(Br)=C1 CDLTWXBTYNNYLN-UHFFFAOYSA-N 0.000 description 1
- WFLOTYSKFUPZQB-UHFFFAOYSA-N 1,2-difluoroethene Chemical group FC=CF WFLOTYSKFUPZQB-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- YYHKGSBCQXPZOP-UHFFFAOYSA-N 1-methoxy-4-[4-(4-methoxyphenyl)butyl]benzene Chemical compound C1=CC(OC)=CC=C1CCCCC1=CC=C(OC)C=C1 YYHKGSBCQXPZOP-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 1
- CQOZJDNCADWEKH-UHFFFAOYSA-N 2-[3,3-bis(2-hydroxyphenyl)propyl]phenol Chemical compound OC1=CC=CC=C1CCC(C=1C(=CC=CC=1)O)C1=CC=CC=C1O CQOZJDNCADWEKH-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- APPZXBHXNCRPGM-UHFFFAOYSA-N 2-bromoethanimidamide Chemical compound NC(=N)CBr APPZXBHXNCRPGM-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- VSDQUOHPLVUMEK-UHFFFAOYSA-N 3-phenylprop-2-enyl hydrogen sulfate Chemical compound OS(=O)(=O)OCC=CC1=CC=CC=C1 VSDQUOHPLVUMEK-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 240000002768 Alpinia galanga Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VJQMOAZGDDKZTM-UHFFFAOYSA-N BrCCC(=O)F Chemical compound BrCCC(=O)F VJQMOAZGDDKZTM-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000985704 Collinsia heterophylla Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- IEJWADYVBFDBEP-UHFFFAOYSA-N N=NC=NN.[Na] Chemical compound N=NC=NN.[Na] IEJWADYVBFDBEP-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000050628 Papilio thoas Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- UAOKXEHOENRFMP-KLHDSHLOSA-N [(2r,3r,4s,5s)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)C=O UAOKXEHOENRFMP-KLHDSHLOSA-N 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-N [Na+].[Na+].S Chemical compound [Na+].[Na+].S VDQVEACBQKUUSU-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- KBGAYAKRZNYFFG-BOHATCBPSA-N aceneuramic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO KBGAYAKRZNYFFG-BOHATCBPSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000006307 alkoxy benzyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- VEWPBNXVANZNAD-UHFFFAOYSA-N argon sodium Chemical compound [Na].[Ar] VEWPBNXVANZNAD-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- PMHQVHHXPFUNSP-UHFFFAOYSA-M copper(1+);methylsulfanylmethane;bromide Chemical compound Br[Cu].CSC PMHQVHHXPFUNSP-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- QGFRSPMTVBPWNK-UHFFFAOYSA-N dilithium;oxygen(2-);hydrate Chemical compound [Li+].[Li+].O.[O-2] QGFRSPMTVBPWNK-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- MXWRJMIKMODSCY-UHFFFAOYSA-N ethane;dihydrochloride Chemical compound Cl.Cl.CC MXWRJMIKMODSCY-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- PDHXVYUQWHNFRV-UHFFFAOYSA-N ethyl 2-[3-[5-[6-[3-[3-(2-ethoxy-2-oxoethyl)phenyl]-4-hydroxyphenyl]hexyl]-2-hydroxyphenyl]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(C=2C(=CC=C(CCCCCCC=3C=C(C(O)=CC=3)C=3C=C(CC(=O)OCC)C=CC=3)C=2)O)=C1 PDHXVYUQWHNFRV-UHFFFAOYSA-N 0.000 description 1
- FVFORSNTIGGKNV-UHFFFAOYSA-N ethyl 6-(6-ethoxy-6-oxohexoxy)hexanoate Chemical compound CCOC(=O)CCCCCOCCCCCC(=O)OCC FVFORSNTIGGKNV-UHFFFAOYSA-N 0.000 description 1
- HYXRUZUPCFVWAH-UHFFFAOYSA-N ethyl 6-hydroxyhexanoate Chemical compound CCOC(=O)CCCCCO HYXRUZUPCFVWAH-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical group [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- WHXVXXYMLCVAEP-UHFFFAOYSA-K trifluoroosmium Chemical compound F[Os](F)F WHXVXXYMLCVAEP-UHFFFAOYSA-K 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
457246 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(1 ) 技術領域 本發明係關於可抑制E-選擇素,P-選擇素或L-選擇素結 合至唾液基-路易士 x(sialyl-Lewisx)或唾液基-路易士 a (sialyl-Lewisa)之化合物及利用該等化合物抑制匕選擇素, P-選擇素或L-選擇素結合至唾液基路易士X或唾液基-路易 士3之方法。本發明亦關於含有可抑制E,p或l-選擇素結 合至唾液酸-路易士 x或唾液基-路易士 a之化合物之具有藥 效之醫藥組合物。 發明之背景 E-選擇素(亦稱爲ELAM-1,即内皮細胞淋巴球吸附分子_ 1,以及稱爲LECAM-2,即親醣蛋白細胞吸附分子)爲一種 酷蛋白質分子,該分子被發現存在於排列在微血管内壁之 内皮細胞上。E-選擇素可辨識位於特定白血球細胞上之碳 水化合物唾液基-路易士 X (sLex)並與之結合。當微血管周 圍组織被感染或受傷時,E-選擇素可幫助白血球細胞辨識 並附著於該微血管管壁〇Ε·選擇素是目前已知三種選擇素 其中之一。其他兩種分別爲L-選擇素及ρ_選擇素。ρ_選擇 素係表現在内皮组織及血小板上,在結.構上與Ε_選擇素非 常相似且亦可辨識唾液基-路易士 X。L_選擇素則係表現於 淋巴球上,並且在結構上與選擇素及?_選擇素非常相似 。唾液基-路易士X及唾液基,路易士a (sLea)之結構由下式 及Ib來表示: 本紙張从適财職家標準(CNS ) A4規格( (請先閲讀背面之注意事項再填寫本頁} -訂 457246 A7 B7 五、發明説明( sLex457246 Printed by A7 B7, Consumer Cooperatives, Central Standards Bureau, Ministry of Economic Affairs 5. Description of the Invention (1) Technical Field The present invention relates to inhibiting the binding of E-selectin, P-selectin or L-selectin to salivary-Louis x (sialyl-Lewisx) or sialyl-Lewisa compounds and use of these compounds to inhibit d-selectin, P-selectin or L-selectin from binding to sialyl-Lewis X or sialyl-Lewis Method of taxi 3. The present invention also relates to a pharmaceutical composition containing a compound that inhibits the binding of E, p or l-selectin to sialic acid-Lewis x or sialyl-Lewis a. Background of the invention E-selectin (also known as ELAM-1, which is an endothelial lymphocyte-adsorbing molecule_1, and also known as LECAM-2, which is a glycoprotein-adsorbing molecule) is a cool protein molecule that was discovered It is present on endothelial cells arranged on the inner wall of microvessels. E-selectin recognizes and binds the sialoyl-Lewis X (sLex) carbohydrate located on specific white blood cells. E-selectin can help white blood cells recognize and attach to the wall of the microvascular tube when the tissue surrounding the microvessel is infected or injured. E · selectin is one of the three currently known selectins. The other two are L-selectin and ρ_selectin. ρ_selectin is expressed on endothelial tissues and platelets. It is very similar in structure to E_selectin and can also recognize salivary-Lewis X. L_selectin is expressed on the lymphosphere, and is structurally similar to selectin? _Selectin is very similar. Saliva-Lewis X and saliva-based, the structure of Louis a (sLea) is expressed by the following formula and Ib: This paper is from the Standard for Financial Professionals (CNS) A4 ((Please read the precautions on the back before filling This page}-Order 457246 A7 B7 V. Description of the invention (sLex
Neu5Ac α2-3 Gal β1-4 GIcNac- I Fuca1-3 la sLeaNeu5Ac α2-3 Gal β1-4 GIcNac- I Fuca1-3 la sLea
HO HO HOHO HO HO
HO AcHN (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部中夹標準局員工消費合作社印製HO AcHN (Please read the notes on the back before filling out this page)
NeuSAc a2-3 Gal β1-3 GIcNac- Fuca1-4 lb -5- 本紙張尺度逍用中國國家標準(CMS ) A4規格(210 X 297公釐) A7 B7NeuSAc a2-3 Gal β1-3 GIcNac- Fuca1-4 lb -5- The size of this paper is Chinese National Standard (CMS) A4 (210 X 297 mm) A7 B7
J 號專利申請案 中文説明書修正頁(87年9月) 五、發明説明(3 ) (讀先閣讀背面之注意事項再填寫本頁) 當一個组織受到微生物侵入或受傷,白血球細胞(亦 稱爲琳巴球)在發炎反應中扮演非常重要的角色。在發炎 反應中最重要的反應其中之一包含了細胞附著這一事件。 白血球細胞一般出現在循環之血流中。然而,當一個组織 受到感染或是受到傷害時,白血球細胞必須能夠辨識受到 侵害或受到傷害之组織,並且能夠與鄰近受到影響組織之 微血管内壁結合,再穿透過微血管進入受到影響之组織 内。P-選擇素係繁助兩種特定之白血球細胞辨識受到影響 之部位並與微血管内壁結合,如此該等白血球細胞便可穿 透進入受到影響之组合物内。- 白血球細胞主要分爲三類:顆粒球,單核球及淋巴球。 在上述之分類中,E-選擇素會辨識嗜中性顆粒球及單核球 上以醣蛋白或醣脂肪存在之sLex。嗜中性顆粒球係一種顆 粒球之亞類,可吞噬並摧毁小的微生物,特別是細菌。.在 穿透過微血管壁離開血流後,單植球會熟化成爲巨喔細胞 而呑嗤並分解侵入之微生物,外來物體及衰老之細胞。 經濟部中央標隼局員工消費合作社印製 當環繞善微血管之组織受到感染或傷害,觀在微血管内 壁之内皮細胞表面會產生E-選擇素,單核球及嗜中性顆粒 球可經由與E-選擇素結合而辨識受傷之組織。基本上,當 鄰近微血管之组織受到影響時,E-選擇素及P-選擇素之產 生會增加。P-選擇素係持續地存在於儲存性顆粒中,當内 皮層被活化後即可迅速地移送至細胞表面。相反地,E-選 擇素則需要自身性RNA及蛋白質合成,而且在經活化之後 約4-6小時表現達到波峰,最後到約24-48小時後漸漸降至 -6 - 本紙張尺度適用中國國家標準(CMS ) A4規格(210X 297公釐} 丨修正 補充 4 5_£i4s扬號專利申請案 中文説明書修正頁(S7年9月) 五、發明説明( 基本水平。白血球細胞可辨識受影響之區域乃因爲白血球 細胞表面所存在之sLex部分會與E-選擇素及p-選擇素結 合。這種形式的結合會使得白血球細胞在血流中的速度變 慢,因爲這種結合發生在由整合素(integrin)所媒介之接觸 與移行之前,先媒介了祙巴球沿著受活化之内皮層滚動, 因而協助白血球細胞局限於受傷或被感染之區域。 當白血球細胞移行至受傷部位協助對抗感染並摧毁外來 物質時,堆積過多的白血球細胞會引起廣大範園的组織受 傷。因此可阻斷這種過程之化合物即有可能作爲治療性物 質。由此來發展可避免白血球知_胞與E-選擇素或p_選擇素 結合之抑制劑即可能有用。舉例言之,有些可經由抑制選 擇素與sLex結合處理之疾病包括(並非限制),局部性 迴腸炎(Crohn’s disease),敗血性休克,受創性休克,多重 器官衰竭’,自體免疫疾病’氣喘,發炎性腸疾病,乾癖, 類風濕性關節炎及發生在心臟病,中風,與器官移植後之 再灌流性傷害(reperfusion injury)。sLea— —種與SLex關係 非给舍切之區域性化學異構物(regiochemical isomer),除 了在部分白血球細胞上發現外,sLea在許多癌細胞上也被 發現’其中包括肺及直腸之癌細胞。曾有人認爲有31#參 與之細胞吸附作用可能亦參與了特定癌細胞之轉移。 美國專利5,44七〇5〇敘述可做爲選擇素抑制劑之吡喃甘露 糖氡基二苯基取代之衍生物及其製備方法,然而,其並未 揭示二或三價之抑制劑。 發明之,综論 本發明提出具有下列結構之式11化合物及其醫藥上可接 受之鹽類,酯類,醯胺類與前藥: (請先閱讀背面之注意事項再填寫本頁)Revised Page of Chinese Specification for Patent Application No. J (September 1987) V. Description of Invention (3) (Read the precautions on the back of the first cabinet and then fill out this page) When a tissue is invaded or injured by microorganisms, white blood cells ( (Also known as Limba Ball) plays a very important role in the inflammatory response. One of the most important reactions in the inflammatory response involves the event of cell attachment. White blood cells generally appear in the circulating blood stream. However, when a tissue is infected or injured, white blood cells must be able to identify the affected or injured tissue, and be able to combine with the inner walls of microvessels adjacent to the affected tissue, and then penetrate through the microvessel to enter the affected tissue. Inside. P-selectin helps two specific white blood cells to identify the affected part and binds to the inner wall of microvessels, so that these white blood cells can penetrate into the affected composition. -White blood cells are mainly divided into three types: granules, monocytes and lymphocytes. In the above classification, E-selectin recognizes sLex present as glycoproteins or glycolipids on neutrophils and monocytes. Neutrophils are a subtype of granules that can engulf and destroy small microorganisms, especially bacteria. After passing through the wall of the microvessel and leaving the blood stream, the single plant bulb will mature into giant cells and decompose and break down the invading microorganisms, foreign objects and aging cells. Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. When tissues surrounding good microvessels are infected or injured, E-selectin will be produced on the surface of endothelial cells on the inner wall of microvessels. Mononuclear spheres and neutrophil particles can pass through E-selectin binds to identify injured tissue. Basically, when tissues adjacent to the microvessels are affected, the production of E-selectin and P-selectin increases. P-selectin is continuously present in storage granules and can be quickly transferred to the cell surface when the endothelial layer is activated. In contrast, E-selectin requires the synthesis of its own RNA and protein, and it peaks in about 4-6 hours after activation, and gradually decreases to -6 after about 24-48 hours-this paper size is applicable to China Standard (CMS) A4 specification (210X 297 mm) 丨 revised supplement 4 5_ £ i4s Yang patent application Chinese manual amendment page (S7 September) 5. Description of the invention (basic level. White blood cells can identify the affected The region is because the sLex part on the surface of white blood cells will bind to E-selectin and p-selectin. This form of binding will make the speed of white blood cells in the blood flow slower, because this binding occurs during integration Prior to the contact and migration of the integrin medium, the sacral ball was rolled along the activated endothelial layer, thereby helping the white blood cells to be confined to the injured or infected area. When the white blood cells migrated to the injured site, they assisted against When infecting and destroying foreign substances, the accumulation of excessive white blood cells can cause damage to the tissues of the vast majority of the gardens. Therefore, compounds that can block this process may act as It is a therapeutic substance. It may be useful to develop inhibitors that prevent the binding of leukocytes to E-selectin or p-selectin. For example, some diseases that can be treated by inhibiting the combination of selectin and sLex include (But not limited to), Crohn's disease, septic shock, invasive shock, multiple organ failure ', autoimmune disease' asthma, inflammatory bowel disease, dry addiction, rheumatoid arthritis and its occurrence In heart disease, stroke, and reperfusion injury after organ transplantation. SLea—a regiochemical isomer that is not related to SLex, except that it is found on some white blood cells In addition, sLea has also been found on many cancer cells, including lung and rectal cancer cells. It has been thought that the cell adsorption effect of 31 # may also be involved in the metastasis of specific cancer cells. US Patent 5,44 VII. 50. Described is a mannanosylbiphenyl substituted derivative which can be used as a selectin inhibitor and a method for preparing the same. However, it does not disclose the divalent or trivalent The formulations of the invention, the present invention has fully made on the compound of formula 11 and the structure of the pharmaceutically acceptable salts, esters, Amides and prodrugs thereof: (Read precautions and then fill the back side of this page)
經濟部中央標準局員工消費合作·社印製 457246 A7 B7 五 '發明説明(5 )Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs · Printed by the company 457246 A7 B7 Five 'Invention (5)
(請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作杜印製 於其中X基團係選自包括 -CN, -(CH2)nC02H, -(CH2)nCONHOH, -0(CH2)mC02H, -0(CH2)mCONHOH,-(CH2)nCONHNH2, -(CH2)nCOZ,-(CH2)nZ, -CH(C02H)(CH2)mC02H, -(CH2)nO(CH2)mC02H5 -C0NH(CH2)mC02H, -CH(0Z)(C02H),-CH(Z)(C02H),<CH2)nS03H,-CXCHAPOgDiE^, -NH(CH2)mCO2H,-C0NH(CHR3)CO2H,(l-H-四唑基-5-烷基-),及-OH; 當爲二價結構時,Y爲-(ch2)「, -CO(CH2)fCO-, -(CH2){0(CH2)r, -COfCH^gSCO^CH^fSCO^CH^gCO-, -(CH2)fV(CH2)r, -(0Η2)^〇ν0Ο(ΟΗ2)Γ, -COCC^^OVCOCC^fCO-, -CO(CH2)fV(CH2)fCO-s -C0NH(CH2)^HC0-, -(CH2)fWSW(CH2)r, -(CHyfCONHCCi^piHCCKCHyf,-(ayfCOMCHdfWCCKCKyr,或 -8- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X297公釐) 4 57 246' A7 B7 經濟部中央德準局貝工消費合作社印製 五、發明説明(6 ) -CH/CHjfWCCHjfCiV其中 V 係-N[(CH2)q]2N-且 q 分別係 2 至 4 ,而W係芳基或雜芳基; 當爲三價結構時,Y爲:(Please read the notes on the back before filling out this page) The consumer cooperation agreement of the Central Standards Bureau of the Ministry of Economic Affairs is printed in which the X group is selected from the group consisting of -CN,-(CH2) nC02H,-(CH2) nCONHOH, -0 (CH2) mC02H, -0 (CH2) mCONHOH,-(CH2) nCONHNH2,-(CH2) nCOZ,-(CH2) nZ, -CH (C02H) (CH2) mC02H,-(CH2) nO (CH2) mC02H5- C0NH (CH2) mC02H, -CH (0Z) (C02H), -CH (Z) (C02H), < CH2) nS03H, -CXCHAPOgDiE ^, -NH (CH2) mCO2H, -C0NH (CHR3) CO2H, (lH -Tetrazolyl-5-alkyl-), and -OH; when it is a divalent structure, Y is-(ch2) ", -CO (CH2) fCO-,-(CH2) {0 (CH2) r, -COfCH ^ gSCO ^ CH ^ fSCO ^ CH ^ gCO-,-(CH2) fV (CH2) r,-(0Η2) ^ 〇ν0Ο (ΟΗ2) Γ, -COCC ^^ OVCOCC ^ fCO-, -CO (CH2) fV (CH2) fCO-s -C0NH (CH2) ^ HC0-,-(CH2) fWSW (CH2) r,-(CHyfCONHCCi ^ piHCCKCHyf,-(ayfCOMCHdfWCCKCKyr, or -8-) This paper size applies to Chinese National Standard (CNS) A4 specifications (210 X297 mm) 4 57 246 'A7 B7 Printed by the Shell German Consumer Cooperative of the Central German Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (6) -CH / CHjfWCCHjfCiV where V is -N [(CH2) q] 2N- And q is 2 to 4 respectively, and W is aryl or heteroaryl; when it is a trivalent structure Y is:
且T基團係選自包括-(CH2)f-, -CO(CH2)f-s -(CH2)gS(0)b(CH2)f-,及-C0(CH2)gS(0)b(CH2)f- ,其中該羰基位置係鄰近該聯苯單位;And the T group is selected from the group consisting of-(CH2) f-, -CO (CH2) fs-(CH2) gS (0) b (CH2) f-, and -C0 (CH2) gS (0) b (CH2) f-, wherein the carbonyl position is adjacent to the biphenyl unit;
Rj及R_2係個別選自.:氮’ 基’齒素’ .-0Z,-N〇2, (CH2)nC02H,-NH2&-NHZ ; R3係選自:氫,烷基,芳烷基,羥基烷基,胺基烷基, 烷基羧酸,及烷基羧醯胺; f係1至1 6,g係0至6,η係0至6,m係1至6,p係0至6 ,b係0至2,Z係烷基,芳基或芳烷基,且D2係個別 爲氫或規*基。 更特言之,本發明提出式III之化合物:. -9 ™ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先聞讀背面之注意事項再填寫本頁)Rj and R_2 are each selected from :: nitrogen 'group' dentin '. -0Z, -NO2, (CH2) nC02H, -NH2 &-NHZ; R3 is selected from: hydrogen, alkyl, aralkyl, Hydroxyalkyl, aminoalkyl, alkylcarboxylic acid, and alkylcarboxamide; f is 1 to 16, g is 0 to 6, η is 0 to 6, m is 1 to 6, and p is 0 to 6, b is 0 to 2, Z is an alkyl group, an aryl group or an aralkyl group, and D2 is a hydrogen group or a hydrogen atom. More specifically, the present invention proposes a compound of formula III: -9 ™ This paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) (Please read the precautions on the back before filling this page)
457246 A7 B7 五、發明説明(457246 A7 B7 V. Description of the invention (
m 其中 X 係-COOH, -(CH2)nCOOH或-0(CH2)nC00H且Y係 -(CH2)n-, -(CH2)nW(CH2)n-, -(CH2)nWOW(CH2)n-, -(CH2)nS(CH2)nS(CH2)n-, -CO(CH2)nCO-,或 -(CH2)nCOW(CH2)nWCO(CH2)n-而 W及n 定義如上述。 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -10- 本紙張尺度逋用中國國家揉準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 457246 a? ______B7 五、發明説明(8 ) 特別佳之化合物包括:m where X is -COOH,-(CH2) nCOOH or -0 (CH2) nC00H and Y is-(CH2) n-,-(CH2) nW (CH2) n-,-(CH2) nWOW (CH2) n- ,-(CH2) nS (CH2) nS (CH2) n-, -CO (CH2) nCO-, or-(CH2) nCOW (CH2) nWCO (CH2) n-, and W and n are defined as above. (Please read the notes on the back before filling this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs -10- This paper size is in accordance with China National Standards (CNS) A4 (210X297 mm) Central Bureau of Standards, Ministry of Economic Affairs Printed by Employee Consumer Cooperative 457246 a? ______B7 V. Description of Invention (8) Particularly good compounds include:
ΒΒ
Η (請先間讀背面之注意事項再填寫本頁)Η (Please read the notes on the back before filling in this page)
、1T 本紙張尺度逋用中國國家榇準(CNS ) Μ規格(210Χ297公釐) 457246 - 五、發明説明(9 )、 1T This paper uses China National Standards (CNS) standard M (210 × 297 mm) 457246-V. Description of the invention (9)
經濟部中央標举局M0:工消費合作社印製Ministry of Economic Affairs Central Marking Bureau M0: Printed by Industrial and Consumer Cooperatives
-12- (請先閲讀背面之注意事項再填寫本頁) Λ' 訂 0 本紙張尺度適用中國國家標準(CNS ) A4規格(2IOX297公釐) '4 5 7 2 4 ό Α7 Β7 五、發明説明(1〇 ) 經濟部中央標準局員工消費合作社印裝 本發明亦提出包含有一種式Π或式III化合物及一種醫藥 上可接受載劑之醫藥組合物。 本發明進一步提出一種抑制E-選擇素,P-選擇紊或L-選 擇素與sLex或sLea結合之方法,該方法係將有效量具有式 II或式III結構之化合物給予病人以抑制E-,P-或L-選擇素 與sLex之結合或P-選擇素與sLea之結合,以及一種包含有 一種式II或式III化合物及一種醫藥上可接受載劑之具有藥 物活性之組合物。 本發明之化合物可使用於諸如ARDS,局部性迴腸炎, 敗血性休克,受創性休克,多重器官衰竭,自體免疫疾病 ’氣喘,發炎性腸疾病,乾癬,類風濕性關節炎及發生在 心臟病,中風,器官移植與癌症後之再灌流性傷害疾病之 療法’該療法係給予該種治療之動物一個有效治療量之式 II或式III化合物以減緩疾病之症狀。 較佳具體實施例之詳細説明 吾人發現具有上示式(II)結構之化合物可抑制E_,p-或 選擇素與sLex或sLea之結合。 在此所用之術語”燒基”係指具有1至i 2個碳原予之單價 直鏈或具支鏈之基團,其中包括(但不限於)甲基,乙基, 正丙基,異丙基,正丁基,二級丁基,異丁基,三級丁基 等等。 術語”低碳烷基"係指具有一至六個碳原子之任何烷基基 團。 &土 術語”齒素”係指選自包括氯,氟,溴及碘之任何原予。 -13 - 本紙張尺度適用中國國家標準(CNS ) 公釐 (請先閎讀背面之注意事項再填寫本頁) :"-12- (Please read the precautions on the back before filling in this page) Λ 'Order 0 This paper size applies to Chinese National Standard (CNS) A4 specification (2IOX297 mm)' 4 5 7 2 4 Α7 Β7 V. Description of the invention (10) Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs The present invention also proposes a pharmaceutical composition comprising a compound of formula II or formula III and a pharmaceutically acceptable carrier. The invention further proposes a method for inhibiting the combination of E-selectin, P-selectin or L-selectin with sLex or sLea. The method is to administer an effective amount of a compound having the structure of formula II or formula III to a patient to inhibit E-, A combination of P- or L-selectin and sLex or a combination of P-selectin and sLea, and a pharmaceutically active composition comprising a compound of formula II or formula III and a pharmaceutically acceptable carrier. The compounds of the present invention are useful for applications such as ARDS, local ileitis, septic shock, invasive shock, multiple organ failure, autoimmune diseases' asthma, inflammatory bowel disease, psoriasis, rheumatoid arthritis and Heart Disease, Stroke, Organ Transplantation and Reperfusion Injury Disease after Cancer 'The therapy is to give the animal treated with an effective therapeutic amount of a compound of formula II or formula III to alleviate the symptoms of the disease. Detailed description of preferred embodiments We have found that compounds having the structure of formula (II) above can inhibit the binding of E_, p- or selectin to sLex or sLea. As used herein, the term "alkyl" refers to a monovalent linear or branched group having 1 to 2 carbon atoms, including, but not limited to, methyl, ethyl, n-propyl, isopropyl Propyl, n-butyl, secondary butyl, isobutyl, tertiary butyl and the like. The term "lower alkyl" means any alkyl group having one to six carbon atoms. &Amp; The term "dentin" means any element selected from the group consisting of chlorine, fluorine, bromine and iodine. -13 -This paper size applies to China National Standard (CNS) mm (please read the precautions on the back before filling this page): "
•、1T U- 經濟部令央標準局負工消費合作社印製 457246 A7 B7 五、發明説明(^) 術語"燒氧基"係指經由一個氧原予與一個分子相接之任 基基圓,其中包括(但不限於)甲氧基,乙氧基,異丙 氧基,正丁氧基,二級丁氧基,異丁氧基,三級丁氧基等 等。 術語”燒胺基"係指具有_NH_(烷基),或_N(烷基)2結構之 基團,舉例吕其中包括甲胺基,乙胺基,4丙胺基等 等。 術語"芳香基,|係指碳環之芳香基基團,其中包括(但不 限於)苯基,1或2-萘基,苐基,(1,2)_二氫茬基,茚基,氫 苹基,p塞吩基,苯幷P塞吩基等等。 術語芳烷基”(亦稱爲芳香烷基)係指與一個烷基相接之 芳香基,其中包括(但不限於)苄基,基甲基,鹵 基笮基’烷氧基苄基,羥基苄基,胺基苄基,硝基芊基, 胍基芊基,第基甲基,苯基甲基(苄基),卜苯基乙基,2_ 苯基乙基,1-審基乙基等等。 術語”羥基烷基"係指—個羥基接在一個烷基上。 術浯胺基烷基"係指—個在娱ι基上接有一個_NRxRy結構 之基團。基團1及Ry係分別選自例如氫,院基及芳香基。 街語”烷基羧酸"係指一個羧基(_C〇2H)接在烷基上。 術語”紀基醯胺"係指一個在燒基上接有一個_C〇NRXRy 結構之基團,而1及Ry係如上述胺基燒基中所定義。 在此所用之術語"醫藥上可接受鹽類,酯類,醯胺類及 前藥”係指本發明化合物之羧酸鹽,胺基酸加成鹽,酯類 ,酶胺類與前藥(若有可能的話,尚可包括本發明化合物 14 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁)• Printed by 1T U- Printed by the Central Bureau of Standards, Ministry of Economic Affairs and Consumer Cooperatives 457246 A7 B7 V. Description of the Invention (^) The term " burnt oxygen " Basic circles, including (but not limited to) methoxy, ethoxy, isopropoxy, n-butoxy, secondary butoxy, isobutoxy, tertiary butoxy and the like. The term "alkylamino" refers to a group having the structure of _NH_ (alkyl), or _N (alkyl) 2. Examples include methylamino, ethylamino, 4propylamino, and the like. Term & quot Aromatic group, | means an aromatic group of a carbocyclic ring, which includes (but is not limited to) phenyl, 1 or 2-naphthyl, fluorenyl, (1,2) -dihydrosulfanyl, indenyl, hydrogen Pingyl, p-secenyl, phenyl-p-phenenyl, etc. The term "aralkyl" (also known as aromatic alkyl) refers to an aromatic group attached to an alkyl group, including (but not limited to) benzyl Methyl, methyl, halomethyl ', alkoxybenzyl, hydroxybenzyl, aminobenzyl, nitromethyl, guanidino, methyl, methylphenyl, phenylmethyl (benzyl), Phenylethyl, 2-phenylethyl, 1-triethyl and so on. The term "hydroxyalkyl" refers to a hydroxyl group attached to an alkyl group. Aminoalkylalkyl "refers to a group attached to an alkyl group with a _NRxRy structure. Groups 1 and Ry is selected from the group consisting of, for example, hydrogen, base, and aromatic. The term "alkylcarboxylic acid" refers to a carboxyl group (_CO2H) attached to an alkyl group. The term "aminomethylamine" refers to a group having a _CONRXRy structure attached to an alkyl group, and 1 and Ry are as defined in the aforementioned aminoalkyl group. The term used herein "medically "Acceptable salts, esters, amines and prodrugs" means the carboxylates, amino acid addition salts, esters, enzyme amines and prodrugs of the compounds of the present invention (if possible, including Compound 14 of the present invention The paper size is applicable to Chinese National Standard (CNS) A4 (210 X 297 mm) (Please read the precautions on the back before filling this page)
A7 B7A7 B7
4 5 7梁號專利申請案 中文説明書修正頁(87年9月) 五、發明説明(12 經濟部中央標準局員工消費合作社印裝 之兩性離子鹽)中適用於(在宣告之醫與病 人之组織接觸而不會有不適當之毒性,刺激性,過斂性反 應,並且有相當合理之4貝益比(benefit/risk ratio)以及對其 所欲應用之用途有效。該術語"鹽類"係指相當無毒性之本 發明化合物之無機及有機酸加成鹽類。該等鹽類可於最後 單離及純化化合物時同時製得,或是另外將純化之化合物 以其游離形式與適當之有機酸或無機酸或鹼反應,再單離 因此所形成之鹽類。代表性之鹽類包括溴酸鹽,鹽酸鹽, 硫酸鹽,硫酸氫鹽,硝酸鹽,乙酸鹽,草酸鹽,戊酸鹽, 油酸鹽,標櫚酸鹽,硬脂酸鹽,肉桂酸鹽,爛酸鹽,苯〒 酸鹽’乳酸鹽’鱗酸鹽,甲基苯續酸鹽,捧檬酸鹽,順丁 烯二酸鹽,反丁烯二酸鹽,琥珀酸鹽,酒石酸鹽,莕酸 鹽’甲績酸鹽,葡萄庚酸鹽(glucoheptonate),乳酿生物酸 鹽(lactiobionate),肉桂醯磺酸鹽等等^其中亦可包含驗金 屬或驗土金屬陽離子,例如納,叙,却,舞,鑊等等, 以及典毒性之铵,四級銨及胺基陽離子其中包括(但不限 於)銨,四甲基銨,四乙基銨,甲基胺,乙基胺,二曱基 胺,二曱基胺,二乙基胺,乙基胺等等。(例如參見S.M. 伯吉(S. M. Berge)等人之”醫藥之鹽類_'j. Pharm〜66; !_ I? (I977),在此列爲參考資料) 醫藥上可接受,本發明化合物之無毒性酯類之實例包括 Ci芏坑基g旨類’於其中貌基係直鏈或具支鐘。可接受之 醋類亦包括C5至(:7環烷基酯類以及例如(但不限於)爷基之 芳香基貌基。較佳者爲(^至^烷基酯類α本發明化合物之 -15- 本紙張尺度適用中_家縣(CNS ) Α4規格(21QX2_楚) 457246 經濟部中央標準局員工消费合作社印裂 A7 ---_!Ζ__五、發明説明(13) 醋類可根據習用之方法製得。 醫藥上可接受,本發明化合物之無毒性醯胺類之實例包 括衍自氨,一級〇丨至<:5烷基胺’及二級(^至£:6烷基胺之醯 胺’於其中該燒基係直鏈或具支鏈。於二級胺之例子中, 該胺可爲含有一個氮原子之5或6員雜環。較佳者爲衍自氨 之醯胺,(^至(:3烷基一級醯胺及(^至(:2二烷基醯胺。本發 明化合物之醯胺可根據習用之方法製得。 術語"前藥"係指可立即在體内轉變(例如在血中經由永解) 成上式母化合物之化合物β τ希顧齊(T. HigucM)&v史逖 扭(V. Stella)在’’以前藥作爲新穎之給藥系統"A. c. s.研討 會系列第14卷,及在艾德華B_羅契(Edward B. Roche)編輯 ’美國製藥協會與坡加蒙出版社(American Pharmaceutical Association and Pergamon Press) 1987年出版之”藥物設計中 生體可轉換載劑”中有冗整的討論,上述二者在此均列爲 參考資料。 本發明亦提出含有本發明化合物之具藥效組合物。本發 明亦意圖提出該具藥效組合物含有一種本發明之化合物以 及其他之化合物,而該組合物可抑制選擇素或p_選擇素 與sLex或sLea之結合,或與其競爭與sLex或sLea之結合,該 組合物中亦可能包含sLex或sLea本身。 本發明之具藥效組合物包含一種生理性載劑與一種式π 或in化合物。 本發明之具藥效組合物可包含一種或更多具上述之式π 或III結構之化合物與一種或更多種無毒性,生理上可接受 -16- 朝巾目國家;^準(CNS ) A4規格(210X297公釐)---------- (請先聞讀背面之注意事項再填寫本育)4 5 7 Revised page of the Chinese manual for the patent application No. 5 (September 87) V. Description of the invention (12 Zwitterionic salt printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs) applies to Contact with tissues without undue toxicity, irritating, overly constrictive responses, and have a reasonably reasonable benefit / risk ratio of 4 and its use for its intended application. The term " "Salts" refers to the inorganic and organic acid addition salts of the compounds of the present invention which are relatively non-toxic. These salts can be prepared at the same time as the final isolation and purification of the compound, or the purified compound can be freed separately. The form is reacted with an appropriate organic or inorganic acid or base, and then the salts formed thereby are isolated. Representative salts include bromate, hydrochloride, sulfate, bisulfate, nitrate, acetate, Oxalate, valerate, oleate, standard palmitate, stearate, cinnamate, rotten salt, benzoate, lactate, phosphonate, methylbenzoate, Citrate, maleate, fumarate , Succinate, tartrate, gallate, formate, glucoheptonate, lactiobionate, cinnamon sulfonate, etc. ^ It can also contain metal or Earth metal cations, such as sodium, Syria, but, mai, hafnium, etc., and typical toxic ammonium, quaternary ammonium and amine cations including (but not limited to) ammonium, tetramethylammonium, tetraethylammonium, methylamine Amines, ethylamines, difluorenylamines, difluorenylamines, diethylamines, ethylamines, etc. (See, for example, SM Berge et al., "Medical salts_'j. Pharm ~ 66;! _ I? (I977), which is listed here as a reference material) Pharmaceutically acceptable, examples of non-toxic esters of the compounds of the present invention include Ci's pentyl group, which is a straight chain Or with a bell. Acceptable vinegars also include C5 to (: 7 cycloalkyl esters) and aromatic groups such as (but not limited to) hexyl. The more preferred are (^ to ^ alkyl esters α -15- The compound of the present invention is applicable to the paper size _ Jiaxian (CNS) A4 specification (21QX2_ Chu) 457246 Member of the Central Standards Bureau of the Ministry of Economic Affairs Consumption cooperative seal A7 ---_! Z___ V. Description of the invention (13) Vinegars can be prepared according to conventional methods. Pharmaceutically acceptable, examples of non-toxic amidines of the compounds of the present invention include derivatives derived from ammonia, First-order 〇 to <: 5 alkylamine 'and second-order (^ to £: 6-alkyl amine amine' in which the alkyl group is linear or branched. In the example of the secondary amine, the The amine may be a 5- or 6-membered heterocyclic ring containing one nitrogen atom. Preferred are ammonium amines derived from ammonia, (^ to (: 3 alkyl primary amidines and (^ to (: 2 dialkyl amidines). The amidines of the compounds of the present invention can be prepared according to conventional methods. The term " prodrug " refers to a compound that can be transformed in the body immediately (for example, by permanent dissolution in blood) into the parent compound of the above formula β τ Xiqi (T. HigucM) & V. Stella in "Previous Drugs as Novel Drug Delivery Systems" Volume 14 of the "A. cs Seminar Series" and at Edward B. Roche (Edward B. Roche) Edited 'American Pharmaceutical Association and Pergamon Press (American Pharmaceutical Association and Pergamon Press) published in 1987 "in drug design Convertible vehicle body "is discussed in whole redundant, both of the above are hereby incorporated by reference materials. The invention also proposes a medicinal composition containing a compound of the invention. The present invention also intends to propose that the medicinal composition contains a compound of the present invention and other compounds, and the composition can inhibit the combination of selectin or p-selectin with sLex or sLea, or compete with sLex or sLea. In combination, the composition may also contain sLex or sLea itself. The medicinal composition of the present invention comprises a physiological carrier and a compound of formula π or in. The medicinal composition of the present invention may include one or more compounds having the above-mentioned structure of formula π or III and one or more non-toxic, physiologically acceptable -16- North Korea countries; quasi (CNS) A4 specification (210X297 mm) ---------- (Please read the notes on the back before filling in this education)
-V-V
'IT r 457246 五 、發明説明(ι4) A7 B7 經濟部中央標準局員工消費合作社印製 爻栽劑,佐劑’或媒液(在此通稱爲载劑)—起調配成可供 =射用’作成固體或液體形式供口服給藥, 局部給藥等等。 該組合物可經由口服,直腸,注射(靜脈内,肌内,或 =下),腦池内,陰道内,腹腔内,局部(粉末,軟膏或滴 ,),或以一種口腔内或經由吸入(經霧化,或作成鼻内噴 務对0方式給予人類或動物。 適合作爲注射劑之組合物可包括生理上可接受之無菌水 性或非水性溶液,分散劑,懸浮劑或乳劑以及無菌之粉劑 再經調配成溶液或分散劑。適用之水性或非水性载劑,稀 釋劑,溶劑或媒液之實例包括水,乙醇,多醇(丙二醇, 聚乙二醇,甘油等等),其適當之混合物,植物油(諸如橄 欖油及菜籽油(cannola oil)及可供注射之有機酯類例如油酸 乙醋。適當之流動性可藉由使用塗覆劑例如卵癖脂,或在 分散劑中保持所需之顆粒大小或是使用界面活性劑來維持。 該等組合物中亦可含有諸如防腐劑,潤溼劑,乳化劑, 及分散劑之佐劑。使用各種抗菌劑及抗黴菌劑例如對氧苯 甲酸酯(paraben),氯基丁醇,酚,山梨酸等等)可有效地預 防細菌之作用。其中亦可包含有等張劑,例如糖,氣化納 等等。可延長吸收之可注射醫藥形式可使用延緩吸收之試 劑(例如單硬脂酸鋁及明膠)來達成。 若有必要,且爲了更有效的供輸,可以將該等化合物併 入缓釋或定時釋放或特定目標給藥系統中,例如聚合物介 質’微脂粒,及微球體(microspheres)。該類組合物可以經 -17- 本紙張尺度適用中國國家標準(CNS ) Μ規格(210X29?公楚;〉 (請先閲讀背面之注意事項再填寫本頁)'IT r 457246 V. Description of the invention (ι4) A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs, a planting agent, adjuvant' or a medium (collectively referred to herein as a carrier)-prepared for use = injection 'Made in solid or liquid form for oral administration, topical administration, etc. The composition can be taken orally, rectally, by injection (intravenously, intramuscularly, or inferiorly), intracranially, intravaginally, intraperitoneally, topically (powder, ointment, or drops), or intraorally or via inhalation ( Nebulized, or formulated as an intranasal spray for administration to humans or animals. Compositions suitable as injections may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders. Formulated into a solution or dispersant. Examples of suitable aqueous or non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), and suitable mixtures thereof Vegetable oils (such as olive oil and cannola oil) and injectable organic esters such as ethyl oleate. Appropriate fluidity can be maintained by the use of coating agents such as ovum fat, or in dispersants The required particle size is maintained using surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers, and dispersants. Various antibacterial agents and Mold agents such as paraben, chlorobutanol, phenol, sorbic acid, etc. can effectively prevent bacteria. It can also contain isotonic agents, such as sugar, sodium carbonate, etc. Injectable pharmaceutical forms that can prolong absorption can be achieved by using agents that delay absorption (such as aluminum monostearate and gelatin). If necessary, and for more effective delivery, these compounds can be incorporated into a sustained release or Timed release or specific target drug delivery systems, such as polymer media 'microlipids, and microspheres. This type of composition can be adapted to the Chinese National Standard (CNS) M specifications (210X29? Gongchu;〉 (Please read the notes on the back before filling in this page)
457246 A7 B7 五、發明説明(15) 由例如濾過一層可留置細菌之濾膜而作成無菌,或是在使 用前立即摻入以無菌水或是其他無菌可注射介質形式之殺 菌劑而使成無菌。 供口服给藥之固體劑型包括有膠囊,錠片,丸劑,散劑 及顆粒劑。於該等固體劑型中,有效之化合物或是—種前 藥酯類係與至少一種惰性之習用賦形劑(或載劑)例如擰檬 酸鈉或磷酸二鈣,或是(a)填充劑或擴充劑,例如澱粉類, 乳糖,蔗糖,葡萄糖,甘露醇及矽酸,(b)黏合劑,例如羧 甲基纖維素,海藻酸鹽類,明膠,聚乙烯吡咯酮,薦糖及 阿拉伯膠,(c)保溼劑,例如甘油,(d)崩散劑,例如瓊膠 ’破酸鈣,馬鈐薯或樹薯澱粉,海藻酸,特定之矽酸鹽錯 合物及碳酸鈉,(e)溶解延遲劑,例如石蠟,(f)加速叹收劑 ,例如四級銨化合物,(g)潤濕劑,例如鯨蠟醇及單硬脂酸 甘油酯,(h)吸附劑,例如高嶺土及矽皀土,(丨)潤滑劑,例 如滑石粉,硬脂酸鈣,硬脂酸鎂,固體聚乙二醇類,肉桂 基硫酸鈉或其混合物。在膠囊,錠片及丸劑之情況下,該 等劑型亦可以含有缓衝劑。 經濟部中央標準局負工消費合作社印製 相似類型之固體組合物亦可填充入軟或硬明膠膠囊中, 其中所使用之賦形劑可爲乳糖或牛奶糖以及高分子量聚乙 二醇類等等。 固體劑型例如錠劑,糖衣丸,膠囊,丸劑及顆粒劑可以 作成有膜衣及有包殼,例如腸溶衣及其他此技界所熟知者 。該等包覆物可含有遮光劑,而且亦可爲一種可控制主成 分化合物在腸道特定部位延緩釋放之組合物。可被使用之 -18- 本紙張尺度通用中國國家標準(CNS > A4規格(210X297公發) 經濟部中央標準局員工消費合咋f±中緊 #57246 at B7 五、發明説明(16) 包覆組合物之實例有聚合物物質及蠟類。 倘若適當,該有效化合物亦可與一種或多種前述之職形 劑作成微包囊形式。 供口服之液體劑型包括醫藥上可接受之乳劑,溶液,懸 浮液,糖漿及酏劑。除了該有效化合物之外,液體劑型中 尚可含有此技界所常用之惰性稀釋劑,_水或其他溶劑,助 溶劑及乳化劑,例如乙醇,異丙醇,碳酸乙酯,乙酸乙酿 ,苯曱基醇,苯甲酸苄基酯,丙二醇,1,3-丁二醇,二甲 基甲醯胺,油類,特別是棉子油,花生油,玉米胚芽油, 橄欖油,菜籽油(cannola oil),篦麻油及芝麻子油,甘油, 四經基呋喃醇,聚乙二醇類及山梨糖之脂肪酸酯類或該等 化合物之混合物等等^ 除了該等惰性之稀釋劑之外,該等組合物中尚可包含佐 劑,諸如潤溼劑,乳化劑及助懸劑,甜味劑,矯味劑及芳 香劑。 懸浮劑中除了有效化合物之外,尚可包含助懸劑,例如 乙氧基化異硬脂醇,聚氧乙烯山.梨醇及山梨糖酯,微晶纖 維素,偏氫氧化鋁,矽包土,瓊膠及西黃蓍膠或該等物質 之混合物等等。 .供直腸給藥之較佳組合物係栓劑,栓劑可以經由將本發 明之化合物與適當之無刺激性賦形劑或載劑例如可可亞奶 油,聚乙二醇或是一種栓劑用蠟混合而製成,栓劑在常溫 時爲固狀但在體溫時則爲液狀,因此在直腸或腔腔中會被 融化而釋放出有效成分。 本紙張尺纽财®I國家標隼(_CNS ) A4規格( (請先閱讀背面之注$項再填寫本頁)457246 A7 B7 V. Description of the invention (15) Sterilized by, for example, filtering a layer of bacteria-retaining filter membrane, or sterilizing with sterile water or other sterile injectable medium immediately before use . Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the effective compound is either a prodrug ester and at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate, or (a) a filler Or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders such as carboxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, saccharose, and gum arabic , (C) humectants, such as glycerin, (d) disintegrating agents, such as agar's calcium breaking acid, potato or tapioca starch, alginic acid, specific silicate complexes, and sodium carbonate, (e ) Dissolution delaying agents, such as paraffin, (f) Accelerators, such as quaternary ammonium compounds, (g) Wetting agents, such as cetyl alcohol and glyceryl monostearate, (h) Adsorbents, such as kaolin and Silica, (丨) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium cinnamyl sulfate or mixtures thereof. In the case of capsules, tablets and pills, these dosage forms may also contain buffering agents. The solid type composition printed by the Central Standards Bureau of the Ministry of Economic Affairs and Consumer Cooperatives can also be filled into soft or hard gelatin capsules. The excipients used can be lactose or milk sugar and high molecular weight polyethylene glycols. Wait. Solid dosage forms such as lozenges, dragees, capsules, pills, and granules can be made with film coatings and shells, such as enteric coatings and others known in the art. These coatings may contain opacifying agents, and may also be a composition that controls the delayed release of the main component compound in specific parts of the intestinal tract. Can be used -18- This paper standard is in accordance with the Chinese National Standard (CNS > A4 size (210X297)) Employees ’Central Standards Bureau, Ministry of Economic Affairs, Consumer Consumption f ± 中 紧 # 57246 at B7 V. Description of Invention (16) Package Examples of coating compositions are polymeric substances and waxes. If appropriate, the effective compounds can also be microencapsulated with one or more of the aforementioned formulations. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions , Suspension, syrup and elixir. In addition to the effective compound, the liquid dosage form may contain inert diluents commonly used in this technology, water or other solvents, co-solvents and emulsifiers, such as ethanol, isopropanol , Ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol, dimethylformamide, oils, especially cottonseed oil, peanut oil, corn germ Oil, olive oil, cannola oil, ramie oil and sesame oil, glycerin, tetrafuryl alcohol, polyethylene glycols and fatty acid esters of sorbose or mixtures of these compounds, etc. ^ Except Inert In addition to diluents, adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and fragrances may be included in these compositions. In addition to effective compounds, suspending agents may also contain Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitol esters, microcrystalline cellulose, aluminum metahydroxide, silica-coated earth, agar and tragacanth or their Mixtures of substances, etc .. Preferred compositions for rectal administration are suppositories. Suppositories may be obtained by combining the compound of the present invention with a suitable non-irritating excipient or vehicle such as cocoa butter, polyethylene glycol or A suppository is made by mixing wax. The suppository is solid at normal temperature but liquid at body temperature, so it will be melted in the rectum or cavity to release active ingredients. This paper rule New Zealand® I National Standard隼 (_CNS) A4 specifications ((Please read the note on the back before filling this page)
V 訂 -19 - 157246 A7 ___ B7 經濟部中央標準局貝工消費合作社印製 五、發明説明(17) 供局部給予本發明化合物之劑型包括有軟膏,散劑,噴 霧劑及吸入劑。 有效成分可在無菌條件下視需要與一種生理上可接受之 載劑及任何需要之防腐劑,緩衝劑或推進劑換合。眼用調 配物,眼藥膏,懸浮劑,散劑及溶液在此均納入爲本發明 之範園。 本發明之化合物亦可以微脂小粒之形式給藥。此技界人 士已知,微脂粒係衍自磷脂或其他脂肪物質。微脂粒將單 層或多層水合液體晶體分散於水溶性介質中而形成。任何 可形成微脂粒且無毒性,生理上可接受以及可被代謝之脂 昉均可採用。以微脂粒形式存在之本組合物除了本發明之 選擇素結合抑制劑之外,尚可包含安定劑,防腐劑,.賦形 劑等等。較佳之脂肪爲天然的或合成之嶙脂或磷脂膽素( 卵磷脂)。形成微脂粒之方法係此技界人士所熟知。 本發明組合物之主成分實際劑量可以視所用之特定組合 物與其施用方法及欲達到治療效果所需主成分量而加以變 化。因此,選擇之劑量將視所欲達到效果,給藥途徑,所 需治療期間及其他因素而定。 將本發明化合物以一次或分爲數次給予—個宿主之每日 總劑量範圍爲每公斤體重自約0.3毫克至5〇毫克。每天分 成數次給藥之單位劑型組合物則依此每天劑量範圍分配來 達到每天劑Φ。然而吾人當明瞭給予任何特定病患(無論 是人或是動物)之特定劑量是依據許多因素而定,其中包 括體重,健康狀況,性別,飲食,投藥之時間與途徑,吸 _____ -20- 本紙適用中ϋ國家標準(CNS ) A4規格(21()><297公^--—~ (請先聞讀背面之注意事項再填寫本頁) IV. 訂_ -or. ! 457246 Α7 Β7 經濟部中央標準局貝工消費合作社印製 五、發明説明(18) 收及排泄速率,與其他藥物併用以及治療特定疾病之嚴重 度。 特言之,本發明之化合物可用於治療許多與發炎,細胞 與細胞辨識及接觸有關之疾病。舉例言之,本發明之化合 物可給予病患用於治療敗血性休克,慢性發炎性疾病,例 如乾癬,類風濕性關節炎及發生在心臟病,中風,與器官 移植後之再灌流性傷害,受創性休克,多重器官衰竭,自 體免疫疾病,氣喘,發炎性腸疾病。於各個情況中係將有 效量之本發明化合物不論是單獨使用或作爲有藥效組合物 之一部份來使用給予需要該項治療之病患。吾人亦明暸亦 可將該等化合物之組合给予需要該項治療之病患。本發明 之化合物可經給藥後用於治療和細胞__細胞接觸有闕之疾 病。因爲本發明化合物抑制了 E_選擇素或p•選擇素與SLex 或之結合,任何與這類交互作用有關之疾病都可能因 爲抑制了這種結合交互作用而得以治療。 sLea除了在部份白血球細胞被發現以外,在許多癌細胞 上亦有發現,其中包括肺及直腸之癌細胞。吾人假設與 SLea有關之細胞接觸可能和癌細胞之移轉有關,因此sLea 結合抑制劑可能可以用於治療某些形式之癌症。 許多本發明之化合物可以根據下列合成方案而合成。 ____ -21 - ( CNS } ( 210Χ297^ίΤ (請先聞讀背面之注意事項再填寫本頁) -'IT' η£ r 4 S 7 2 Λ 6 Α7 _ Β7 經+濟.-5)1十央樣率对月工消费舍作社中製 五、發明説明(19) 方案1Rev. -19-157246 A7 ___ B7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (17) Dosage forms for topical administration of the compounds of this invention include ointments, powders, sprays and inhalants. The active ingredient can be exchanged with a physiologically acceptable carrier and any needed preservatives, buffers or propellants under sterile conditions as needed. Ophthalmic formulations, eye ointments, suspensions, powders, and solutions are all incorporated into the scope of the present invention. The compounds of the present invention may also be administered in the form of microfat granules. It is known to those skilled in the art that microlipids are derived from phospholipids or other fatty substances. Microlipids are formed by dispersing single or multiple hydrated liquid crystals in a water-soluble medium. Any liposome that can form microlipids and is non-toxic, physiologically acceptable and metabolizable can be used. In addition to the selectin binding inhibitor of the present invention, the present composition in the form of microlipids may further include a stabilizer, a preservative, an excipient, and the like. Preferred fats are natural or synthetic lipids or phosphocholin (lecithin). The method for forming the liposomes is well known to those skilled in the art. The actual dosage of the main ingredients of the composition of the present invention may vary depending on the particular composition used and the method of administration thereof, and the amount of the main ingredients required to achieve a therapeutic effect. Therefore, the dosage chosen will depend on the desired effect, the route of administration, the period of treatment required, and other factors. The compounds of the present invention are administered in one or several divided doses-the total daily dosage of each host ranges from about 0.3 mg to 50 mg per kg of body weight. Unit-dose composition divided into several doses per day is then distributed according to this daily dose range to achieve the daily dose Φ. However, I understand that the specific dose given to any particular patient (whether human or animal) depends on many factors, including weight, health status, gender, diet, time and route of administration, smoking ___ -20- This paper applies the China National Standard (CNS) A4 specification (21 () > < 297 Gong ^ --- ~ (Please read the precautions on the back before filling this page) IV. Order _ -or.! 457246 Α7 Β7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (18) The rate of collection and excretion, combined with other drugs and the severity of specific diseases. In particular, the compounds of the present invention can be used to treat many and inflammation Diseases related to cell and cell recognition and contact. For example, the compounds of the present invention can be administered to patients for the treatment of septic shock, chronic inflammatory diseases such as psoriasis, rheumatoid arthritis and heart disease, stroke And reperfusion injury after organ transplantation, invasive shock, multiple organ failure, autoimmune disease, asthma, inflammatory bowel disease. In each case it will be an effective amount The compound of the invention is used alone or as part of a pharmacologically effective composition for administration to a patient in need of the treatment. I also understand that a combination of these compounds can also be administered to a patient in need of the treatment. The present invention The compounds can be used for the treatment of diseases that are in contact with cells. Since the compounds of the present invention inhibit the binding of E-selectin or p-selectin to SLex, anything related to such interactions Diseases may be treated by inhibiting this binding interaction. In addition to being found in some white blood cells, sLea is also found in many cancer cells, including lung and rectal cancer cells. I hypothesize that it is related to SLea Cell contact may be related to the migration of cancer cells, so sLea binding inhibitors may be used to treat certain forms of cancer. Many of the compounds of the present invention can be synthesized according to the following synthetic schemes. ____ -21-(CNS) (210 × 297 ^ ίΤ (Please read the precautions on the back before filling in this page) -'IT 'η £ r 4 S 7 2 Λ 6 Α7 _ Β7 Economic + Economic. -5) 1 Shiyang sample rate for monthly labor consumption Co., Ltd. as the five homes, description of the invention (19) Scheme 1
在本方案中,一種經取代之聨笨(j_»美國專利案第 5,444,050號)與一種二酸氱化物反應可得二芳香基二酮圣 較佳之實例包括5至16個破原子之直鏈與具支鏈之二酸氣 化物。該等化合物可以經由彼精於此技人士所熟知之數種 方沽其t之一種方法來進行運原,例如催化性氬化,沃夫 -凱司納(Wolff-Kishncr)還原,金屬氲化物諸如三乙基矽烷 ,或克里門森(Clemensen)還原》結果所產生之化合物(1) -22 - 本紙張尺度適用中周阄家樣华{ CNS ) A4規格(210X21)7公矩) (请先閱-^背面之注盘皁項再嗔寫本瓦〕 訂 457246 A7 B7 五、發明説明(20) 在於0。(:至室溫下,卤素化溶劑中藉由三溴化硼之作用而 轉變成酚類1。利用一種經保護之甘露糖單位在三氟化棚 已醚合物存在下進行醣嘗化,接著再藉由驗水解可得欲得 之化合物1。 方案2In this solution, a substituted dibenzyl (US Patent No. 5,444,050) is reacted with a diacid halide to obtain a diaryl dione. The preferred examples include a straight chain with 5 to 16 broken atoms and Branched diacid gaseous compounds. These compounds can be transported by one of several methods known to those skilled in the art, such as catalytic argonization, Wolff-Kishncr reduction, metal halide Such as triethylsilane, or the compounds produced by the reduction of Clemensen (1) -22-This paper size is applicable to Zhong Zhou's family sample China {CNS) A4 size (210X21) 7 moments) ( Please read the soap on the back of the-^ before copying the tile.] Order 457246 A7 B7 V. Description of the invention (20) lies at 0. (: At room temperature, the halogenated solvent is affected by the action of boron Conversion to phenols 1. A protected mannose unit is used to carry out sugar taste in the presence of trifluoride shed ether compounds, and then the desired compound 1 can be obtained by experimental hydrolysis. Scheme 2
還原reduction
MeOMeO
8 OMe8 OMe
1. BuU. Z Pd(0) X S(0Me)31. BuU. Z Pd (0) X S (0Me) 3
iX (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 1. BBr3iX (Please read the notes on the back before filling out this page) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 1. BBr3
2. {R〇)sMan, BF3*OEU or (RO^Man-F, BF3*0Et 3. 姜保1 金 23- 本紙杀尺度適用中國國家椋準(CNS ) A4規格(210X 297公釐) ,,丨4572 4 0 A7 -----____B7 五、發明説明(21 ) 吾人亦可以在特定情況中在環接上一個具有羧酸之環之前 ,於兩個壤(間先建構一個連接子,然後再於環上取代以 一個甘露糖單位。例如在這個方案中,一種諸如4_(4_甲氧 基苯基)丁酸先利用氯化亞硫醯轉變成酸氯化物,接著再 利用彿萊德-卡夫特(Friedel-Craft)反應與甲氧基苯反應而 得酮1。利用彼精於此技人士所熟知之許多不同方法任何 一種方法將酮還原可得化合物i。將甲氧基之鄰位鋰化後 ,經轉換成硼烷基酸(boronic acid)再藉由鈀-媒介之雙芳香 基偶合可得。將醚類去甲基化之後在經醣苷化並再經去 保護後即得標的化合物1〇。 & (請先閱讀背面之注意事項再填寫本頁) r 經濟部中央標準局貝工消費合作社印裝 -24- 本紙張尺度適用t國國家標準(CNS ) A4規格(2〖0X297公釐) 457246 A7 B7 五、發明説明(22)方案3 經濟部中央梯隼局員工消費合作社印製2. {R〇) sMan, BF3 * OEU or (RO ^ Man-F, BF3 * 0Et) 3. Jiang Bao 1 Jin 23- The standard of this paper is applicable to China National Standard (CNS) A4 (210X 297 mm), , 4572 4 0 A7 -----____ B7 V. Description of the invention (21) In certain cases, we can also construct a linker between the two soils (before the ring is connected with a carboxylic acid ring). It is then replaced with a mannose unit on the ring. For example, in this scheme, a 4- (4-methoxyphenyl) butanoic acid is first converted to acid chloride using thionyl chloride, and then Fry The Friedel-Craft reaction is reacted with methoxybenzene to obtain ketone 1. Compound i can be obtained by reducing the ketone using any of many different methods known to those skilled in the art. The methoxy group After ortho-lithiation, it can be converted to boronic acid and then obtained by palladium-diaryl coupling. After demethylating the ethers, it is glycosylated and deprotected. The target compound is 10. & (Please read the notes on the back before filling this page) r Central Bureau of Standards, Ministry of Economic Affairs Cooperatives fee scale printing equipment -24- This paper applies t National Standards (CNS) A4 size (2 〖0X297 mm) 457246 A7 B7 V. invention is described in (22) Option 3 Ministry of Economic Affairs Bureau of the Central Falcon ladder employees consumer cooperatives printed
在其他情況,則最好在例如在ϋ的一種化合物(美國專利 (請先閲讀背面之注意事項再填寫本頁) Λ' *βτ. -25- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A7 B7 457246 五、發明説明(23) 案第5,444,050號,其中已經有醣基部分接於其上)道行彿 萊德卡夫特反應舉例言之,例如ϋ可以在諸如氣化無 'H+岛-士-醍孖彺τ以琥珀酸釺處理可得酮酸U °將酮基以 一種精於此技人士所熟知之許多方法其中之一種方法還原 可得酸,再利用氣化亞硫醯在產化溶劑中低溫下(或其 他方法)轉變成酸氟化物11。再將該酸氯化物與各種一級 或二級胺(特別是諸如伸乙基二胺,六氬吡畊,同六氩吡 畊(homopiperazine),4,4·-三亞甲基二六氫,或其-他現 基二胺)其中之一種胺反應可得例如jj_之多元體化合物。 將醢胺在氧化溶劑中低溫下以棚虼或其他適當試劑還原, 接著再將保護基水解可得所欲得之化合物甚者,醯胺 ϋ可直接水解而得醯胺12 υ 方窠4 (请先聞讀背而之注項再填鸿冬瓦) k--- 經黄郎中央棣孪^κ工消资合作社印策In other cases, it is best to use a compound such as ϋ (U.S. patent (please read the precautions on the back before filling this page) Λ '* βτ. -25- This paper size applies Chinese National Standard (CNS) A4 (210X297 mm) A7 B7 457246 V. Description of the Invention (23) Case No. 5,444,050, in which a glycosyl moiety is already attached thereto) The Dao-Fried Kraft reaction is exemplified, for example, tritium can be No 'H + island-shi- 醍 孖 彺 τ can be treated with succinic acid to obtain keto acid U ° The keto group is reduced by one of many methods known to those skilled in the art to obtain the acid, which is then gasified Thiosulfur is converted into acid fluoride 11 at low temperature (or other methods) in a production solvent. The acid chloride is then reacted with various primary or secondary amines (especially such as ethylene diamine, hexapyrine, homopiperazine, 4,4 · -trimethylene dihexahydro, or The reaction of one of the amines of other-diaminodiamine) can give a polyvalent compound such as jj_. Reduction of amidine in an oxidizing solvent at low temperature with stilbene or other appropriate reagents, followed by hydrolysis of the protecting group to obtain the desired compound, or amidine may be directly hydrolyzed to obtain amidine 12 υ square 窠 4 ( Please read the back note first and then fill in the Hongdong tile) k --- by Huang Langzhong Chuan ^ κ Industry and Consumer Cooperatives India
23 -26 - 本紙掁茂度通用中國闺家襟枣(f:M;)八4规格(21ϋχ m公+楚) 457246 B7 經濟部中央-#準?員工消費合作社印製 五、發明説明(24 ) 含有醚基聯接之化合物可依方案4製成。巍基酯類(18)經 氧化成趁類接著再經自我縮合可得醚類(12_),該醚類再轉 變成酸氯化物(@。依序經彿莱德-卡夫特偶合,還原,去 曱基化,糖站化及去保護基而得醚類(H)。 方案523 -26-The paper is full of paper. General Chinese girl's lapel (f: M;) 8 4 size (21ϋχ m 公 + 楚) 457246 B7 Central Ministry of Economic Affairs-# quasi? Printed by Employee Consumer Cooperatives 5. Description of the Invention (24) Compounds containing ether linkages can be made according to Scheme 4. The ether esters (18) are oxidized into ethers and then self-condensed to obtain ethers (12_), which are then converted into acid chlorides (@. In sequence via Fryd-Kraft coupling and reduction , Demethylation, sugar stationation and deprotection to obtain ethers (H). Scheme 5
-27- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (諳先閱讀背面之注意事項再填寫本頁) 457246 A7 B7 五、發明説明(25 ) 在某些情況下則最好依方案5所示之一連串反應製備其他 化合物。因此’ 1_可以其他鹵化酸氯化物,例如3 _溴丙酸 氟化物進行彿菜德-卡夫特反應而得^1。苄基酮可以彼經 於此技人士所熟知之方法其中之一種方法還原而得氣化物 ϋ。將g與1,3-丙烷二硫醇,或其他適當之二硫化物在適 當之鹼存在下反應可得化合物廷。去曱.基化可以藉由許多 方法其中之一種,特別是以三溴化硼在鹵化溶劑中低溫下 芫成,由此可得酚類红。該酚類再利用三氟化硼乙醚合物 在鹵化溶劑中與一種經保護之略喃甘露糖钵反應,以鹼水 溶液將保護基移除後可得化合物另一方面,糖芬^可 以一種適當之氧化劑諸如間氣過氧苯甲酸在適當之溶劑中 處理而得颯。以鹼水溶液處理可得最終化合物拉。 方案6 ‘ (請先聞讀背面之注意事項再填寫本頁) 訂 經濟部l標準局員工消費合作社印製-27- This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) (谙 Please read the notes on the back before filling this page) 457246 A7 B7 V. Description of invention (25) In some cases, It is possible to prepare other compounds according to a series of reactions shown in Scheme 5. Therefore, '1_ can be obtained by carrying out the Fletcher-Kraft reaction of other halogenated acid chlorides, such as 3-bromopropionic acid fluoride. The benzyl ketone can be reduced by one of the methods well known to those skilled in the art to obtain the gaseous compound ϋ. Compound g can be obtained by reacting g with 1,3-propane dithiol, or other appropriate disulfide in the presence of a suitable base. Dehydration can be achieved by one of a number of methods, in particular by boron tribromide in a halogenated solvent at a low temperature to obtain phenol red. The phenols are re-used with boron trifluoride etherate in a halogenated solvent and reacted with a protected mannose bowl. The compound can be obtained by removing the protecting group with an alkaline aqueous solution. An oxidizing agent such as m-peroxybenzoic acid is obtained in a suitable solvent. Treatment with an alkaline aqueous solution gives the final compound pull. Option 6 ‘(Please read the notes on the back before filling this page) Order Printed by the Consumers’ Cooperative of the Standards Bureau, Ministry of Economic Affairs
CCH2)f -28- 本紙張以適用t關家擦準(CNS )从規格(2歡297公幻 -ml i - I— I — I — ,"45724 〇 A7 B7CCH2) f -28- This paper is in accordance with applicable standards (CNS) from the specifications (2 Huan 297 public magic -ml i-I — I — I —, " 45724 〇 A7 B7
Me。- 1Me. - 1
.* Β8Γ3 五、發明説明(26 ) 在其他情況下,中間物]^與一種二酸氯化物在it化溶劑中 氣化鋁或其他適當之路易士酸存在下進行彿莱德 '卡夫特 反應可得U。利用氫氣化物水溶液或甲氧化物水溶液接著 再以氫氧化物水溶液將甘露糖部分去保護基之後可得最終 化合物。 方案7 (CH2)£· -Ph (請先閱讀背面之注意事項再填寫本頁〕 k'_. * Β8Γ3 V. Description of the invention (26) In other cases, the intermediate] ^ with a diacid chloride in the presence of gasification of aluminum or other appropriate Lewis acid in Fide 'Kraft The reaction yields U. The final compound can be obtained by deprotecting the mannose moiety with an aqueous solution of hydrogenide or an aqueous solution of methoxide followed by an aqueous solution of hydroxide. Option 7 (CH2) £ · -Ph (Please read the notes on the back before filling this page) k'_
AlCljAlClj
L,3r5-PhL, 3r5-Ph
Jo 0H l#3,S-Ph 2, (RO)sMan, BF3*Et2〇 or (RO)4Man-F, BF3*Et2〇 去保護 訂 經濟部中央標準局負工消費合作社印製 35 於本方案中,一種經取代之聯苯(J_,美國專利案第 5,444,050號)係與一種三酸氯化物反應而得苄基酮21。該 等酮類可以彼精於此技人士所熟知之許多方法(列於方案1 中)之其中一種方法還原。結果產生之化合物經去曱基 化,糖苷化再去保護基之後可得所欲得之化合物g。 -29- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4· 5 7 2 15686號專利申請案 4 5 7 2 4^説明書修正頁(87年9月) 五、發明説明( 方案8 27Jo 0H l # 3, S-Ph 2, (RO) sMan, BF3 * Et2〇or (RO) 4Man-F, BF3 * Et2〇 to protect and subscribe to the Ministry of Economic Affairs Central Standards Bureau Off-line Consumer Cooperatives Print 35 in this plan Among them, a substituted biphenyl (J_, US Patent No. 5,444,050) is reacted with a triacid chloride to obtain benzyl ketone 21. These ketones can be reduced by one of many methods well-known to those skilled in the art (listed in Scheme 1). The resulting compound is deglycosylated, glycosylated and then deprotected to obtain the desired compound g. -29- This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) 4 · 5 7 2 15686 Patent Application 4 5 7 2 4 ^ Revision Sheet (September 1987) V. Description of the invention (Option 8 27
(CHj)mS {CH2J /-1,3,5-Ph 33 <請先閲讀背面之注意事項再填寫本頁) 訂 以類似之方法,將11與溴烷基酸溴化物進行彿萊德-卡 夫特反應可得。將該溴基嗣於一種驗存在下與i,3,5_經 取代I苯三硫醇反應可得化合物立。將保護基水解後可得 所欲得之化合物(21) 0 本發明可以下列代表性之實例來説明: 實例1 M-雙-[3-(3-幾甲基苯基)-4-(2-a -D-说喃甘露糖基氧)苯 基]己烷 經濟部中央標準局員工消費合作社印製 步驟1 :己二醯氯化物(2.0克,10.9毫莫耳)先溶於丨,2_二 氯乙烷(55毫升)再於冰浴中冷卻。加入氣化鋁(5 8克,43 5 毫莫耳)之後再加入3-(2-甲氧基苯基)苯乙酸甲基酯(575 克,22.4毫莫耳)[Τ. Ρ.柯甘,Β.度皮耶,I. L.史考特,Κ.凱勒, Η.道,及Ρ.貝克,美國專利案第5,444,〇5〇號及Τ_ Ρ.柯甘 30 - 本紙張尺度適用中國國家標準(CNS ) Α4規袼(210Χ297公釐) 烛濟部中央樣苹局負工消費合作社印製 r 45724b A7 B7 五、發明説明(28) ,B,度皮耶,K. M.訊勒,I_ L.史考特,H.布衣R, V.馬其特 *卩‘ J.貞克,J,A·福伊特司,M.蕊芙莉及D.史考特,[ Med_ Chcm. 1995, 38: 4976-49841接著將混合物於室溫下授 拌30分鐘,然後再與冰水(30毫升)混合。分離有機物質之 後,再以二氣甲烷萃取水溶液部份(3 X 5毫升。有機物質 合併後,經脱水(MgS04.)再減壓濃縮。殘渣經快速層析法 (Si02,由己烷至3 :丨已烷/乙酸乙酯梯度溶離)純化可得產 物圣(2.23克,33%)。ll·INMJl(400MHz,CDCi3):7.96(£l£J, J=6.6S 1,9 Hz, 2H), 7,92 (d, J~].9 Hz: 2H), 7.42 (m, 2H)7 7.34 (t, J-6 Hz, 2H): 7.18-7.28 (m, 4TI), 7.00 (d, J-6.3 ][/, 2H),3,87 (s, 6Π),3.69 (s, 6H)· 3 .68 (s: 4H), 3 0 丨(m, 4TI), LS4 (m,4H) ppm。TR (MaCl): 1741,1677 cm·1 c 步驟2 : A部份:由步驟1所得之產物(2.23克,3,6毫莫耳) 溶於乙腈中再以氫氧化鋰(0.8克.丨8毫莫耳虱氧化鋰單水 合物於8毫升之水中)處理ύ ::昆合物於室溫下攪拌隔夜,然 後再以2Ν HC1酸化至pH 4 τ接著再以乙酸乙酯萃取。合併 萃取物,脱水(1^804)然悛再減墼濃縮。Ut (NaCl): Π11, 1677 cm·1。 B部份ι由A-萍份所得之酮酸(1.86克,3 Λ毫莫耳)先溶於 二f基亞颯(15毫升)再與肼(丨.0毫升,3】毫莫耳)混合5將 該混合物於氮氛下在SOT:加熱2,5小時’然後冷卻。將第 三級丁氧化鉀(3.5克,3 1毫奠耳)加入後再將混合物於氮氛 下80°C加熱至陨夜,接著與水(30毫升)混合並以2N HC1將 其酸化,最再以匕酸乙酯萃取^合併萃取液,脱水(Μβ〇4) 本紙依尺度逋用中®®家禕?M OJS ) Λ4规烙(2 U1 x 公釐 (计先闓讀背面之泣意事项再填怒本頁)(CHj) mS {CH2J / -1,3,5-Ph 33 < Please read the notes on the back before filling out this page) Order a similar method to Fryde 11 with bromoalkyl bromide- Kraft reaction is available. The bromofluorene is reacted with i, 3,5_ substituted I benzenetrithiol in the presence of a compound to obtain a compound. The desired compound (21) can be obtained after the protecting group is hydrolyzed. The present invention can be illustrated by the following representative examples: Example 1 M-bis- [3- (3-Epimethylphenyl) -4- (2 -a -D- Said mannosyloxy) phenyl] hexane Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Step 1: Adipic acid chloride (2.0 g, 10.9 mmol) was first dissolved in 丨, 2 Dichloroethane (55 ml) was cooled in an ice bath. Add gasified aluminum (58 g, 43 5 mmol) followed by methyl 3- (2-methoxyphenyl) phenylacetate (575 g, 22.4 mmol) [Τ. Ρ. 柯 甘, B. Doupier, IL Scott, K. Keller, D. Dow, and P. Baker, U.S. Patent No. 5,444,050 and T_P. Cogan 30-This paper is applicable to China Standard (CNS) Α4 Regulations (210 × 297 mm) Printed by the Central Consumer Bureau of the Ministry of Economic Affairs and Consumer Cooperatives r 45724b A7 B7 V. Description of the Invention (28), B, Du Pier, KM Xunle, I_L. Scott, H. Commoner R, V. Machit * 卩 'J. Zhenke, J, A. Voith, M. Reeve and D. Scott, [Med_ Chcm. 1995, 38 : 4976-49841 The mixture is then stirred at room temperature for 30 minutes, and then mixed with ice water (30 ml). After the organic matter was separated, the aqueous part was extracted with methane gas (3 X 5 ml. After the organic matter was combined, it was dehydrated (MgS04.) And concentrated under reduced pressure. The residue was subjected to flash chromatography (Si02, from hexane to 3: 3).丨 Hexane / ethyl acetate gradient dissociation) to obtain the product (2.23 g, 33%). Ll · INMJl (400MHz, CDCi3): 7.96 (£ l £ J, J = 6.6S 1,9 Hz, 2H) , 7,92 (d, J ~). 9 Hz: 2H), 7.42 (m, 2H) 7 7.34 (t, J-6 Hz, 2H): 7.18-7.28 (m, 4TI), 7.00 (d, J -6.3] [/, 2H), 3,87 (s, 6Π), 3.69 (s, 6H) · 3.68 (s: 4H), 3 0 丨 (m, 4TI), LS4 (m, 4H) ppm TR (MaCl): 1741, 1677 cm · 1 c Step 2: Part A: The product obtained from step 1 (2.23 g, 3,6 mmol) was dissolved in acetonitrile and then lithium hydroxide (0.8 g.丨 8 millimolar lice lithium oxide monohydrate in 8 ml of water) treatment :: Kun compound was stirred at room temperature overnight, then acidified to pH 4 τ with 2N HC1 and then extracted with ethyl acetate. Combined The extract was dehydrated (1 ^ 804) and then reduced and concentrated. Ut (NaCl): Π11, 1677 cm · 1. Part B: Keto acids (1.86 g, 3 Λmmol) ) Dissolved in di-fmidine (15 ml) and mixed with hydrazine (.0 ml, 3] millimolar) 5 The mixture was heated under nitrogen in a SOT: 2,5 hours' and then cooled. Tertiary potassium butoxide (3.5 g, 31 mmol) was added, and the mixture was heated to 80 ° C under a nitrogen atmosphere until meteoric night, then mixed with water (30 ml) and acidified with 2N HC1. Extract with ethyl acetate ^ Combine the extracts, and dehydrate (Μβ〇4) The paper is used according to the standard ®® furniture? M OJS Λ 4 gauge (2 U1 x mm (count the first cry on the back) Matters fill out this page again)
457246 Α7 Β7 五、發明説明(29) 後冉減I濃縮可得1(1.6克,91%) D iR (NaCl): 1713 cm·1。 步驟3 : A部份:由步驟2,B部份所得之二酸(L6克,2.8 莫耳)於氮吩中溶於二氯甲烷(14毫升),然悛置於乾冰/2-丙 踔浴中冷卻。將三溴化硼(1 Λ毫升,1 4毫莫耳)緩緩加入; 混合物於室溫下攪拌2小時,然後與冰-水(25毫升)混合= 有機物質經分離後,以鉋和碳酸氫納水溶液(20毫升),水 (20亳升),飽和鹽水(20毫升)萃洗後,經脱水(MgS04)再減壓 濃垴5Γ得2.38克粗產物= B部份:由A部份所得之殘潰與甲醇(5 0亳升)嚴合後加入 硫酸(5滴)β將混合物於回流溫度下加熱至隔夜,然後減壓 濃縮。將殘渣溶於二氣甲烷(50毫升)再以碳酸納處理,然 後經由一層矽膠過濾^濾液經減壓濃縮後,殘渣以快速層 析法(Si02,由己熄至3:1己烷/乙酸乙酯梯度溶離)純化吁得 I,6-雙- (3-(3 - f氧羰基甲基笨基M-輕基笨基)己炕(0.9 g, 38%) 〇 !H NMR (400 MHz., CDC13): 6.BO-7.50 (m, 14H), 3.70 (s, 6H), 3,68 (S. 4H). 2.55 (dd, J = 5,S, 5,5 Hz, 4H), 1.59 (m, 4H), 1.36 (m, 4H) ppm ^ 1R (NaCl): 3430, 1731 cm'J ^ 組濟部中失榇卒^wac工消費合作杜印敢 I —l·--_n I n I ^ ^ -I (许先踅汶#1&之注'£_項再^舄本頁) 步驟4 : 1,6·雙-(3-(3-甲氧羰基甲基笨基)-4-羥基笨基)已 虼(0.9克,1,6毫莫卑)溶入l,2-二氣乙烷(8毫升)中β將戌 D-甘露糖五乙酸酯(1.9克τ 4.8毫莫耳)以一次加入’然後 緩緩加入三氟化硼乙醚合物(2,5毫升f 19,2毫莫耳)ϋ將混 合物於室溫下氮氛中搅拌隔夜然後再加入水(丨5毫升分 離有機物質後再以二氣Τ使萃取水溶液(3 χ 2毫升)。將苹 取液與原來之有機部份合併,經脱水㈡後典減壓7浪 -32- 本紙張KJlii珂中困固家梯隼{ CNS ) A4他格(2ί〇Χ297公釐) 较濟部中夾橾隼局W工消費合作社印製 4 5 7 2 4 6 A7 B7 五、發明説明(30) 縮。將殘渣以快速層析法(s丨〇2 ’由己览至3 :丨己故’己酸己 酯梯度溶離)純化可得丨=6-雙-(3__肀氧談基甲基苯基)-4( 四十-乙酿基-找-⑴比味甘露糖基)氧基幕基j已婉*(1·5 S f 77%) ^ lII NMR (400 ΜΠζ, CDC13): 7.31-7.3^ (m, 6n)s 7.19-7.24 (m, 4H), 7.09-7.13 (m, 4H), 5.25 (d: J-0.6 Hz, 2H), 3.57-3.66 (m, 6H), 3,3-3.50 (m; 10H), 2,54 (m, 4H)f l.5fi (m, 4II)f l, 34 (m: 4H) jppm。TR (NaCl): 1752 cm·1。 步驟5 :將步服4所得之糖甞(1.5克,1.2臺莫耳)溶入乙腈 <6毫升)中,再以氫氧化鋰單水合物(1.0克^ 24毫莫耳)於水 (10毫升)之水溶液處理η將混合物於宣溫下授掉隔夜’然 後再以濃鹽酸將其酸化至ΡΗ 2 u將混合物滅壓濃縮之後再 以HPLC純化(逆相,以5-50%乙腈於水進行梯度溶離’ >乂 254 nm監控)可得白色固體之丨,6-雙-(3-(3-幾甲基苯基)-4-(2wL>吡喃甘露糖基氧.)苯基J己烷,⑺,(〇‘35g,33%), m. p : 115-1 I7'C : !H NMR (400 MHz, CDCl3): 7.31-7.37 (m, 6H), 7.19-7.24 (m, 4H); 7.09-7.13 (m7 4H), 5.25 (d, J^0.6 Hz, 2H)? 3,57-3.66 (m; 6Π), 3.3-3,50 (m, 10H), 2.54 (m, 4H), ).58 (m: 4H), 1-34 (m: 4ΤΪ) ppm, IR (KBr): 3420T 17)1 cm'1 n f例2 雙-[3-(3-羧f基笨基)-4-(2^ -D-咕喃甘露糖基氧)笨 基]己烷,二鈉逋(另一種方法) 步驟1 :將已二醯氱化物(16.8毫升,112毫莫斗)及3-(2-甲氧基笨基)笨乙酸甲基酿(60-9克,225毫莫耳)溶入二氣 甲烷(300毫升)中再於〇°C中冷卻n加入氮化鋁(67,7克’ (韵允¾讀背面之-ΐίι—項再填寫本頁) ,y9 33 本故浪尺度適用中國S客樘準(CNS〉Λ4規格(2[〇Χ2!^公楚) 457246 A7 B7 經濟部中央標準局貝工消費合作社印製 五、發明説明(31) 507毫莫耳),於(TC下攪拌5分鐘然後再加入冰中止反應。 將產物以EtOAc(l公升)萃取,再以水(5〇〇亳升),飽和碳酸 氬鈉水溶液(50毫升),飽和鹽水(50毫升)萃洗。溶液經 Na2S〇4脱水後再通過一層硫酸摸過濾,濃縮後自乙酸/乙 酸乙酯再結晶可得圣,(64·7克,89%)。 步驟2 :將雙-酮1(15克,23.1毫莫耳)溶入熱Et〇Ac/ EtOH(4:1,100毫升)内。結果所產生之溶液經冷卻後再加 入二氟乙fe(l毫升)及皮爾笑催化劑(Pearlman's catalyst, 〇·75克)。將混合物於氫氣氛(50 psi)下振盪1 8小時,然後 再透過一層鐵鋁酸四鈣鹽(celite)過濾。溶液以飽和碳酸氫 鈉水溶液,水’飽和鹽水萃洗後,經MgS04脱水再濃縮。 將甲苯與產物一起蒸發以除去乙酸乙酯,然後再於高眞空 下乾燥可定量地得到1,6-雙-[3-(3-乙氧羰基甲基苯基)_4,甲 氧基苯基]己烷。 步驟3 :將該雙-甲基醚(25_6克,41毫莫耳)溶入二氯甲院 (165毫升)再冷卻至0°C。缓緩加入三溴化硼於二氯甲烷(33 毫升)之溶液,移除冷卻浴之後再將混合物於室溫下攪拌 20分鐘。將反應混合物置於冰浴中冷卻,再於氮氣入口處 安置一根CaCl2乾燥管,然後逐滴加入乙醇(35毫升)。接著 將反應混合物傾入冰上再以乙酸乙酯萃取。將有機物質分 離後’經水’食鹽水萃洗後,再脱水(MgS04)然後減壓濃 縮可得1,6-雙-[3-(3-乙氧羰基甲基苯基)-4-羥基苯基]已烷 (24.2克,100〇/〇)。 步驟4 :將該雙-酚(25.37克,42.7毫莫耳)及四三甲基 -34- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X2,97公釐) (請先閲讀背面之注$項再填寫本頁) ^ 457246 at B7 經濟部中央梂率扃貝工消於合作钍印犁 五、發明説明(32) 乙贐基,tf-L)吡喃甘蕗糖基氟化物(66.4克,128毫莫耳 史考特及T. P.柯甘,於1996年提出之美网專利申請案,標 題11高產率立體專一之甘露糖化f•於二氣甲烷(427毫升)之冰 冷落液遥滴加入BF0E〖2( 47 3毫升,3 84毫莫耳),然後再 將該冰冷溶液攪拌彳小時"涵合物以匕酸乙酯稀釋後再以 水(2 X),氫氧亿鈉(2 M),水及飽和鹽水举洗,經硫酸錢脱 水後再減壓濃縮。經層析純化(矽膠,以己恍/FtOAt: 3ί):1 至6:1之梯度溶離)可得U6-雙-13-(3-乙氧羰基f基苯基)-4-( W -Qr三甲基乙醯基π _〇11比味甘露糠基氧)苯基1己烷(59,8 克,89%)^ 歩驟5 : Α部份:將甲醇(24.4毫汁)加入該雙·糖笛於 +TTHF(24毫升)之溶液内,接著再新鮮製備之甲氡化鈉(由鈉 ,0.5克,22毫莫耳)於甲酵之冰冷溶液加入,然後將混合 物於室溫下攪拌隔夜。以過濾收集沉澱物之後,先以少量 之T1IF/·甲醇洗(2 X),接著再以两酮洗=該固體烷氣化鈉 (6,3克)再進一步經丙酮攬拌後過濾純化。 B部份:將沉澱物於水(27毫升)中室溫下攪拌30分鐘。然 後將pH調整至〗4並於攪拌期問以少量之氫氧化鈉(2 M)維 持於丨4。經過4小時之後以逆相HPLC完成去保護=將溶液 β先經預洗之離子交換樹脂(Dowex ’氣離子型)中和,再 透過一層鐵鋁酸四鈣鹽(cdite)過濾。溶液經冷凍乾燥之後 可得一種稍易吸潮白色粉朱之1,6-雙-[3-(3-羧甲基笨基)-4-(2-a -D吡喃甘露糖基氧)苯基]己烷,二納.鹽(6.0克,90%) ^ m.p.243-245O ; Ή NMR (400 MTIz, D20): 7.64 (s? 2H), -35 - (猗先¾靖背1&之注宏事項再填W本頁) 本紙张尺及通用中剖阄家標-準(CNS )八4炔凇(公绝) 457246 ΑΊ Β7 經濟部中央標準局員工消費合作社印敦 五、發明説明(33 ) 7.58 (d, J=7.7 Hz,2H),7.49 (t,J=7.5 Hz, 2H),7·37 (d,J=8‘4 Hz, 2H), 7.19 (d, J=7.3 Hz, 2H), 7.12 (s? 2H), 7.07 (d, J=8.0 Hz, 2H), 5.66 (s, 2H), 4.27 (s, 2H), 4.00-4.20 (ms 4H), 4.04 (dd,J=12,l及 3.3 Hz, 2H), 3.80-3.92 (m, 6H),3.72 (d,J=9‘2 Hz,2H),2.52 (m, 4H),1.60 (br, 4H),1.39 (br, 4H); 13C NMR (100 MHz, D20) 180.9, 151.5, 138.4, 137.5, 137.4, 132.5, 130.9, 129.1, 129.0, 128.9, 127.3, 117.2, 100.2, 74.2, 70.9, 66.6, 60.9, 45·5, 32.3, 31.6, 29.5;實驗値:57.54% C, 5.98% H,5.12 Na: C46H52016Na2o3H20之計算値:57.50% C, 6.08% H, 4.78 Na 〇 實例3 Μ-雙-[3-(3-羧甲基苯基)-4-(2·π -D-吡喃甘露糖基氧)苯 基]丁烷 步驟1 :將4-(4-甲氧基苯基)丁酸(2.0克,10.3毫莫耳)以 氯化亞硫醯(20毫升)處理。反應於室溫下攪拌3小時之後再 於65°C加熱隔夜,然後減壓濃縮可得黃色油狀物之4-(4-甲 氧基苯基)丁醯氣化物(2.3克),可直接使用而不須進一步 純化。IR (NaCl): 1795, 1510, 1244 cm·1。 將該粗酸氣化物(2.07克,9·7毫莫耳)及甲氧基苯(1.26克 ,11.6毫莫耳)溶入1,2-二氯乙烷(32毫升)中再置入冰浴中 冷卻。混合物以氣化鋁(3,9克,29.1毫莫耳)分數次處理, 攪拌5分鐘,然後再與冰水(50毫升)混合。混合物以二氯甲 燒萃取(3 X 1 〇毫升),萃取液合併後以飽和氯化鈉萃洗, -36- (請先閲讀背面之注意事項再填窝本頁) -訂_ ή· :u;u_: 本紙張尺度適用中國國家標準(CNS ) A4规格(210X297公釐) π 一一一: 457246 A7 B7 五、發明説明(34 ) 脱水(MgS04),然後再減壓濃縮。殘渣以1〇: 1己坑/乙酸乙 酯快速通過矽膠然後再濃縮可得1,4-雙-(甲氧基苯基)丁 _ i _ 酮(2.49 g,82%)。4 NMR (400 MHz, CDC13): 7·90 (d, J=8.8 Hz, 2H), 7.11 (d5 J=8.4 Hz, 2H), 6.91 (d, J=8.8 Hz, 2H), 6.83 (d, J=8.4 Hz, 2H), 3.86 (s, 3H), 3.78 (s, 3H), 2.90 (t,J=7.3 Hz, 2H),2.65 (t,J=7.7 Hz, 2H),2.02 (m,2H) ppm。 IR(NaCl): 1674, 1602, 1244 cm'1 ° 步驟2:將酮(2·49克,8.8亳莫耳)溶入二氯曱烷(30毫升) 再依序以三氟乙酸(2.7毫升,35.2毫莫耳),三乙基矽燒 (2.8毫升,17.6毫莫耳)以及三氟化硼乙醚合物(4.4毫升, 3 5.2毫莫耳)處理。混合物於室溫下撥拌2小時然後再於冰 浴中冷卻並與水(50毫升)混合。混合物以二氯甲烷萃取(3 X 5亳升),有機物質經合併後,以飽和鹽水(1 〇〇毫升)萃洗 並脱水(MgS04),然後減壓濃縮。殘渣以1 〇: 1己烷,乙酸乙 酯快速通過矽膠然後再濃縮可得成澄清油狀物之丨,4_雙_(4_ 甲氧基苯基)丁燒(2.0克,85%)。4 NMR (400 MHz, CDC13): 7.07 (d, J=8.4 Hz, 4H), 6.81 (d, J=8.4 Hz, 4H), 3.78 (s,6H),2.56 (m,4H), 1.61 (m, 4H) ppm。IR (NaCl): 1605, 1248 cm-1 0 經濟部中央標準局貝工消費合阼江中良 步驟3 :將1,4-雙-(4-甲氧基苯基)丁烷(1.78克,6.6毫莫 耳)及TMEDA(4‘0毫升,26.5毫莫耳)與無水乙醚(3〇毫升) 混合再置於冰浴中冷卻。加入正丁基鐘(1〇,5毫升之2.5 Μ 溶液,26·5毫莫耳)後將混合物回溫至室溫並攪拌τ小時。 再將混合物冷卻至0°C再以硼酸三甲基酯(3.〇毫升,26.5毫 -37- 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X:297公釐) 457246 經濟部中央梯準局貝工消費合乍;ϋ .fai A7 B7 五、發明説明(35) 莫耳)處理。混合物於室溫下攪拌隔夜,經加入2N HC1(至 pH 2)中止反應後再攪拌丨小時。有機相經分離後,以乙酸 乙酯萃取水落液(3 χ5毫升)。將萃取液與先前之有機部份 合併並脱水(MgS〇4),然後經減壓濃縮後得可直接使用而 不須純化之硼醯酸(3.0克)。lR (NaC1): 16〇3, 149〇, 1416, 1328, 1234 cm'1 〇 將粗硼醯酸及乙酸3-溴苯基酯(3,8克,16.8毫莫耳)與二 甲氧基乙燒(30毫升)混合並於氮氛下除去空氣。將混合物 以磷酸三鉀(10.7克,50.5毫莫耳)及雙_(三苯基膦)鈀(η)氯 化物(100¾克’ Chl7毫莫耳)處理。將混合物再—次除去空 氣,然後於回流下加熱2小時,接著冷卻至室溫並與水 (100毫升)混合。將混合物以二氯甲烷萃取(3 χ 1〇毫升)並 合併萃取液,經水(5〇毫升),飽和氣化鈉(5〇毫升)萃洗, 脱水(MgS04)後再減壓濃縮。殘渣以快速層析法純化(Si〇2 ’梯度溶離,8:1己烷/乙酸乙酯至4:1己烷/乙酸乙酯)可得 澄清油狀物之1,4-雙-[3-(3-曱氧羰基甲基苯基)(4-甲氧基) 苯基]丁烷(1.14g,24%)。iHNMROOOMHz, CDC13): 7.41-7.44 (m, 4H), 7.34 (t, J=7.7 Hz, 2H), 7.21-7.60 (m, 2H), 7.08-7.13 (m, 4H), 6.87 (d, J=8.0 Hz, 2H), 3.77 (s, 6H), 3.68 (s, 6H),3.66 (s, 4H), 2.61 (m» 4H), 1·67 (m, 4H) ppm。IR (NaCl): 1737, 1606, 1239 cm.1。 步驟4 :將1,4-雙-[3-(3-甲氧羰基曱基苯基)(4-甲氧基)苯 基]丁烷(0.9克,1.6毫莫耳)溶於二氣甲烷(3.0毫升〉,於乾 冰浴中冷卻,再以三溴化硼(1.2毫升,12.8毫莫耳)處理。 -38- 本纸張A度適用中國國家標準(CNS ) A4規格(210X297公釐) ---:---;-----VW衣-- (請先聞讀背面之注意事項再填寫本頁) 訂 • H— - —^1 457246 A7 B7 經濟部中央標準局員工消費合作社印裂 五、發明説明(36) 將混合物於-78°C攪拌3小時再置於-lot之冷凍櫃隔夜。加 入冰水(10毫升)中止反應 <,再以二氣甲烷萃取(3 χ 5毫升) 。有機物質合併後,經水(25毫升),飽和氯化鈉(25毫升) 萃洗,脱水(MgS〇4)然後再減壓濃縮。殘渣以快速層析法 純化(Si〇2,5:1己烷/乙酸乙酯)可得1‘雙-[3_(3_甲氧羰基 甲基笨基)-4-羥基苯基]丁烷(〇 4克,47%)。iH NMR (400 MHz, CDC13): 7.42 (d, J=7.4 Hz, 2H), 7.35-7.38 (m, 4H), 7.27-7.32 (m, 2H)} 7.02-7.05 (m, 4H), 6.87 (d, J=8.0 Hz, 2H), 5.12 (s5 2H), 3.70 (s5 6H), 3.68 (s, 4H), 2.59 (m, 4H), 1.65 (m, 4H) ppm ° IR (NaCl): 3439, 1732, 1606, 1263 cm'1 〇 步驟5 :將1,4-雙-[3_(3_甲氧羰基甲基苯基)_4_幾基苯基] 丁烷(〇_4克,0.74毫莫耳)及々_D-甘露糖五乙酸酯(0.72克, 1.85毫莫耳)溶入1,2-二氯乙烷(4·〇毫升)中,然後以三氟化 硼乙醚合物(1.1毫升,8.9毫莫耳)處理。將混合物於室溫 下攪拌隔夜然後再加入水(10毫升)中止反應,再以二氯甲 烷萃取水溶液(3 X 4毫升)。將有機物質合併,先經水(15毫 升),飽和氣化鈉(20毫升)萃洗,.脱水(MgS〇4)後再減壓濃 縮。將殘渣以快速層析法(Si〇2,2:2己烷/乙酸乙酯)純化可 得泡沫狀之M-雙-[3-(3-甲氧羰基甲基苯基)-4-(2,3,4,6-四-2_-乙驢基比喃甘露糖基氧)苯基]丁嫁(0.88克,99%) 。]H NMR (400 MHz, CDC13): 7.38-7.44 (m, 6H), 7.25-7.29 (m, 2H), 7.17 (br s, 2H), 7.07-7.11 ((ms 4H), 5.40 (s, 2H), 5,20-5.30 (m, 6H),4.15 (dd,J=12.3, 4.8 Hz, 2H), 3.93 (dd, J=12.4, 2.2 Hz, 2H)? 3.76-3.82 (m, 2H), 3.72 (s, 4H), 3.68 (s, -39- (請先聞讀背面之注意事項再填寫本頁) -IL. '裝· 訂_ :π :.11 本紙張尺度適用中圏國参標準(CNS ) A4規格(210x297公釐) 457246 第85II5086號專利申請案 t文說明書修正頁(S9年7月) 五、發明説明( 37 !ϊ 正 補充 m 6H), 2.63 (m, 4H), 2.13 (s, 6H), 2.01 (s, 6H), 2.00 (s, 6H), 1.97 (s,6H),lj7 (m,4H) ppin。iR (NaCl): 1748, 1219 cm·1。 步驟6 :該6基酯(0.87克,0.73毫莫耳)溶入乙腈(3毫井) 中’再以氫氧化鋰單水合物(0.46克,11毫莫耳於2毫升水) 之水溶液處理,接著將混合物於室溫下攪拌隔夜。經滅歷: 除去溶劑再以濃鹽酸將其酸化至pH 2。將一部份混合物以 逆相HPLC純化(C18,以45分鐘進行20-80%乙腈於水之梯度 溶離,以254 nm監控)可得白色固體之M-雙-[3-(3-羧甲基 苯基)-4-( α-D-吡喃甘露糖基氧)苯基]丁烷(230毫克),m.p.: 195-197。。。lH NMR (400 MHz, DMSO-d6): 7.31-7.39 (m, 6H), 6.20-7.25 (m, 4H), 7.10-7.15 (m, 4H), 5.25 (s, 2H), 4.88 (br d, J=4.0 Hz, 2H), 4.76 (bT ss 2H), 4.60 (br s, 2H), 4.45 (br t, J=5.9 Hz, 2H), 3.55-3.68 (m, 5H), 3.62 (s, 4H), 3.40-3.50 (m, 7H), 2.60 (m,,4H), 1.62 (m, 4H) ppm。IR (KBr): 3333,3229, 1729,1224 cm·1。實驗值:61.3% C,6.15% H: C44H5〇016.〇.4 TFA之計算值 > 61.32% C, 5.79% H。 實例4 N,N,-雙-[4-(3-羧甲基笨基)-4-(α -D-吡喃甘露糖基氧)苯基] 丁-1-醯基]-4,4匕三亞甲基六氫峨 Ί.·;二 . _ · · . ·' 經濟部中央標隼局員工消費合作社印裝 步驟1 ··琥珀酸酐(2.0克,19.9毫莫耳)及氯化銘(17.7克’ 132毫莫耳)與1,2-二氣乙烷(45毫升)混合後置於冰浴上冷 卻。將混合物以3-(2-(2,3,4,6-四三甲基乙酿基_ α 比 喃甘露糖基氧)苯基]苯基乙酸乙酯(10.0克,132毫莫耳)於 二氣乙烷(10毫升)中之溶液處理’接著將水浴溫度徐徐回溫 -40 - 本紙張尺度適用中國國家標準(CNS ) A4規梢·(210X297公釐) Λ7 B7 457246 第Ml 15686竑專利申請案 中文說明I修王頁(的年7月) 五、發明説明() 38457246 Α7 Β7 V. Description of the invention (29) Subtracting I and concentrating to obtain 1 (1.6 g, 91%) D iR (NaCl): 1713 cm · 1. Step 3: Part A: The diacid (L6 g, 2.8 moles) obtained in step 2, part B is dissolved in dichloromethane (14 ml) in nitrophene, and then placed on dry ice / 2-propane Cool in the bath. Slowly add boron tribromide (1 ΛmL, 14 mmol); the mixture is stirred at room temperature for 2 hours, and then mixed with ice-water (25mL) = after the organic matter is separated, it is shaved and carbonic acid Aqueous hydrogen solution (20 ml), water (20 ml), saturated brine (20 ml), washed and dehydrated (MgS04) and concentrated under reduced pressure to 5 Γ to obtain 2.38 g of crude product = part B: from part A The obtained residue was strictly combined with methanol (50 liters), sulfuric acid (5 drops) was added to the mixture, and the mixture was heated to reflux temperature overnight, and then concentrated under reduced pressure. The residue was dissolved in methane (50 ml) and treated with sodium carbonate, and then filtered through a layer of silica gel. The filtrate was concentrated under reduced pressure. The residue was subjected to flash chromatography (Si02, from hexane to 3: 1 hexane / ethyl acetate). Ester gradient dissociation) purification of 1,6-bis- (3- (3-foxycarbonylmethylbenzylM-lightbenzyl) hexane (0.9 g, 38%). H NMR (400 MHz. , CDC13): 6.BO-7.50 (m, 14H), 3.70 (s, 6H), 3,68 (S. 4H). 2.55 (dd, J = 5, S, 5,5 Hz, 4H), 1.59 (m, 4H), 1.36 (m, 4H) ppm ^ 1R (NaCl): 3430, 1731 cm'J ^ Miscellaneous death of the Ministry of Economic Affairs and Economic Cooperation ^ Wac Industry and Consumer Cooperation Du Yingan I —l · --_ n I n I ^ ^ -I (Xu Xianyi Wen # 1 & Note '£ _item again ^ this page) Step 4: 1,6 · bis- (3- (3-methoxycarbonylmethylbenzyl) -4 -Hydroxybenzyl) hydrazone (0.9 g, 1,6 mmol) dissolved in 1,2-digas ethane (8 ml) β-Ammonium D-mannose pentaacetate (1.9 g τ 4.8 mmol) Mol) was added in one portion, then boron trifluoride etherate (2,5 ml f 19,2 mmol) was slowly added. The mixture was stirred overnight at room temperature under a nitrogen atmosphere, and then water (5 After separating organic matter in ml The extraction aqueous solution (3 x 2 ml) was made with two gas T. The apple extract was combined with the original organic part, and dehydrated after dehydration, and the pressure was reduced to 7 waves. -32- KJlii Ke in this paper {CNS ) A4 Tag (2ί〇 × 297mm) Printed by the Industrial and Commercial Bureau of the Ministry of Economic Affairs, China Industrial Cooperative Cooperative 4 5 7 2 4 6 A7 B7 V. Description of the invention (30) Shrink. The residue is subjected to flash chromatography ( s 丨 〇2 'From hexadecimal to 3: hexadecyl hexanoate hexanoate gradient dissociation) purification can be obtained 丨 = 6-bis- (3__oxanylmethylphenyl) -4 (forty-ethyl Base-finding-many mannosyl) oxy group base has been wan * (1.5 S f 77%) ^ II NMR (400 ΜΠζ, CDC13): 7.31-7.3 ^ (m, 6n) s 7.19- 7.24 (m, 4H), 7.09-7.13 (m, 4H), 5.25 (d: J-0.6 Hz, 2H), 3.57-3.66 (m, 6H), 3,3-3.50 (m; 10H), 2, 54 (m, 4H) f l.5fi (m, 4II) fl, 34 (m: 4H) jppm. TR (NaCl): 1752 cm · 1. Step 5: Saccharin (1.5 g, 1.2 mols) were dissolved in acetonitrile < 6 ml), and then treated with an aqueous solution of lithium hydroxide monohydrate (1.0 g ^ 24 mmol) in water (10 ml), and the mixture was transferred at Xuan temperature Overnight It was acidified to pH 2 u with concentrated hydrochloric acid, and the mixture was concentrated under reduced pressure, and then purified by HPLC (reverse phase, gradient dissolution with 5-50% acetonitrile in water '> 乂 254 nm monitoring) to obtain a white solid. , 6-bis- (3- (3-kismethylphenyl) -4- (2wL > pyranosyloxy.) Phenyl J hexane, hydrazone, (0'35g, 33%), m. p: 115-1 I7'C:! H NMR (400 MHz, CDCl3): 7.31-7.37 (m, 6H), 7.19-7.24 (m, 4H); 7.09-7.13 (m7 4H), 5.25 (d, J ^ 0.6 Hz, 2H)? 3,57-3.66 (m; 6Π), 3.3-3,50 (m, 10H), 2.54 (m, 4H),) .58 (m: 4H), 1-34 (m : 4ΤΪ) ppm, IR (KBr): 3420T 17) 1 cm'1 nf Example 2 Bis- [3- (3-carboxyf-based benzyl) -4- (2 ^ -D-grumannosyloxy) Benzyl] hexane, disodium sulfonium (another method) Step 1: Diethyl ether (16.8 ml, 112 mmol) and methyl 3- (2-methoxybenzyl) benzylacetate ( 60-9 grams, 225 millimoles) dissolved in methane (300 milliliters) and cooled at 0 ° C n added aluminum nitride (67,7 grams' (Yun Yun ¾ read the back of -ΐίι-Xiang Zai) (Fill in this page), y9 33 This original wave standard is applicable to China S passenger standard (CNS> Λ4 specifications (2 [〇Χ2! ^ 公 楚) 457246 A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the Invention (31) 507 millimoles), stir at (TC for 5 minutes and then add ice to stop the reaction. The product was extracted with EtOAc (1 liter) and then washed with water (500 liters), saturated aqueous sodium bicarbonate solution (50 ml), and saturated brine (50 ml). The solution was dehydrated with Na2SO4 and filtered through a layer of sulfuric acid. After concentration, it was recrystallized from acetic acid / ethyl acetate to obtain saint, (64 · 7 g, 89%). Step 2: Dissolve bis-ketone 1 (15 g, 23.1 mmol) into hot EtoAc / EtOH (4: 1, 100 ml). As a result, the resulting solution was cooled and then added with difluoroethylene fe (1 ml) and Pearlman's catalyst (0.75 g). The mixture was shaken under a hydrogen atmosphere (50 psi) for 18 hours, and then filtered through a layer of celite. The solution was extracted and washed with a saturated aqueous solution of sodium bicarbonate and water'saturated brine, and then dehydrated with MgS04 and concentrated. Toluene was evaporated with the product to remove ethyl acetate, and then dried under high vacuum to quantitatively obtain 1,6-bis- [3- (3-ethoxycarbonylmethylphenyl) _4, methoxyphenyl ] Hexane. Step 3: Dissolve the bis-methyl ether (25-6 g, 41 mmol) in dichloromethane (165 ml) and cool to 0 ° C. Slowly add a solution of boron tribromide in dichloromethane (33 mL), remove the cooling bath and stir the mixture at room temperature for 20 minutes. The reaction mixture was cooled in an ice bath, a CaCl2 drying tube was placed at the nitrogen inlet, and ethanol (35 ml) was added dropwise. The reaction mixture was then poured onto ice and extracted with ethyl acetate. Organic matter is separated and extracted with 'water' brine, then dehydrated (MgS04) and concentrated under reduced pressure to obtain 1,6-bis- [3- (3-ethoxycarbonylmethylphenyl) -4-hydroxyl Phenyl] hexane (24.2 g, 100/0). Step 4: The bis-phenol (25.37 g, 42.7 mmol) and tetratrimethyl-34- This paper size applies the Chinese National Standard (CNS) A4 specification (210X2, 97 mm) (Please read the back Note $ item and fill out this page again) ^ 457246 at B7 Central Ministry of Economics and Economics Co., Ltd. Cooperate in Printing Co., Ltd. V. Inventory Description of the Invention (32) Acetyl, tf-L) Pyranoglycosyl fluoride ( 66.4 grams, 128 millimolar Scott and TP Cogan, US Open patent application filed in 1996, titled 11 High-yield stereospecific mannose saccharification f • Remote dripping of ice-cold methane (427 ml) Add BF0E 2 (47 3 ml, 3 84 mmol), and then stir the ice-cold solution for 彳 hours " after diluting the conjugation with ethyl dicarboxylate and then water (2 X), sodium hydroxide ( 2 M), water and saturated saline are lifted and washed, dehydrated with sulfuric acid, and concentrated under reduced pressure. Purified by chromatography (silica gel, dissolved in a gradient of hexane / FtOAt: 3ί): 1 to 6: 1 to obtain U6- Bis-13- (3-ethoxycarbonyl f-phenylphenyl) -4- (W-Qr trimethylethylfluorenyl π — 〇11 than mannan furfuryloxy) phenyl 1 hexane (59,8 g, 89%) ^ Step 5: Part A Methanol (24.4 milligrams) was added to the solution of this double sugar cane in + TTHF (24 mL), and then freshly prepared sodium formazan (from sodium, 0.5 g, 22 millimoles) was cooled in formazan The solution was added and the mixture was stirred at room temperature overnight. After the precipitate was collected by filtration, it was first washed with a small amount of T1IF / methanol (2X), and then washed with two ketones = the solid sodium alkane gas (6,3 g), and then stirred and purified by acetone. Part B: Stir the precipitate in water (27 ml) at room temperature for 30 minutes. Then adjust the pH to 4 and keep it at 4 with a small amount of sodium hydroxide (2 M) during the stirring period. After 4 hours, deprotection was completed by reverse-phase HPLC = the solution β was first neutralized with pre-washed ion exchange resin (Dowex 'gas ion type), and then filtered through a layer of tetracalcium iron aluminate (cdite). After the solution was freeze-dried, a slightly hygroscopic white powder Zhu Zhi 1,6-bis- [3- (3-carboxymethylbenzyl) -4- (2-a-D-pyranosyloxy) was obtained. Phenyl] hexane, dina. Salt (6.0 g, 90%) ^ 243-245O; Ή NMR (400 MTIz, D20): 7.64 (s? 2H), -35-(猗 先 ¾ 靖 背 1 & Note the macro items and fill in this page again.) This paper ruler and the universal mid-profile family standard-quasi (CNS) eight 4 acetylene (public absolute) 457246 ΑΊ Β7 Employees' Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. (33) 7.58 (d, J = 7.7 Hz, 2H), 7.49 (t, J = 7.5 Hz, 2H), 7.37 (d, J = 8'4 Hz, 2H), 7.19 (d, J = 7.3 Hz, 2H), 7.12 (s? 2H), 7.07 (d, J = 8.0 Hz, 2H), 5.66 (s, 2H), 4.27 (s, 2H), 4.00-4.20 (ms 4H), 4.04 (dd, J = 12, l and 3.3 Hz, 2H), 3.80-3.92 (m, 6H), 3.72 (d, J = 9'2 Hz, 2H), 2.52 (m, 4H), 1.60 (br, 4H), 1.39 (br, 4H); 13C NMR (100 MHz, D20) 180.9, 151.5, 138.4, 137.5, 137.4, 132.5, 130.9, 129.1, 129.0, 128.9, 127.3, 117.2, 100.2, 74.2, 70.9, 66.6, 60.9, 45 5, 32.3, 31.6, 29.5; Experiment 値: 57.54% C, 5.98% H, 5.12 Na: C46H52016Na2o3H20 Calculated 値: 57.50% C, 6.08% H, 4.78 Na 〇 Example 3 M-bis- [3- (3-carboxymethylphenyl) -4- (2 · π-D-pyranosyloxy) benzene Butyl] butane Step 1: 4- (4-methoxyphenyl) butanoic acid (2.0 g, 10.3 mmol) was treated with thionyl chloride (20 ml). The reaction was stirred at room temperature for 3 hours, and then heated at 65 ° C overnight, and then concentrated under reduced pressure to obtain 4- (4-methoxyphenyl) butanium vapor (2.3 g) as a yellow oil. Used without further purification. IR (NaCl): 1795, 1510, 1244 cm · 1. This crude acid gaseous product (2.07 g, 9.7 mmol) and methoxybenzene (1.26 g, 11.6 mmol) were dissolved in 1,2-dichloroethane (32 ml) and then placed in ice. Cool in the bath. The mixture was partially treated with vaporized aluminum (3,9 g, 29.1 mmol), stirred for 5 minutes, and then mixed with ice water (50 ml). The mixture was extracted with dichloromethane (3 X 10 ml), and the extracts were combined and washed with saturated sodium chloride, -36- (Please read the precautions on the back before filling this page) -Order_ Price ·: u; u_: This paper size is in accordance with Chinese National Standard (CNS) A4 (210X297 mm) π one by one: 457246 A7 B7 V. Description of the invention (34) Dehydration (MgS04), and then concentrated under reduced pressure. The residue was quickly passed through silica gel at 10: 1 hexane / ethyl acetate and then concentrated to obtain 1,4-bis- (methoxyphenyl) buti-one (2.49 g, 82%). 4 NMR (400 MHz, CDC13): 7.90 (d, J = 8.8 Hz, 2H), 7.11 (d5 J = 8.4 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 3.86 (s, 3H), 3.78 (s, 3H), 2.90 (t, J = 7.3 Hz, 2H), 2.65 (t, J = 7.7 Hz, 2H), 2.02 (m, 2H) ppm. IR (NaCl): 1674, 1602, 1244 cm'1 ° Step 2: Dissolve the ketone (2.49 g, 8.8 mol) into dichloromethane (30 ml) and then sequentially with trifluoroacetic acid (2.7 ml , 35.2 mmol), triethylsilicon (2.8 ml, 17.6 mmol) and boron trifluoride etherate (4.4 ml, 3 5.2 mmol). The mixture was stirred at room temperature for 2 hours and then cooled in an ice bath and mixed with water (50 ml). The mixture was extracted with dichloromethane (3 x 5 ml), and the organic materials were combined, washed with saturated brine (100 ml) and dehydrated (MgSO4), and then concentrated under reduced pressure. The residue was quickly passed through silica gel with 10: 1 hexane and ethyl acetate and then concentrated to obtain a clear oily substance, 4-bis- (4-methoxyphenyl) butane (2.0 g, 85%). 4 NMR (400 MHz, CDC13): 7.07 (d, J = 8.4 Hz, 4H), 6.81 (d, J = 8.4 Hz, 4H), 3.78 (s, 6H), 2.56 (m, 4H), 1.61 (m , 4H) ppm. IR (NaCl): 1605, 1248 cm-1 0 Shellfish Consumption by Central Standards Bureau of the Ministry of Economic Affairs Hezhong Jiangliang Step 3: Put 1,4-bis- (4-methoxyphenyl) butane (1.78 g, 6.6 milligrams) Mol) and TMEDA (4'0 mL, 26.5 mmol) were mixed with anhydrous ether (30 mL) and cooled in an ice bath. After adding n-butyl bell (1,5 ml of 2.5 M solution, 26.5 mmol), the mixture was warmed to room temperature and stirred for τ hours. Then the mixture was cooled to 0 ° C, and then trimethyl borate (3.0 ml, 26.5 mmol-37- This paper size is applicable to China National Standard (CNS) A4 (210X: 297 mm) 457246 Central Ministry of Economic Affairs Tizhan Bureau shellfish consumption is right; ϋ .fai A7 B7 V. Invention description (35) Moore). The mixture was stirred at room temperature overnight, and the reaction was stopped by the addition of 2N HC1 (to pH 2), followed by stirring for 丨 hours. After the organic phase was separated, the aqueous solution was extracted with ethyl acetate (3 x 5 ml). The extract was combined with the previous organic portion and dehydrated (MgSO4), and then concentrated under reduced pressure to obtain boronic acid (3.0 g) which was used directly without purification. lR (NaC1): 16〇3, 149〇, 1416, 1328, 1234 cm'1〇 Crude boronic acid and 3-bromophenyl acetate (3,8 g, 16.8 mmol) and dimethoxy Ethane (30 ml) was mixed and the air was removed under a nitrogen atmosphere. The mixture was treated with tripotassium phosphate (10.7 g, 50.5 mmol) and bis- (triphenylphosphine) palladium (η) chloride (100¾ g'Chl7 mmol). The mixture was de-aired once more, then heated under reflux for 2 hours, then cooled to room temperature and mixed with water (100 ml). The mixture was extracted with dichloromethane (3 x 10 ml) and the extracts were combined, washed with water (50 ml), saturated sodium vaporized (50 ml), dehydrated (MgSO4) and concentrated under reduced pressure. The residue was purified by flash chromatography (SiO 2 'gradient separation, 8: 1 hexane / ethyl acetate to 4: 1 hexane / ethyl acetate) to obtain 1,4-bis- [3 as a clear oil. -(3-fluorenyloxymethylphenyl) (4-methoxy) phenyl] butane (1.14 g, 24%). iHNMROOOMHz, CDC13): 7.41-7.44 (m, 4H), 7.34 (t, J = 7.7 Hz, 2H), 7.21-7.60 (m, 2H), 7.08-7.13 (m, 4H), 6.87 (d, J = 8.0 Hz, 2H), 3.77 (s, 6H), 3.68 (s, 6H), 3.66 (s, 4H), 2.61 (m »4H), 1.67 (m, 4H) ppm. IR (NaCl): 1737, 1606, 1239 cm.1. Step 4: Dissolve 1,4-bis- [3- (3-methoxycarbonylfluorenylphenyl) (4-methoxy) phenyl] butane (0.9 g, 1.6 mmol) in methane gas. (3.0 ml), cooled in a dry ice bath, and then treated with boron tribromide (1.2 ml, 12.8 mmol). -38- The A degree of this paper applies the Chinese National Standard (CNS) A4 specification (210X297 mm) ---: ---; ----- VW clothing-- (Please read the precautions on the back before filling out this page) Order • H —-— ^ 1 457246 A7 B7 Employee Consumer Cooperatives, Central Standards Bureau, Ministry of Economic Affairs 5. The description of the invention (36) The mixture was stirred at -78 ° C for 3 hours and then placed in a -lot freezer overnight. The reaction was stopped by adding ice water (10 ml), and then extracted with methane (3 x 5 ml). After combining the organic materials, it was extracted and washed with water (25 ml), saturated sodium chloride (25 ml), dehydrated (MgS04) and concentrated under reduced pressure. The residue was purified by flash chromatography (Si02). , 5: 1 hexane / ethyl acetate) to obtain 1'bis- [3- (3-methoxycarbonylmethylbenzyl) -4-hydroxyphenyl] butane (0.4 g, 47%). IH NMR (400 MHz, CDC13): 7.42 (d, J = 7.4 Hz, 2H), 7.35-7. 38 (m, 4H), 7.27-7.32 (m, 2H)} 7.02-7.05 (m, 4H), 6.87 (d, J = 8.0 Hz, 2H), 5.12 (s5 2H), 3.70 (s5 6H), 3.68 (s, 4H), 2.59 (m, 4H), 1.65 (m, 4H) ppm ° IR (NaCl): 3439, 1732, 1606, 1263 cm'1 〇 Step 5: Put 1,4-double- [3_ ( 3-Methoxycarbonylmethylphenyl) _4-Chlorylphenyl] butane (0.4 g, 0.74 mmol) and 々D-mannose pentaacetate (0.72 g, 1.85 mmol) Dissolved in 1,2-dichloroethane (4.0 ml) and treated with boron trifluoride etherate (1.1 ml, 8.9 mmol). The mixture was stirred at room temperature overnight and then water was added. (10 ml) to stop the reaction, and then extract the aqueous solution (3 x 4 ml) with dichloromethane. Combine the organic materials, first wash with water (15 ml), saturated sodium gaseous (20 ml), and dehydrate (MgS. 4) and then concentrated under reduced pressure. The residue was purified by flash chromatography (SiO2, 2: 2 hexane / ethyl acetate) to obtain M-bis- [3- (3-methoxycarbonylmethyl) in the form of a foam. Phenyl) -4- (2,3,4,6-tetra-2_-ethynylpyranosyloxy) phenyl] butane (0.88 g, 99%). ] H NMR (400 MHz, CDC13): 7.38-7.44 (m, 6H), 7.25-7.29 (m, 2H), 7.17 (br s, 2H), 7.07-7.11 ((ms 4H), 5.40 (s, 2H ), 5,20-5.30 (m, 6H), 4.15 (dd, J = 12.3, 4.8 Hz, 2H), 3.93 (dd, J = 12.4, 2.2 Hz, 2H)? 3.76-3.82 (m, 2H), 3.72 (s, 4H), 3.68 (s, -39- (Please read the precautions on the reverse side before filling out this page) -IL. 'Binding · Order_: π: .11 This paper size is subject to the Chinese standard (CNS) A4 Specification (210x297 mm) 457246 Patent Application Specification No. 85II5086 Revised Sheet (July S9) V. Description of the Invention (37! Ϊ Positive supplement m 6H), 2.63 (m, 4H), 2.13 (s, 6H), 2.01 (s, 6H), 2.00 (s, 6H), 1.97 (s, 6H), lj7 (m, 4H) ppin. iR (NaCl): 1748, 1219 cm · 1. Step 6: The 6-based ester (0.87 g, 0.73 mmol) was dissolved in acetonitrile (3 mmol) and then treated with an aqueous solution of lithium hydroxide monohydrate (0.46 g, 11 mmol in 2 ml of water). The mixture was stirred at room temperature overnight. After extinction: the solvent was removed and acidified to pH 2 with concentrated hydrochloric acid. A portion of the mixture was purified by reverse-phase HPLC (C18, 20-80% acetonitrile over 45 minutes). Gradient dissolution in water, monitored at 254 nm) M-bis- [3- (3-carboxymethylphenyl) -4- (α-D-mannanyloxy) phenyl] as a white solid] Butane (230 mg), mp: 195-197 ... lH NMR (400 MHz, DMSO-d6): 7.31-7.39 (m, 6H), 6.20-7.25 (m, 4H), 7.10-7.15 (m, 4H), 5.25 (s, 2H), 4.88 (br d, J = 4.0 Hz, 2H), 4.76 (bT ss 2H), 4.60 (br s, 2H), 4.45 (br t, J = 5.9 Hz, 2H) , 3.55-3.68 (m, 5H), 3.62 (s, 4H), 3.40-3.50 (m, 7H), 2.60 (m, 4H), 1.62 (m, 4H) ppm. IR (KBr): 3333, 3229 , 1729, 1224 cm · 1. Experimental value: 61.3% C, 6.15% H: C44H Calculated value of 0016.0.4 TFA > 61.32% C, 5.79% H. Example 4 N, N, -bis- [4- (3-carboxymethylbenzyl) -4- (α-D-pyranosyloxy) phenyl] but-1-fluorenyl] -4,4 Trimethylene hexahydroemei. ·; 2. _ · ·. · 'Step of printing by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 1 ·· Succinic anhydride (2.0 g, 19.9 mmol) and chlorinated name ( 17.7 g (132 mmol) and 1,2-digas ethane (45 ml) were mixed and cooled on an ice bath. The mixture was treated with 3- (2- (2,3,4,6-tetratrimethylethyl) -α-mannanyloxy) phenyl] phenylacetate (10.0 g, 132 mmol) Treatment of the solution in digas ethane (10 ml) 'The temperature of the water bath is slowly returned to -40-This paper size applies to Chinese National Standard (CNS) A4 gauge · (210X297 mm) Λ7 B7 457246 Article Ml 15686 竑Chinese Instructions for Patent Application I Revise King Page (July of Year) 5. Description of Invention () 38
\ I — - - . . · _· j 到室溫之下,將渌合物攪掉隔夜。將反應物與冰水(1 00毫 升)混合1再攪拌15分鐘》分離出有機物質,再以二氣甲虼 (3 X 5毫升)萃取水層部份u將有機物質合併t脫水(MgS〇4) 後·再減壓·:農縮’得可直換使用而無須純化之辽(13.5克)3 IK (NaCl): 1738, 1685, 1228 cm'1 - 步驟2 :將酸(ϋ_) (13_5克,19.7毫莫耳)溶於二氣甲烷(65 毫升)中,再以三氟化硼乙醚合物(15.3毫升,122毫莫耳)處 理。然後以三氟乙酸(9.4毫升,122毫莫耳)處理。:¾合物 以三乙基矽烷(9.4毫升,59.1毫莫耳)處理,再於室溫下攪 掉隔夜’將反應物與水(200毫井)混合τ然後分離出有機物 質。以二氯甲玟(3 X 10毫升)萃取水層部份,將萃取物與原 先的有機部份合併,脫水(MgS04)後再減壓濃縮,可得為 澄清油之4-(3-(3-乙氧羰基甲基笨基)-4-(273,4,6-四·α·三f 基乙醯基-α-D-吡喃甘露糖基氣)苯基]丁坑(丄2) (1_49克, 97%) » IR (NaCl): 1737, 1 132 cm*1 - 步驟3 :將酸UJ16.0克,:Ϊ3.8毫莫耳)以氣化亞硫醯(50毫 升)處理•再將混合物於室溫下攪拌3 6小時,然覘減壓濃縮 得可直接使用而無須純化之酸氣化物1£_(16.3克,99%)。IR (NaCl): 2974, 1797, 1740,Π35 cm-1 ° 步驟4 :將474__三亞甲基二六氬吡啶(0.4克,1.9毫莫耳)於 二氣甲烷(5毫升)中之溶液,於0°C加入酸氣化物K2.S 克f 3.26毫莫斗)於二氣甲故(5毫升)中之溶液争3加入三乙 基胺(0.61毫升,4.4毫莫耳)4-二T基胺基吡啶(35毫克1 L0 莫耳%),再將混合物於室溫下摱拌丨小時,然後與水(2 〇 41 - 本紙張疋度通用中®®家榫率(CNS ) A4規格ί 210x29?公韙) ^^1 In J- - - - - ^A"^.^11 - - - - ί - - ^^^1 ; ^ (汴先梵請背面之注意事項再填寫本頁) 维濟部中丧樣乘扃員工消貧合伟社印1S- A 7 B7 457246 第SSI 15邮6號專利申請案 令文說明莘脩土瓦(的年7月) 五 '發明説明() 丨丨修 毫升)混合。將有機物質經飽和氣化鉀(20毫升)萃洗,脫水 (MgS〇4)後丹減恩濃縮。殘造以快速層析法(Si02,2:1己酸 乙酯./己烷)純化可得雙醯胺g * IS%) ^ NMR (400 CDClj): 7,40-7.45 (m, 4HJ, 6.98-7,30 (m, l〇H)( 5.25-5.42 (m. 6H), 4.09-4 19 (m, 4H), 3.50-3.96 (m, 8H), 2.62-2,69 (m, 4H), 2.28-2,36 (m, 4H), 1.90-2.02 (m, 4H)f 1.60-1.74 (m, 6H), 1.35-1.50 (m, 2H), 1,24 (ϋ, 18H), t.ij (s, 18H), 1.11 (s, 36H), 1.08-1.28 (m, 26H) - IR (NaCl): 1739 cm'1 ^ 步驟5 :將雙醯胺克i 0.54毫莫耳)溶於THF (3毫升) t,再以氫氧化鈉(0.40克,10毫莫耳,於3毫升水_)水溶 液處理。將混合物於室溫下攪拌隔夜,減壓除去THF,殘 渣經濃盪酸酸化至pH 2,再以逆相HPLC純化得白色固體之 Ν,Ν1·雙_[4-(3-(3 +羧甲基苯基)-4-( a,D·甘露糖苷基氧基)苯 基)丁- I-遮基]4,4·-三亞甲基二六氣p比咬(17、(3 0 mg,5 %), m.p:119-mgC-1HNMR(400 MHz,DMSO-<i6):7.32_ 7.40 (m7 6H), 7.20-7.27 (m. 4H), 7.10-7.14 (m, 4H), 5,26 (br s( 2H)f 4.36 (br d, J=U Hz, 2H)S 4.05 (br s, 8H), 3.77 (br d, J=U Hz, 2H), 3.50-3.70 (mf 8H), 3.40-3,52 (m7 5H), 3.31-3.40 (m, 2H), 2.92 (br t, J=l4 Hi, 2H), 2.55-2.62 (m, 4H); 2 42-2.53 (m, 3H), 2.27^2.34 (m, 4H), 1.73-1.82 (mt 4H), 1.57-1,67 (m, 4H), 1.36-Γ47 (m, 2H)T 1.22- 1,33 (m, 2H), 1.11-L20 (m, 4H)f 0.80-1.02 (m, 4H) a IR (KBr): 3415,IM3,1609 cm]。iViS (FAB): 1150 (M + + Na卜分析: C61H78N2Oia“.4 TFA: 59.54% C,6 22% H, 2.18¼ N ° 實驗植: -42- 本呔张尺度通用tSSI家標準(CMS ) A4規洛(.公麾) — 11 -----.―F ί I ^ 装------ - - ----- (诗先《請背面之;:i意事項再琪宵本莨)\ I —--.. · _ · J Let the mixture stir overnight at room temperature. The reaction was mixed with ice water (100 ml) for 1 minute and stirred for 15 minutes. The organic matter was separated, and the aqueous layer was extracted with dichloromethane (3 x 5 ml). The organic matter was combined and dehydrated (MgS. 4) Post-decompression: Liaoning's Deco can be used directly without purification (13.5 g) 3 IK (NaCl): 1738, 1685, 1228 cm'1-Step 2: Acid (ϋ_) ( 13_5 g, 19.7 mmoles) were dissolved in methane (65 ml) and treated with boron trifluoride etherate (15.3 ml, 122 mmoles). It was then treated with trifluoroacetic acid (9.4 ml, 122 mmol). : Compound was treated with triethylsilane (9.4 ml, 59.1 mmol) and stirred overnight at room temperature. The reaction was mixed with water (200 mmol) and then organic matter was separated. Dichloromethane (3 X 10 ml) was used to extract the aqueous layer portion, the extract was combined with the original organic portion, dehydrated (MgS04), and then concentrated under reduced pressure to obtain 4- (3- ( 3-ethoxycarbonylmethylbenzyl) -4- (273,4,6-tetra · α · trifylethylfluorenyl-α-D-pyranosyl) phenyl] butyl ) (1_49 g, 97%) »IR (NaCl): 1737, 1 132 cm * 1-Step 3: Acid UJ (16.0 g, Ϊ: 3.8 mmol) to vaporize thionine (50 ml) Treatment • The mixture was stirred at room temperature for 3 6 hours, and then concentrated under reduced pressure to obtain an acid gas which can be used directly without purification 1 £ (16.3 g, 99%). IR (NaCl): 2974, 1797, 1740, Π35 cm-1 ° Step 4: A solution of 474__trimethylene dihexapyridine (0.4 g, 1.9 mmol) in methane (5 ml), At 0 ° C, add the acid gaseous K2.S (g 3.26 mmol) to a solution in dichloromethane (5 ml). 3 Add triethylamine (0.61 ml, 4.4 mmol) 4-di T Aminopyridine (35 mg 1 L0 mol%), and then the mixture was stirred at room temperature for 丨 hours, and then with water (2 041-this paper's universal medium ® ® household tenon ratio (CNS) A4 specifications ί 210x29? Public 韪) ^^ 1 In J-----^ A " ^. ^ 11----ί--^^^ 1; ^ (汴 Please refer to the notice on the back before filling this page) In the Ministry of Health and Welfare, the employees of the Ministry of Health and Wealth Poverty Alleviation and Sealing of Hewei News Agency 1S- A 7 B7 457246 Patent Application Sling Order No. SSI 15 Post No. 6 Description of repairing earthen tiles (July of the year) Five Description of inventions () 丨丨 Repair ml) mix. The organic material was extracted and washed with saturated potassium gas (20 ml), dehydrated (MgS04), and then concentrated by tanzine. The residue was purified by flash chromatography (Si02, 2: 1 ethyl hexanoate / hexane) to obtain bisphosphonium g * IS%) ^ NMR (400 CDClj): 7,40-7.45 (m, 4HJ, 6.98-7,30 (m, 10H) (5.25-5.42 (m. 6H), 4.09-4 19 (m, 4H), 3.50-3.96 (m, 8H), 2.62-2,69 (m, 4H ), 2.28-2,36 (m, 4H), 1.90-2.02 (m, 4H) f 1.60-1.74 (m, 6H), 1.35-1.50 (m, 2H), 1,24 (ϋ, 18H), t .ij (s, 18H), 1.11 (s, 36H), 1.08-1.28 (m, 26H)-IR (NaCl): 1739 cm'1 ^ Step 5: Dissolve diamidine g i 0.54 mmol) THF (3 ml) t, and then treated with an aqueous solution of sodium hydroxide (0.40 g, 10 mmol, in 3 ml of water). The mixture was stirred at room temperature overnight, the THF was removed under reduced pressure, and the residue was acidified with concentrated acid. It was purified to pH 2 by reverse phase HPLC to obtain N, N1 · bis_ [4- (3- (3 + carboxymethylphenyl) -4- (a, D · mannosyloxy) benzene as a white solid. Butyl) -I-hexyl] 4,4 · -trimethylene hexagas p specific bite (17, (30 mg, 5%), mp: 119-mgC-1HNMR (400 MHz, DMSO- < i6): 7.32_ 7.40 (m7 6H), 7.20-7.27 (m. 4H), 7.10-7.14 (m, 4H), 5,26 (br s (2H) f 4.36 (br d, J = U Hz, 2H ) S 4.05 (br s, 8H), 3.77 (br d, J = U Hz, 2H), 3.50-3.70 (mf 8H), 3.40-3,52 (m7 5H), 3.31-3.40 (m, 2H), 2.92 (br t, J = l4 Hi, 2H), 2.55- 2.62 (m, 4H); 2 42-2.53 (m, 3H), 2.27 ^ 2.34 (m, 4H), 1.73-1.82 (mt 4H), 1.57-1,67 (m, 4H), 1.36-Γ47 (m , 2H) T 1.22- 1,33 (m, 2H), 1.11-L20 (m, 4H) f 0.80-1.02 (m, 4H) a IR (KBr): 3415, IM3, 1609 cm]. iViS (FAB): 1150 (M + + Na) Analysis: C61H78N2Oia ".4 TFA: 59.54% C, 6 22% H, 2.18¼ N ° Experimental plant: -42- General standard tSSI home standard (CMS) A4 Guiluo (. 公 麾) — 11 -----.― F ί I ^ Outfit ------------- (Poems First, "Please on the back;: I intend matters and then Qi Xiao (Benedict)
荦濟邹中失棣率局w工消t合作杜印A 457246 A" 五、發明説明(40) 59.65% C, 6.56% H, 2.23% N - f例5 二-6-丨3 - (3-瘦甲基苯基)-4-(2 - 4 -D-^t喃甘露搪基氧_)笨基| 己基醚 步驟1 :將箪醯氣化物(〗_65毫井,2 Μ於二氣f烷,3_3ϋ 毫荚耳)於-78"C下加入無水之二氣甲貌(1 ϋ毫升)内。以數 分鐘的時間將二甲基乙砜(0.5(5毫升,7_26毫莫耳)逐滴加入 其中,再將結果產生之溶液攪拌1 0分鐘,逐滴加入6-羥基 己酸乙基酯(0.5 0毫升,3.07毫莫茸),經過3 0分鐘之後#逐 滴加入三乙基胺(2.1 0毫升,1 5.1毫莫耳p混合物攪拌1 0分 鐘,分離各液相,以二氣甲烷萃取水溶液層。有機物質經 合併,脱水(MgS()4),然後抽眞空除去溶劑=經矽膠層析 法(2:1己烷:乙酸乙酯)可得純產物(0.44克,91%) = Α1.Ι NMR (400 MHz, CDC13): 9J5 (1 ΪΤ)( 4,10 (2Η), 2.45 (211), 2.30 (211), j .ή5 (4Π), 1.24 (3Η)= 經漭部央橾窣工消Φ:合作妊印策 (甸先閱读背而之注$痄再填窝本I ) 步騍2 :於(TC將三乙基矽烷(0.89¾升,5,57毫莫耳)及三 氟甲烷磺酸三甲基矽烷酯(63毫升,0.28毫莫耳)溶於無水 二氣平烷中(6毫升),然後加入一個5-ΐ氧羰基戊醛(0.44克 ,2.78毫莫耳)於二氯甲虼(3毫升)之溶液。將冷卻浴移除 然後使反應於室溫下進行80分鐘。以眞空除去溶劑後再以 矽膠層析法純化(6:1己烷:乙酸乙酯)可得產物(0.31克, 74%)。]11 NMR (400 MHz, CDC1.): 4.10 (4H)f 3.37 (4H), 2.28 (4Π), 1.60 (RU); i J6 (4Π), 1.24 (fill)= 步驟3 :將二_5-乙氧羰基戊基醚(〇·16毫升,0.53毫莫耳) 本紙张尺度通邛t嗶阄家標牟(CXS > Λ4規ί 210Χ 297公着) 457246 A7 B7 五、發明説明(41) 溶於甲哮(1毫升)再扣入1 N氫氣化鈉(1,05毫升,1,05毫莫 耳)。捋結果產生之溶液於室溫下撹拌3小時。減壓瞭去甲 醇後將殘餘之液體酸化(濃鹽酸)再以雨份二乙基醚萃取。 萃取液經合併,脱水(MgS04.)#減.譽濃缩。將殘濟以乙腈 再濃縮兩次可得白色固體之產物(0」6克,等量生成)。 lH NMR (400 MHz, CDC1-;): 3.40 (4H)? 2.36 (4H), L60 (8H), 1.42 (4H) ^ 步騄4:將二-5-羧戊基醚(0.15毫升,()J3毫莫耳)及DMF (1滴)溶入無水二氣甲烷(2.5毫升)中並使冷卻至〇fC u緩緩 加入草酿氣化物溶液(0.5 9毫升於二氣甲懷之2 Μ溶液, 1 -丨S毫莫耳)。反應於(TC攪拌20分鐘之後移除冷卻浴洱繼 續於室溫下搅拌20分鐘。溶液再冷卻至〇°C後加入3-(2-甲 氧基苯基)笨乙酸乙基酯(0.29克,1,07毫莫耳)於二氣甲烷 (1毫升)之溶液=將氯化鋁以1分鐘之時間分三部份(〇, 1 7克 ,0_17克,0_08克,共3.15毫莫耳)加入。將溶液攪拌5分鐘 ,然後傾入冰中再以兩份之乙醆乙酯萃取。有機層經合併 後阵依序以水,飽和碳酸氫鈉水溶液,及飽和氣化鈉溶液 萃洗。結果產生之溶液經脱水(MgS04)後減壓濃縮。經矽 經濟部中夬棵準局負工消费合作社印策 {誚先閱谇背而之注意亨項再填莴本vx ) 膠層析法純化(4:丨至1:1之梯度)可得黃色油狀物之產物 (0.34克,85%)〇 iHNMRGOOMHz, CDC13):7_91(4H), 7.41 (6H), 7.28 (2ΤΪ), 6.99 (2H): 4.14 (4H)f 3.86 (6H), 3,66 (4Π), 3.40 (4H), 2.94 (4H), 2.16 (4H), L75 (4H); 1.59 (4H), J-43 (4H), 1,26 (6Π)。 步驟5 :二-6-L3-(3-乙氧羰基甲基苯基)-4-甲氡基笨基丨_6- -44- 本紙張尺度適用十阐图家標準(CN_S )八4说格{ 2Η)Χ2ίί7公t 457246 Λ7 B7 五、發明説明(椏) 氡代已基醚(0.34克,0.45毫莫耳)先溶於無水二氣肀坑{2.5 毫许)内再將結果產生之溶液冷卻(TC。加入三氟乙酸 (0.23毫升,3.0毫莫再),然後再加入三乙基矽烷(0_29毫升 ,1,8毫莫耳)及三氟化嗍乙醚合物(0_33毫升,2_7毫莫耳) 。移去冷卻浴之後將反應物於室溫下攪拌卜j、時。加入二 氣甲虼後再以飽和碳酸氫鈉溶液及水萃取。有機層經脱水 (MgS04)後再減壓濃縮。經矽膠層桁法純化(6:1已烷:乙 酸乙酯)後可得澄清油狀物之產物((K23克,71%)。4 NMR (4()() MHz,CDC13): 7_42 (4H), 7J5 (2H),7,25 (2Π), 7-09 (4H), 6,87 (2H), 4.16 (4TI), 3.77 (6H), 3.65 (4Η), 3.37 (4Η); 2.57 (4Π), 1.57 (10Η)? 1.35 (ΚΗ); 1.25 (fill) ^ 步雁6 :二-6·[3-(3-乙氧羰基甲基苯基)-4-甲氧基苯基1己 基醚(0.23克,0.32毫莫耳)先溶於無水二氣f烷(1,6毫井)内 #將結果產生之溶液冷卻至tTC s逐滴加入三溴化蝴溶液 (丨1VI於二氣肀虼,1.40毫井,1.40毫莫耳)後移去冷卻浴。 二十分鐘之後再度將溶液冷卻至〇 t並逐滴力入無水乙醇 (1毫升然後將反應混合物倾入冰中再以乙酸乙酯萃取。 有機層經鉋和氣化鈉及水萃洗後脱水(MgS()4),接著再減 經濟部中央棵辛扃見工消费合作社印製 FIJI ^^^^1 ^^^^1 ^^^^1 ^^^^1 ^^^^1 ^^^^1 ^ ^^^^1 ^^^^1 ^^^^1 ^^^^1 ^^^^1 ^^^^1 V" (is九閲讀背面之;iJ·宏事巧卉填筘本頁〕 壓濃縮。經矽膠層析法純化(2:1至1:1之己烷:乙酸乙酯) 後可得產物(〇. Π 克,50%)。]II NMR (400 MIIz, CDCI3): 7.42 (8H), 7.04 (4FT), 6.RR (2H)? 5.J4 (2H), 4.16 (4H), 3.67 (4H), 3,38 (4H), 2.57 (4H); 1.85 (4H)? 1.62 (6H), 1.40 (6H), 1.27 (6H)。 步驟7 :將2,3,4,6-四三甲基乙醯基,cr -D-吡喃甘露糖 -4S- 本紙张尺度適用中囷國家榇隼(OS } Λ4^格(210X297公S } d57246 A7 B7 五、發明説明(43 ) 基-氟化物(0.52克,1.00毫莫耳)及二-6_[3-(3-乙氧巍基甲基 笨基)-4-羥基苯基]已基瞇(0‘23克,〇_33毫莫耳)溶於無水二 氣甲烷(2毫井)内再將結果產生之溶液冷卻至〇 t a緩緩加 入三氟化硼乙醚合物(0.3S毫升,3,丨〇毫莫耳)再將反應物攪 拌90分鐘。以乙酸乙酯將反應混合物稀釋後先以兩份水萃 洗,然後再繼續以1 N NaOH ’水’及飽和氣化納溶液萃洗 。結果所產生之溶液經脱水(Μ@〇4)之後再減壓濃縮。殘 渣經矽膠層析法純化(15 :1己烷:乙酸乙酯)後可得產物 (0‘45 克,82%)。4刪只(400 刪7;〔〇(:!3):7.45(7叩 訂 7.15 (7Η), 5.32 (8Η), 4.14 (4Η), 3.86 (4Η); 3.72 (4ΤΤ), 3-54 (2Π); 3.40 (4Η), 2,59 (4Η), 1.85 (4Η), 1.62 (4Η), 1.46 (4Η), 1.36 (4Η), 1-26 (24Π), 1.15 (1ΗΗ): Κΐϋ (36Η)=荦 中 局 中 中 棣 失 棣 局 局 工 工 消 t cooperation Du Yin A 457246 A " V. Description of the invention (40) 59.65% C, 6.56% H, 2.23% N-f Example 5 2-6- 丨 3-(3 -Lean methylphenyl) -4- (2-4 -D- ^ t-mannanyloxy_) benzyl | hexyl ether Step 1: The tritium gasification (〗 _65 milliwells, 2 Μ in two gases f-alkane, 3_3ϋ millipods) was added to -78 " C in anhydrous two gas form (1ϋml). Dimethyl ethyl sulfone (0.5 (5 ml, 7-26 millimoles)) was added dropwise over a period of several minutes, and the resulting solution was stirred for 10 minutes, and ethyl 6-hydroxyhexanoate was added dropwise ( 0.50 ml, 3.07 mmol, after 30 minutes # Triethylamine (2.10 ml, 15.1 mmol) was added dropwise and the mixture was stirred for 10 minutes. The liquid phases were separated and extracted with methane. Aqueous solution layer. The organic materials were combined, dehydrated (MgS () 4), and then evacuated to remove the solvent = silica chromatography (2: 1 hexane: ethyl acetate) to obtain the pure product (0.44 g, 91%) = Α1.Ι NMR (400 MHz, CDC13): 9J5 (1 ΪΤ) (4,10 (2Η), 2.45 (211), 2.30 (211), j .ή5 (4Π), 1.24 (3Η) =橾 窣 工 消 Φ: Cooperative Pregnancy Indications (Dian first read the back note and then write the book I) Step 2: Yu (TC will be triethylsilane (0.89¾ liter, 5,57 millimoles) And trimethylsilyl trifluoromethanesulfonate (63 ml, 0.28 mmol) were dissolved in anhydrous diflatoxane (6 ml), and then 5-pentyloxycarbonylvaleraldehyde (0.44 g, 2.78 mmol) was added. Ear) in methylene chloride (3 ml) Solution. Remove the cooling bath and allow the reaction to proceed at room temperature for 80 minutes. After removing the solvent with air, the product is purified by silica gel chromatography (6: 1 hexane: ethyl acetate) to obtain the product (0.31 g, 74%). ).] 11 NMR (400 MHz, CDC1.): 4.10 (4H) f 3.37 (4H), 2.28 (4Π), 1.60 (RU); i J6 (4Π), 1.24 (fill) = Step 3: 5-Ethoxycarbonylpentyl ether (0.16 ml, 0.53 mmol) This paper is available in standard paper (CXS > Λ4 gauge 210 × 297) 457246 A7 B7 V. Description of the invention ( 41) Dissolve in methyl cyanide (1 ml) and deduct 1 N sodium hydride (1,05 ml, 1,05 mmol). The resulting solution was stirred at room temperature for 3 hours. The methanol was removed under reduced pressure. After that, the residual liquid was acidified (concentrated hydrochloric acid) and then extracted with diethyl ether. The extracts were combined, dehydrated (MgS04.) # Min., And concentrated. The residue was concentrated twice more with acetonitrile to obtain a white solid. The product (0 "6 g, generated in equal amounts). LH NMR (400 MHz, CDC1-;): 3.40 (4H)? 2.36 (4H), L60 (8H), 1.42 (4H) ^ Step 4: -5-Carboxypentyl ether (0.15 ml, (J3 mmol) and DMF (1 ) Was dissolved in anhydrous methane gas (2.5 mL) and cooled to 〇fC u slowly added oxalyl stuffed vaporized solution (0.5 to 9 ml of the second gas 2 [mu] A pregnant solution of 1 - S Shu mmol). After the reaction was stirred at TC for 20 minutes, the cooling bath was removed and the mixture was stirred at room temperature for 20 minutes. After the solution was cooled to 0 ° C, 3- (2-methoxyphenyl) benzyl acetate (0.29 g) was added. , 1,07 millimoles) in methane gas (1 ml) = aluminum chloride is divided into three parts (0, 17 grams, 0_17 grams, 0_08 grams, a total of 3.15 millimoles in 1 minute) ) Add. Stir the solution for 5 minutes, then pour it into ice and extract with two portions of ethyl acetate. The organic layers are combined and extracted with water, saturated sodium bicarbonate aqueous solution, and saturated sodium gas solution in order. .Results The solution was dehydrated (MgS04) and concentrated under reduced pressure. It was printed by the Ministry of Economic Affairs of the Ministry of Economics and Technology in China. (诮 Please read the back first and pay attention to the item before filling the lettuce vx). Gel chromatography Purification by a method (gradient from 4: 丨 to 1: 1) gave the product as a yellow oil (0.34 g, 85%). IHNMRGOOMHz, CDC13): 7_91 (4H), 7.41 (6H), 7.28 (2ΤΪ), 6.99 (2H): 4.14 (4H) f 3.86 (6H), 3,66 (4Π), 3.40 (4H), 2.94 (4H), 2.16 (4H), L75 (4H); 1.59 (4H), J-43 ( 4H), 1,26 (6Π). Step 5: Di-6-L3- (3-ethoxycarbonylmethylphenyl) -4-methylfluorenylbenzyl 丨 6-6-44- This paper size is applicable to the standard of ten charters (CN_S) 8-4格 {2Η) Χ2ί7 male t 457246 Λ7 B7 V. Description of the invention (桠) The hexadecyl ether (0.34 g, 0.45 mmol) is first dissolved in an anhydrous digas pit {2.5 mmol) and the result is produced. The solution was cooled (TC. Trifluoroacetic acid (0.23 ml, 3.0 mmole) was added, followed by triethylsilane (0_29 ml, 1,8 mmoles) and osmium trifluoride etherate (0_33 ml, 2_7) Millimoles). After removing the cooling bath, the reaction was stirred at room temperature for 2 h. After adding digas formamidine, it was extracted with saturated sodium bicarbonate solution and water. The organic layer was dehydrated (MgS04) and then reduced. Concentrated under pressure. The product was obtained as a clear oil ((K23 g, 71%) after purification by silica gel string method (6: 1 hexane: ethyl acetate). 4 NMR (4 () () MHz, CDC13) : 7_42 (4H), 7J5 (2H), 7,25 (2Π), 7-09 (4H), 6,87 (2H), 4.16 (4TI), 3.77 (6H), 3.65 (4Η), 3.37 (4Η ); 2.57 (4Π), 1.57 (10Η)? 1.35 (ΚΗ); 1.25 (fill) ^ Step 6: Di-6 · [3- (3-ethoxycarbonyl Methylphenyl) -4-methoxyphenyl 1-hexyl ether (0.23 g, 0.32 mmol) was first dissolved in anhydrous dioxane (1,6 mmol) #The resulting solution was cooled to tTC s Add the bromide solution (1VI in digas, 1.40 milliwells, 1.40 millimoles) dropwise and remove the cooling bath. Twenty minutes later, the solution is cooled to 0t and dripped into anhydrous water. Ethanol (1 ml, then the reaction mixture was poured into ice and then extracted with ethyl acetate. The organic layer was dehydrated (MgS () 4) after being washed with a planer, sodium gaseous extract and water, and then minified by the Central Ministry of Economic Affairs Printed by the consumer cooperative FIJI ^^^^ 1 ^^^^ 1 ^^^^ 1 ^^^^ 1 ^^^^ 1 ^^^^ 1 ^ ^^^^ 1 ^^^^ 1 ^^^^ 1 ^^^^ 1 ^^^^ 1 ^^^^ 1 V " (is on the back of the reading; iJ · Hongshiqiaohui fills in this page) Pressure concentration. Purified by silica gel chromatography (2: 1 to The product was obtained after 1: 1 hexane: ethyl acetate (0.2 g, 50%).] II NMR (400 MIIz, CDCI3): 7.42 (8H), 7.04 (4FT), 6.RR (2H )? 5.J4 (2H), 4.16 (4H), 3.67 (4H), 3,38 (4H), 2.57 (4H); 1.85 (4H)? 1.62 (6H), 1.40 (6H), 1.27 (6H) . Step 7: Put 2,3,4,6-tetratrimethylethylsulfonium, cr -D-pyranomannose-4S- This paper size applies to the countries of China 囷 (OS) Λ4 ^ grid (210X297 male S } d57246 A7 B7 V. Description of the invention (43) -fluoride (0.52 g, 1.00 mmol) and di-6_ [3- (3-ethoxycarbylmethylbenzyl) -4-hydroxyphenyl] Hexafluorene (0'23 g, 0-33 millimoles) was dissolved in anhydrous digas methane (2 milliwells) and the resulting solution was cooled to 0ta. Boron trifluoride etherate (0.3 S ml, 3,0 mmol), and the reaction was stirred for 90 minutes. The reaction mixture was diluted with ethyl acetate, first washed with two portions of water, and then continued with 1 N NaOH 'water' and saturated gasification. The solution was extracted and washed. The resulting solution was dehydrated (M @ 〇4) and concentrated under reduced pressure. The residue was purified by silica gel chromatography (15: 1 hexane: ethyl acetate) to obtain the product (0'45 Grams, 82%). 4 delete only (400 delete 7; [〇 (:! 3): 7.45 (7 (7.15 (7 (), 5.32 (8Η), 4.14 (4Η), 3.86 (4Η); 3.72 (4ΤΤ ), 3-54 (2Π); 3.40 (4Η), 2,59 (4Η), 1.85 (4Η), 1.62 (4Η), 1.46 (4Η), 1.36 (4Η), 1-26 (24Π), 1.15 (1ΗΗ): Κΐϋ (36Η) =
步驟S 經濟部中夹橾苹局員工消费合作社印製 將二-6-丨3-(3-乙氧羰基ΐ基苯基)-4-(2,3,4,6-四-g-三f基 乙醢基-c-D-吡喃甘露糖基氧)苯基]己基醚(0,45克,0,27 毫莫耳)溶入無水四氫呋喃(0.9毫升)及甲醇(1,8毫升)中a 將甲氧化鈉(49毫克,0,84毫莫耳)加入,再將反應晶合物 於宣溫下攪拌隔夜3將另一份Ψ氧化鈉(50毫克,t).93毫莫 耳)加入,經過4小時之後再加入第三份(]丨2毫克,21(〗7毫 莫耳)4反應繼續再搅拌4小時之後過濾並以2:1四氫呋喃及 甲醇之混合物清洗收集之固體=然後將固體溶於水(〗毫升) ,加入氫氣化納水齒液(1 M)直至p ]丨達14。溶液再搜拌4小 時之後再以經過預洗之Dowcx 50離子交換樹脂(H1.®!)中和 。樹脂經過濾除去後,再將濾液冷凍乾燥。然後將產物於 -46-Step S Printed by the Consumers Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs of the People's Republic of China. f-Acetoethyl-cD-pyranosyloxy) phenyl] hexyl ether (0,45 g, 0,27 mmol) was dissolved in anhydrous tetrahydrofuran (0.9 ml) and methanol (1,8 ml) a Add sodium methoxide (49 mg, 0,84 millimoles), and stir the reaction crystals at Xuan temperature overnight. 3 Add another portion of sodium trioxide (50 mg, t). 93 millimoles) Add, after 4 hours, add a third portion () 丨 2 mg, 21 (7 7 mol) 4 The reaction is continued to stir for another 4 hours, then filtered and washed with a 2: 1 mixture of tetrahydrofuran and methanol = collected solid = then Dissolve the solid in water (〗 ml), add hydrogenated sodium water tooth solution (1 M) until p] 丨 reaches 14. The solution is searched and stirred for 4 hours, and then Dowcx 50 ion exchange resin (H1.® !) Neutralization. After the resin is removed by filtration, the filtrate is freeze-dried. Then the product is dried at -46-
在57 2步t§5U5658號卑利中請案 中文說明書修正頁(90年6月) 五、發明説明(44 ) 中P;:〇5中真空乾燥可得二·6_[3_(3_羧乎基笨基)-4,(2 H说喃甘露糖氧基)苯基1己基醚(〇 21克,7S%)。【Η NMR (400 MHz, CD3CN/D20): 7.46 (2H), 7.34 (2H), 7.16 (10H), 5.31 (2H)7 3.79 (2H)S 3.66 (2H), 3,51 (4H), 3.42 (5H)S 28 (2H), 2.56 (4H), 1.80 (4HX 1.60 (4H), 1.36 (6H)。 實fd 雙-[3_(3·|甲基苯基)_4- 〇 -〇_7比喃甘露糖基氧)_3_苯 两-1 -基]-1,3-二硫代丙貌 步驟1:_八部分:將3-(2-〒氧基苯基)苯乙酸乙基酯(5.〇4 克* 18.66毫莫耳)及3-溴基雨醯氣化物(1.88毫升,18.66毫 莫耳)與二氣甲烷(30毫升)混合。混合物於冰水浴十冷卻後 以氣化鋁(7.6克,57毫莫耳)處理。15分鐘之後再與冰水 (1 00毫克)混合,並分離有機物質u永.溶液相以二氣曱規萃 取(3 x 5毫升)t經合併有機物質後,以飽和氣化鈉水溶液 (50毫升)萃洗,脫水(MgS〇4),再減壓濃縮a殘渣可直接在 下一步鲒中使用不須純化, B部分:A部分之產物(8.5克,1_9毫莫耳)溶於二氣甲烷(40 毫升)後再於冰水浴十冷卻□然後加入三氟乙酸(5.9毫升, 76毫莫耳),三乙基矽烷(6,丨毫升》38毫莫耳)及三氣化硼乙 醚合物(9.4毫升^ 76毫莫耳)並除去冰水浴=將混合物於室 溫下揽拌隔夜然後再度放至冰水浴中冷卻並加入冰水(1 〇〇 毫升)以中止反應。t機物質Μ分離後,以二氣甲烷(3 X 5 毫升)萃取水溶液相,合併有機物質,經飽和氣化鈉溶液 (5 0毫升)萃洗,脫水(M g S Ο 4 )再減壓濃縮可得:J - ( 2 -甲 -47- id (請先閱讀背*之泣意事碩存填本瓦) -=5 % 培»部令央梯皁局貫工消费合作社印製 本紙张又度過丹中圃固家標準f CNS } A4規格ί ZIUX 公釐) 457246 經濟邹t央揉準馮萁工消費合作杜印製 A7 B7 五、發明説明(45) 氧基笨基-5·(3-溴基丙基)笨乙酸乙基酯(0.53克1 90%)。4 NMR (400 MHz, CDC1;,): 7.4J-7.45 (m, 2H), 7,36 (t, J=8 Hz: ill), 7.25-7.28 (m, 1H). 7,12-7,16 (m, 2H), 6.90 (d, J-8.6 TIz, 1H), 4.15 (q, J=? 〇 2H): 3,78 (s, 3H), 3.67 (s, 2H)? 3.41 (t, J=6,6 Hz, 2H), 2.75 (t, J=7.〇 Hz, 2H), 2,15 (m, 2H), 1.26 (t, J=7.3 I]尽 3U), IR (Nadi): 1736 cm1。 步驟2 :將M-丙烷二硫醇(〇」09克,0.94毫莫耳)於ΪΗΗ (4_5毫升)之溶液在氮氛下除去空氣,再置於冰水浴中冷卻 。加入氬化鈉(Κ6.5毫克,2.1毫莫耳)之後骑邋合物於室溫 下攪拌2小時。將步驃丨所得溴化物(0.83克,2.12毫莫耳+)於 THF (1 0毫汁)之溶液加入,並將混合物於回流溫度下攪拌 隔夜"將反應物分配於水及乙酸乙酯(20毫井]:1之混合物) 之間,分離有機物質1以飽和氣化鈉(20毫升)萃洗,脱水 (MgS04)再減壓澴縮。殘渣經快速層析法(Si〇2,已烷至3:1 己烷/乙較L酯梯度溶離)S,S-雙 [3-(3-乙氧羰基甲基笨基)-4-(肀氧基)-3-苯丙-I-基]-1,3-二硫代丙烷(166.2毫克,24%) 。MT NMR (400 MHz; CDC13): 7.39-7.45 (m, AU), 7.32-7.38 (m, 2H); 7.21-7.28 (m, 211), 7.08-7.[5 (m, 4TI)5 6.85-6.92 (m, 2H), 4.14 (q, J=7.0 TT/, 4IT), 3.77 (s, ήΠ), 3.65 (s, 4ΪΤ), 2.80-2.95 (m; 2H); 2.77 (tf J=7,3 Hz, 2H), 2.68 (t, J=8,0 Hz; 4H)3 2.60 (t; } = Ί,ΰ Hz, 2H), 2.52 (t, J=7.0 Hz? 2H), 2.04-2.16 {m, 2H), 1.81-1.93 (m, 4H), 1-25 (U J=7-0 Τϊζ5 6H)。TR (NaCI): 173 1 cm'1 -步骢3 : -48- ^紙浪尺度ϋ用中®困象榜芈(CNS ) M规格(uouy地矩) ϋ n n _ _ ____^ _____ ,.: J— . : [_ T }^I ^ rt n [ — .¾ (讳先閱该背面之"'"事項再填竓本瓦) 457246 A7 ______B? 五、發明説明(46 ) 將步驟2之雙-硫醚(+70,7毫克,0.1毫莫耳)於二氣甲烷(2 毫升)之溶液置於乾冰/丙酮浴+冷卻再以三溴化硼(0.8毫 升’ 1 Μ於二氣甲烷之溶液内,〇.8毫莫耳)處理在經混合物 1於-1 05C隔夜。反應物與水(1 〇毫升)混合後以二氣甲虼(3 乂2毫升)萃取。有機物質經合併,脱水(MgS04)再減|濃縮 可得S,S-雙·13·(3·乙氧羧基甲基苯基卜4-(羥基)-3-苯丙-卜基] -1:3-二硫代丙烷(68毫克,100%) 〇 lIT NMR (400 MTT7, CDC13): 7,43 (ί,J-7.7 Hz, 2Η),7.34.7,39 (m, 4Π), 7-30 (br d, J=7.3 Nzf 2H), 7.03-7.08 (m, 4II); 6.87 (br ά, J-8.8 Hz, 2H), 4.96-^.30 (br s, 2H): 4.15 (q, J = 7.0 IT/, 4M): 3.6ή (s, 4H)f 2.66 (L, J-7.3 Hz, 4H), 2,60 (t, .1=7.0 Πζ: 2H), 2.52 (l: J-7.0 H7, 4II)f 1.80-1,92 (m; 6ΤΓ), 1.26 (l, J-7.3 Hz, 6H), 1,21-1.27 (m, 2H) ^ 1R (NaCl): 3420, 1726 cm1 ^In the 57 2 step t§5U5658 Bailey's application for the amendment to the Chinese manual (June 90) V. In the description of the invention (44) P ;: Vacuum drying in 05 can get 2 · 6_ [3_ (3_carboxyl Alkylbenzyl) -4, (2H said mannoseoxy) phenyl 1hexyl ether (0 21 g, 7S%). (Η NMR (400 MHz, CD3CN / D20): 7.46 (2H), 7.34 (2H), 7.16 (10H), 5.31 (2H) 7 3.79 (2H) S 3.66 (2H), 3,51 (4H), 3.42 (5H) S 28 (2H), 2.56 (4H), 1.80 (4HX 1.60 (4H), 1.36 (6H). Real fd bis- [3_ (3 · | methylphenyl) _4- 〇-〇_7 ratio Mannosyloxy) _3_benzenebis-1 -yl] -1,3-dithiopropionate Step 1: _ Part eight: Put 3- (2-methoxyoxyphenyl) phenylacetate ethyl ester ( 5.04 g * 18.66 millimoles) and 3-bromobenzene gaseous (1.88 mL, 18.66 millimoles) were mixed with methane (30 mL). The mixture was cooled in an ice-water bath and treated with vaporized aluminum (7.6 g, 57 mmol). After 15 minutes, it was mixed with ice water (100 mg), and the organic matter was separated. The solution phase was extracted with a two-gauge radon gauge (3 x 5 ml). After combining the organic matter, the solution was saturated with a saturated aqueous sodium hydroxide solution (50 Milliliter) extraction, dehydration (MgS04), and then concentrated under reduced pressure a residue can be used directly in the next step without purification, part B: the product of part A (8.5 g, 1-9 millimoles) dissolved in methane (40 ml) and then cooled in an ice-water bath. Then add trifluoroacetic acid (5.9 ml, 76 millimoles), triethylsilane (6, 丨 ml> 38 millimoles), and tri-gas boron etherate. (9.4 ml ^ 76 millimoles) and remove the ice water bath = stir the mixture overnight at room temperature and then put it back in the ice water bath to cool and add ice water (100 ml) to stop the reaction. After the separation of the organic substance M, the aqueous phase was extracted with methane (3 X 5 ml), the organic substances were combined, extracted and washed with a saturated sodium gas solution (50 ml), dehydrated (M g S Ο 4), and then decompressed. Concentration can be obtained: J-(2-甲 -47- id (please read the weeping of the back * to save the original tile)-= 5% training Passed the standard of Danzhongpu Family Home (CNS} A4 specification Ø ZIUX mm) 457246 Economy Zou Tyang Jun Jun Feng Fenggong Consumer Cooperation Du printed A7 B7 V. Description of the invention (45) Oxybenzyl-5 · (3 -Ethyl bromopropyl) benzyl acetate (0.53 g 1 90%). 4 NMR (400 MHz, CDC1 ;,): 7.4J-7.45 (m, 2H), 7,36 (t, J = 8 Hz: ill), 7.25-7.28 (m, 1H). 7,12-7, 16 (m, 2H), 6.90 (d, J-8.6 TIz, 1H), 4.15 (q, J =? 〇2H): 3,78 (s, 3H), 3.67 (s, 2H)? 3.41 (t, J = 6, 6 Hz, 2H), 2.75 (t, J = 7.〇Hz, 2H), 2,15 (m, 2H), 1.26 (t, J = 7.3 I) to 3U), IR (Nadi) : 1736 cm1. Step 2: A solution of M-propane dithiol (0.09 g, 0.94 mmol) in tritium (4-5 ml) was used to remove air under a nitrogen atmosphere, and then cooled in an ice-water bath. After adding sodium argon (K6.5 mg, 2.1 mmol), the mixture was stirred at room temperature for 2 hours. A solution of the bromide (0.83 g, 2.12 mmol) in THF (10 mmol) was added, and the mixture was stirred overnight at reflux temperature. The reaction was partitioned between water and ethyl acetate. (20 milliwells: 1 mixture), the organic substance 1 was separated and extracted with saturated sodium gaseous (20 ml), dehydrated (MgS04) and then decompressed under reduced pressure. The residue was subjected to flash chromatography (Si02, hexane to 3: 1 hexane / ethyl acetate gradient gradient separation) S, S-bis [3- (3-ethoxycarbonylmethylbenzyl) -4- ( (Methoxy) -3-phenylpropan-I-yl] -1,3-dithiopropane (166.2 mg, 24%). MT NMR (400 MHz; CDC13): 7.39-7.45 (m, AU), 7.32-7.38 (m, 2H); 7.21-7.28 (m, 211), 7.08-7. [5 (m, 4TI) 5 6.85- 6.92 (m, 2H), 4.14 (q, J = 7.0 TT /, 4IT), 3.77 (s, price), 3.65 (s, 4ΪΤ), 2.80-2.95 (m; 2H); 2.77 (tf J = 7, 3 Hz, 2H), 2.68 (t, J = 8,0 Hz; 4H) 3 2.60 (t;) = Ί, ΰ Hz, 2H), 2.52 (t, J = 7.0 Hz? 2H), 2.04-2.16 { m, 2H), 1.81-1.93 (m, 4H), 1-25 (UJ = 7-0 Τϊζ5 6H). TR (NaCI): 173 1 cm'1 -steps 3: -48- ^ Paper Wave Scales in use ® Sleepy Elephant List (CNS) M Specification (uouy moment) ϋ nn _ _ ____ ^ _____,.: J—.: [_ T} ^ I ^ rt n [— .¾ (tabularly read the "&"; "items on the back and fill in this tile) 457246 A7 ______B? V. Description of the invention (46) Step 2 Solution of bis-sulfide (+70,7 mg, 0.1 mmol) in digas methane (2 ml) in a dry ice / acetone bath + cooling and boron tribromide (0.8 ml '1 M in digas In a solution of methane, 0.8 millimolar) was treated with Mixture 1 at -1 05C overnight. The reaction was mixed with water (10 mL) and extracted with digas formamidine (3.2 mL). Organic substances are combined, dehydrated (MgS04) and then reduced | concentrated to obtain S, S-bis · 13 · (3 · ethoxycarboxymethylphenylphenyl 4- (hydroxy) -3-phenylpropyl-butyl) -1 : 3-dithiopropane (68 mg, 100%) 〇lIT NMR (400 MTT7, CDC13): 7,43 (ί, J-7.7 Hz, 2Η), 7.34.7, 39 (m, 4Π), 7 -30 (br d, J = 7.3 Nzf 2H), 7.03-7.08 (m, 4II); 6.87 (brά, J-8.8 Hz, 2H), 4.96-^. 30 (br s, 2H): 4.15 (q , J = 7.0 IT /, 4M): 3.6 (s, 4H) f 2.66 (L, J-7.3 Hz, 4H), 2,60 (t, .1 = 7.0 Πζ: 2H), 2.52 (l: J -7.0 H7, 4II) f 1.80-1,92 (m; 6ΤΓ), 1.26 (l, J-7.3 Hz, 6H), 1,21-1.27 (m, 2H) ^ 1R (NaCl): 3420, 1726 cm1 ^
^濟部中央榫準局s工消费合作社印I ^^^1 urn ^^^1 ^^^1 ^^^1 ^^^1·*1 J 牙-a (^先閑讀背由之汰宏亊^再填-衫本頁} 步驟4 :將酚((M7克,毫莫耳)與a -D-甘露糖五乙醯 酯(0_8克,2_0毫莫耳)與二氣乙虼(8毫升)混合再以三氟化 硼乙醚合物(1.0毫升,8,0毫莫耳)處理。反應於室溫下攪 拌隔夜,然後加入水(10毫升)中止反應。有機物質經分離 後β二氣甲虼萃取(3 X 2毫讣)t合併有機物t,脱水 (MgS04)再減歷濃縮。殘渣經快述層析法(Si02 ’ 3 :1己提/ 乙酸乙酯至1:1己烷/乙酸乙酯之梯度溶離)可得雙-I 3 (3-乙氧羰基甲基苯基)-4-(2,3,4,6-四_士乙醯基^-〇-吡喃 甘露糖基氧)-3-苯丙-1-基卜1,3-二硫代丙坑<0.331克f 36%) IR (NaCl): 1752 cm'1 c 步驟5 :前步驟所得之乙醢酯(0,64克* <M7毫莫耳)溶入 -49 - __ 表紙乐尺度邁別t周固家榇车iCNS ) A4此格(2;0Χ乃7公釐) 457246 A7 B7 經濟部中央梯苹,^Μ Η消#合作社印製 五、發明説明(47 ) 乙腈(5毫并)内再以氳氡化鈉溶液(2 N溶液5.0毫升,〗〇毫 莫耳)處理,然後於室溫下搅拌隔夜。混合物以濃鹽酸化 至pH 2,再將揮發性物質減壓除去,一部分之水溶性殘渣 以逆相層析法純化可得白色因體之S,S-雙-[3-(3-羧甲基苯 基)-4- tv -D-吡喃甘露糖氡基]-3-笨丙-1-基卜1,3-二硫代丙烷 m.p,: 96-1 0〇rC " lH NMR (400 MHz, DMSO-d6): 7.3 1-7.39 {m: 6H), 7,20-7.27 4H), 7.11-7.15 (m, 4H), 5.26 (s: 2TT), 3.30-3,75 (m, 2R[]); 2.64 (t? J=7.7 Hz, 4H), 2.57 (t, J=7(〇 Hz, 4H), 2.45-2,52 (m, 4K), 1.75-1.84 (m, 4H), 1.66-],74 2H) ^ TR (K.Br): 3430, 1711 cm'1 5 實例7 1:6-雙-3-(3_#甲基笔基)-4-U -D-喊喃甘霜:糖基氧)苯基 ]-l,6-雙-氡代己烷 步騾1 : 3-(2-(2,3,4,6-四-士乙醯基-α-D-吡喃甘露糖氡基) 笨基)苯乙酸乙基酯(0,56克,0A6亳奠耳)及己二醯氯化物 (0-068克,〇.47毫莫耳)先溶於二氯乙烷0¾:升)中再置入冰 水浴中冷卻,然後以氣化鋁(2.56克,19.2毫莫耳)處理。經 】_5小時後,將反應物與冰永(25毫升)混合再榄拌15分鐘= 單離有機物質再以二氣甲烷(3 X 2毫升)萃取水溶液部分d 合併有機物質後經脱水(MgS〇4)再減壓濃縮。殘渣以快速 層析法(Si〇2,] :1已烷/乙酸乙酯)純化可得雙-[3-(3-乙 氧羰基曱基笨基)-4-卜-D-吡喃甘露糖基氧)苯基]-1,6-雙· 氧代已烷(0,43 g,35%) « NMR (40ϋ MHz, CDC13): M)〇 (d, J-2.2 Hz, 2H), 7.93 (dd, J=8-6; 2.2 Hz, 2H), 7.42-7.48 (m? _ - 50- 本紙法尺度用中阄囤苳標牟(CNS〉A4現格(21 OX公梦) (請先閱請背而之注意事項耳填岛本貝 " 訂^ Institute of Industrial and Consumer Cooperatives, Central Bureau of Tension of the Ministry of Economic Affairs ^^^ 1 urn ^^^ 1 ^^^ 1 ^^^ 1 ^^^ 1 · * 1 J Tooth-a Acer ^ Refill-this page} Step 4: Mix phenol ((M7 g, millimolar) with a-D-mannose pentaethylacetoate (0_8g, 2_0 millimolar) and digas acetamidine ( 8 ml) mixed and then treated with boron trifluoride etherate (1.0 ml, 8,0 mmol). The reaction was stirred overnight at room temperature, then water (10 ml) was added to stop the reaction. After separation of the organic substances β Two-gas formazan extraction (3 X 2 milliliters) t combined with organic matter t, dehydration (MgS04) and reduced concentration. The residue was subjected to rapid chromatography (Si02 '3: 1 hexane / ethyl acetate to 1: 1 hexane). Gradient dissociation of alkane / ethyl acetate) to obtain bis-I 3 (3-ethoxycarbonylmethylphenyl) -4- (2,3,4,6-tetra-ethylacetinyl ^ -〇-pyran Mannyloxy) -3-phenylpropan-1-ylb, 1,3-dithiopropane pits <0.331 g f 36%) IR (NaCl): 1752 cm'1 c Step 5: The ethyl from the previous step Ethyl ester (0,64g * < M7 millimolar) dissolved in -49-__ Surface paper Le scale Maibiet Zhou Gujia car iCNS) A4 this grid (2; 0 × is 7 mm) 457246 A7 B7 Economy Central ladder Ping, ^ Μ Η 消 #Printed by a cooperative V. Description of the invention (47) Acetonitrile (5 mmol) was treated with sodium trioxide solution (5.0 ml of 2 N solution, 0 mmol) and then at room temperature Stir overnight. The mixture was concentrated to pH 2 with concentrated hydrochloric acid, and the volatile materials were removed under reduced pressure. A part of the water-soluble residue was purified by reverse phase chromatography to obtain S, S-bis- [3- (3-carboxymethyl) Phenyl) -4-tv-D-pyranosylmethyl] -3-benzyl-1-ylb 1,3-dithiopropane mp, 96-1 0〇rC " lH NMR ( 400 MHz, DMSO-d6): 7.3 1-7.39 (m: 6H), 7,20-7.27 4H), 7.11-7.15 (m, 4H), 5.26 (s: 2TT), 3.30-3,75 (m, 2R []); 2.64 (t? J = 7.7 Hz, 4H), 2.57 (t, J = 7 (〇Hz, 4H), 2.45-2,52 (m, 4K), 1.75-1.84 (m, 4H) , 1.66-], 74 2H) ^ TR (K.Br): 3430, 1711 cm'1 5 Example 7 1: 6-bis-3- (3_ # methylpenyl) -4-U -D- Gansu: glycosyloxy) phenyl] -1,6-bis-fluorinated hexane Step 1: 3- (2- (2,3,4,6-tetra-ethylethyl-α-D- Pyranylmannosyl) Benzoyl) Ethyl phenylacetate (0,56 g, 0A6 mol) and adipic acid chloride (0-068 g, 0.47 mmol) are first dissolved in dichloride Ethane (0¾: liter) was cooled in an ice-water bath, and then treated with vaporized aluminum (2.56 g, 19.2 mmol). After _5 hours, mix the reactants with Bingyong (25 ml) and stir for 15 minutes = separate the organic matter and extract the aqueous part with methane (3 X 2 ml). D Combine the organic matter and dehydrate it (MgS (4) It was then concentrated under reduced pressure. The residue was purified by flash chromatography (Si02,]: 1 hexane / ethyl acetate) to obtain bis- [3- (3-ethoxycarbonylfluorenylbenzyl) -4-b-D-pyranomannan. Glycosyloxy) phenyl] -1,6-bis · oxohexane (0,43 g, 35%) «NMR (40ϋ MHz, CDC13): M) 〇 (d, J-2.2 Hz, 2H), 7.93 (dd, J = 8-6; 2.2 Hz, 2H), 7.42-7.48 (m? _-50- Chinese paper stock standard scales (CNS> A4 present grid (21 OX public dream)) (Please Please read the first note, please fill in the ears and fill in the island " order
45724G A7 __B7 五、發明説明(48 ) 6H), 7.31-7.35 (m, 2H), 7.25-7.29 (m. 2H)f 5.60 (d, J-0.2 Hz, 211), 5,31-5.34 (m; 2TT), 5.28 (ά, J=9.1 Hz, 2H), 5.23-5-2S (m, 2H); 4.21 (dd; J^12.3, 5.1 Η/, 2ΪΤ), 4,15 ^ j-7.4 Hz, 4H), 3.9K (dd, J=12,4, 2.2 IJz. 2H), 3.79-3.85 (m, 2H), 3.73 (s, 4H), 3.00-3.06 (m, 4H), 2.17 (s, 6H)t 2.03 (s. 6IT); 2.01 (s, 6H), 1.98 (s, 6ΤΪ), LiU-1.85 (m, 4H), 1.26 (t, J=7.5 Hz. 611) -IR (NaCl): 1747, 1680 cm'1 ^ 步驟2 :先前步驟所得之乙醯铝(〇,43克,0_33毫莫耳)渰 於6腈(4毫升)後將溶液與2 N氳氡化鈉(丨8毫升,毫莫 耳)--起槐掉。經室溫撒拌1 8」' 時後,將反應物以Do we X 50W酸性離子交換街脂中和,再利用減屬r將揮發性物質除 去3接著將一部分殘渣以逆相層析ΗΡΤΧ純化可得白色囱 體之1,6-雙-[3-(3-羧甲基笨基)-4-(找-D_毗喃甘露糖氡基(蓼 基 J-l,6-雙-氧代已虼,m.p : 127-12VC。⑴ NMR (400 MIlz, DMSO-d5): 7.98 (dt J=K.K Hz, 2H), 7,90 (s, 2H), 7.35-7,48 (mf SH); 7.27 (d, J=8.6 Hz, 2H), 5.53 (s, 2H): 3.71 (s? 2H), 3.66 (s, 4Π), 3.ΰϋ (d? J=11.4 H7, 2IT), 3.42-3.51 (m7 6H), 3.2B-3.35 (m, 2ΤΪ), 3.07-3.15 (m, 4H), 1.67-K73 (m, 4Π) - IR (KBr): 3430, 1716, 1672 cm1。分折:c:46H500ls*〇 6 TFA之計 算值:59.1 0% C:f 5.32% H。實驗値:5Κ·92ΰ/〇 Cf 5.68% H。45724G A7 __B7 V. Description of the invention (48) 6H), 7.31-7.35 (m, 2H), 7.25-7.29 (m. 2H) f 5.60 (d, J-0.2 Hz, 211), 5,31-5.34 (m ; 2TT), 5.28 (ά, J = 9.1 Hz, 2H), 5.23-5-2S (m, 2H); 4.21 (dd; J ^ 12.3, 5.1 Η /, 2ΪΤ), 4,15 ^ j-7.4 Hz , 4H), 3.9K (dd, J = 12,4, 2.2 IJz. 2H), 3.79-3.85 (m, 2H), 3.73 (s, 4H), 3.00-3.06 (m, 4H), 2.17 (s, 6H) t 2.03 (s. 6IT); 2.01 (s, 6H), 1.98 (s, 6ΤΪ), LiU-1.85 (m, 4H), 1.26 (t, J = 7.5 Hz. 611) -IR (NaCl): 1747, 1680 cm'1 ^ Step 2: Aluminium acetamate (0,43 g, 0_33 mmol) obtained in the previous step was mixed with 6 nitrile (4 ml) and the solution was mixed with 2 N sodium halide (8 ml , No mol)-from the locust. After being stirred at room temperature for 18 hours, the reaction was neutralized with Do we X 50W acidic ion-exchange lipids, and then the volatile substances were removed by using minus r. 3 Then a part of the residue was purified by reverse phase chromatography HPTX. 1,6-bis- [3- (3-carboxymethylbenzyl) -4- (can be found in -D-pyranomanninomethyl group (fluorenyl Jl, 6-bis-oxo虼, mp: 127-12VC. ⑴ NMR (400 MIlz, DMSO-d5): 7.98 (dt J = KK Hz, 2H), 7,90 (s, 2H), 7.35-7, 48 (mf SH); 7.27 (d, J = 8.6 Hz, 2H), 5.53 (s, 2H): 3.71 (s? 2H), 3.66 (s, 4Π), 3.ΰϋ (d? J = 11.4 H7, 2IT), 3.42-3.51 ( m7 6H), 3.2B-3.35 (m, 2ΤΪ), 3.07-3.15 (m, 4H), 1.67-K73 (m, 4Π)-IR (KBr): 3430, 1716, 1672 cm1. Sub-fold: c: 46H500ls * 〇6 Calculated value of TFA: 59.1 0% C: f 5.32% H. Experiment 値: 5K · 92ΰ / 〇Cf 5.68% H.
實例S 1,3,5-三-[3,(3-截甲基苯基)-4-(2- λ -D峨喃甘露糖基氡) 苯基甲基J笨 步驟1 :將1,3>三羧基三氣化物(1.0克,3.8毫莫耳)先溶 -51 - 本紙張尺成通用t S國家梂準(} Λ4蚍格(2〗0 X 297公龙) :诗先聞·^#命之注意亨項再f本S ) 訂 457241) A 7 B7 _____ 五、發明説明(49 ) 於1,2-二氣乙沈(20毫升)。加入氣化鋁(2.6克’ 18'8毫莫耳) 之後,接著加入3(2-甲氧基笨基)苯乙酸节基酯(4·8克’ 18.8毫莫-ΐ),然後將混合物於65,0加熱隔夜經冰浴冷卻 後,緩緩加入冰水(2〇毫升)3單離有機物質之後f以—氣 甲烷(3 X 5毫并)萃取水溶液部分u將有機物質合併後’脱 水(MgS04)再減壓濃縮◊殘渣以快速層析法,己抗至 1:1已烷/乙酸乙酯之梯度溶離)純化可得該三酮lllf = 1 ) ’ (I.Od^CT/OJHNMRHOOMHz’CDCDUiidh-l」Example S 1,3,5-tris- [3, (3-Tanmethylphenyl) -4- (2-λ-D mannosylhydrazone) phenylmethyl J. Step 1: 3 > Tricarboxyl trigas (1.0 g, 3.8 mmol) first dissolved -51-This paper ruler becomes a universal t S national standard (} Λ4 蚍 grid (2〗 0 X 297 male dragon): Shi Xianwen · ^ # Mingzhi Note Heng Xiang Fen S) Order 457241) A 7 B7 _____ V. Description of the invention (49) in 1,2-Digas (20 ml). After adding aluminum vaporization (2.6 g '18'8 mmol), 3 (2-methoxybenzyl) phenylacetic acid benzyl ester (4.8 g' 18.8 mmol- 毫) was added, and the mixture was mixed. After heating at 65,0 overnight and cooling in an ice bath, slowly add ice water (20 ml) 3 to separate the organic matter, and then extract the aqueous solution with -methane (3 X 5 mmol) to combine the organic matter. Dehydration (MgS04) and concentrated under reduced pressure, the residue was purified by flash chromatography, and the gradient was 1: 1 hexane / ethyl acetate gradient purification) to obtain the triketone lllf = 1) '(I.Od ^ CT / OJHNMRHOOMHz'CDCDUiidh-l ''
Hz. 3H), 7.93 (m: 3ti), 7.80-7.83 (m, 3H)? 7.45 (m? 6II); 7.38 {l; J-7.3 Hz, 3H), 7.21-7.29 (m, 3H), 6.95 (dd7 J=8.76, 1.44 Hz; 3H), 3,88 (s,9T”,3.67 (、6H),〇, 911) ppm。1R (NaCl): 1734, 1654 cm'1 - 步驟2 :將該三酮拉(3」3克,3.4毫莫耳)先溶於二氣甲 烷(16毫升),置於冰浴中冷钿,再以三乙基矽坑(3.8毫升 ,23,7毫莫耳),三氟乙陵(2.6毫升,33.S毫莫耳),三氣化 硼二乙基醚合物(4 J毫升,33, R毫莫耳)處理。混合物於室 溫下攪拌卜h時後與水(25毫升)混合。分離有機物質後以二 氯甲烷(3 X 5毫升)萃取水溶液蔀分&將有機物質合併後, 脱水(MgS04)再減壓濃縮。將殘渣以己姹:乙酸乙酯:丨溶 趣济部中央梂準为貝工消费合作社印策 ^^1- ^^^1 ^^^1 - - ii—p L_E - - 1 (請先閘读背而之注意净頊再f表頁) 離快速通過矽膠後再濃縮吁得1,3,5-三-「3-(3-Τ氧羰基甲基 笨基)-4-(2-甲氧基)苯基甲基1苯(0_S8克,28%)。4 NMR (400 MH7, CDCl3): 7.38-7,43 (m, 6H), 7.33 (i5 J-7.68 Hz, 3H): 7.23 (s; 3H)f 7.14 (d, J=2,2 Η/, 3ΤΪ), 7.08 (dd, J-8.08, 1.84 Hzf 3Π), 6,90 (s, 3H), 6-85 (D, J-8.4 Hzf 3H)( 3.89 (s. 本紙涞尺及迖用中闼阄家核半{CNS ) A4AU^ ( 公釐1 457246 經濟郎中夹楯準局兵工消費合作社印策 A7 B7 五、發明説明(5〇) ήΤΐ), 3.76 (s, 9H), 3,68 (s, 9Η), 3.66 (s, 6Η) ppm ^ TR (NaCl): 173S cm'1 ^ 步驟3 : A部分:將1,3,5-三-13-(3-甲氧羰基甲基苯基)-4-(2-f氧基)苯基甲基]笨(〇,以克1 1 〇毫莫耳)先溶於二氣甲 故(5毫升)中再置入乾冰/丙酮浴中冷郤11緩緩加入三溴化 硼(0,7毫升,7.0毫莫耳),然後於()_:C下攪拌2小時,接著再 铒冰水(10毫升)混合"分離有機物質後以二氯甲烷(.3 X 5毫 升)苹取水溶液部分。將有機物質合併後,脱水(MgS04)再 減壓濃縮W得〇 .82克之粗產物。 Β部分:由Α郎分所得之殘清與V醇(20毫升)+¾合後再加 入硫酸(1毫汁)◊將混合物於回流溫度下加熱隔夜’然後每 減壓濃縮。將殘渣與二氯甲烷(20毫升)與飽和碳酸氩鈉溶 液(10毫升)混合。分籬有機相物質後經脱水(MgS04)再減 .壓濃縮。將殘渣以己忱:己酸乙酯/]:1溶離快速通過矽膠 後再濃缩可得U3f5-三-[3-(3-肀氧默基甲基笨基卜4-(2-藉基) 笨基 T 基]笨(0.63 克,75%)。Hi NMR (400 MHz, CDC13): 7.20-7.50 (m, 12H), 7.0 (d, J=2.2 Ilz; 2H)7 6.98 (s, 2H), 6,9i (dd, 1=8,08 , 2.2 Hz, 2H), 6.83 (s, 3H)f 6.77 (d, J=8.44, 3Π), 3.85 (s, 6H), 3<69 (s, 9H), 3,66 (s, 61T) ppm = 1R (NaCl): 3429, 1 737 cm'1 ^ 步騍4 :將三酚(0.62克,0.7毫莫耳)溶入1,2-二氯乙烷(4 毫升),再加入甘露糖五乙酸酿(1.4克’ 3.7毫莫耳)’ 接著再緩緩加入三氟化硼乙醚合物(U2井,13.3毫莫耳 混合物於室溫下攪拌隔夜後再與水(1 〇毫升)混合。分離有 (請先"讀背面之注貪孝項#填筘太.-1)Hz. 3H), 7.93 (m: 3ti), 7.80-7.83 (m, 3H)? 7.45 (m? 6II); 7.38 (l; J-7.3 Hz, 3H), 7.21-7.29 (m, 3H), 6.95 (dd7 J = 8.76, 1.44 Hz; 3H), 3,88 (s, 9T ”, 3.67 (, 6H), 〇, 911) ppm. 1R (NaCl): 1734, 1654 cm'1-Step 2: Triketone (3 ", 3 g, 3.4 mmol) is first dissolved in methane (16 ml), cold-chilled in an ice bath, and then triethylsilicon pit (3.8 ml, 23.7 mmol) ), Ethyl trifluoroacetate (2.6 ml, 33.S mmol), boron triethyl ether dihydrate (4 J ml, 33, R mmol). The mixture was stirred at room temperature and then mixed with water (25 ml). The organic material was separated and the aqueous solution was extracted with dichloromethane (3 X 5 ml). The organic materials were combined, dehydrated (MgS04) and concentrated under reduced pressure. Take the residue as ethyl acetate: 丨 The central government of the Ministry of Economics and Economics of the People's Republic of China must print the policy for the shellfish consumer cooperative ^^ 1- ^^^ 1 ^^^ 1--ii—p L_E--1 (Please turn on the gate first Read it carefully and pay attention to the following table.) After passing through the silica gel quickly and concentrating, you can get 1,3,5-tri- "3- (3-Toxycarbonylmethylbenzyl) -4- (2-form Oxy) phenylmethyl 1benzene (0_S8 g, 28%). 4 NMR (400 MH7, CDCl3): 7.38-7,43 (m, 6H), 7.33 (i5 J-7.68 Hz, 3H): 7.23 ( s; 3H) f 7.14 (d, J = 2,2 Η /, 3ΤΪ), 7.08 (dd, J-8.08, 1.84 Hzf 3Π), 6,90 (s, 3H), 6-85 (D, J- 8.4 Hzf 3H) (3.89 (s. Paper ruler and user's home nuclear half (CNS) A4AU ^ (mm 1 457 246 economy Langzhong 楯 楯 楯 楯 楯 消费 工 合作 工 合作 工 合作 合作 社 印 印 A 7 7) A7 B7 V. Description of the invention ( 5〇) ήΤΐ), 3.76 (s, 9H), 3,68 (s, 9Η), 3.66 (s, 6Η) ppm ^ TR (NaCl): 173S cm'1 ^ Step 3: Part A: Put 1,3 , 5-tri-13- (3-methoxycarbonylmethylphenyl) -4- (2-foxy) phenylmethyl] benzyl (0, in grams of 110 mmol) is first dissolved in di Put it into a dry ice / acetone bath and cool it in 11ml (5ml). Slowly add boron tribromide (0,7ml, 7.0mmol). ), And then stirred at () _: C for 2 hours, and then mixed with ice water (10 ml) " separate the organic matter and take the aqueous solution with dichloromethane (.3 X 5 ml). Combine the organic matter After that, it was dehydrated (MgS04) and concentrated under reduced pressure to obtain 0.82 g of a crude product. Part B: The residue obtained from A Lang was combined with V alcohol (20 ml) + ¾, and then sulfuric acid (1 mmol) was added. The mixture was heated overnight at reflux temperature and then concentrated under reduced pressure. The residue was mixed with dichloromethane (20 ml) and saturated sodium bicarbonate solution (10 ml). The organic phase material was separated and dehydrated (MgS04) and then reduced. .Pressure concentration. Dissolve the residue with ethyl ether: ethyl hexanoate /]: 1, dissolve it quickly, and then concentrate it through silica gel to obtain U3f5-tri- [3- (3-methyloxomethylmethylbenzyl 4- ( 2-boryl) Benzoyl Tyl] Benzoyl (0.63 g, 75%). Hi NMR (400 MHz, CDC13): 7.20-7.50 (m, 12H), 7.0 (d, J = 2.2 Ilz; 2H) 7 6.98 (s, 2H), 6,9i (dd, 1 = 8,08, 2.2 Hz, 2H), 6.83 (s, 3H) f 6.77 (d, J = 8.44, 3Π), 3.85 (s, 6H), 3 < 69 (s, 9H), 3,66 (s, 61T) ppm = 1R (NaCl): 3429, 1 737 cm'1 ^ Step 4: Triphenol (0.6 2 grams, 0.7 millimoles) dissolved in 1,2-dichloroethane (4 ml), and then added mannose pentaacetic acid (1.4 grams '3.7 millimoles)' and then slowly added boron trifluoride ether The mixture (well U2, 13.3 mmol) was stirred at room temperature overnight and then mixed with water (10 ml). Separated with (please read the note on the back of the greet filial piety ## 筘 筘 太 .-1)
本纸乐尺度通相中國S家樣率(CNS) A4规格(210X2W公庚) 457246 A? B7 M.清_中去榡率局貝工消费合作社印狀 五、發明説明(51 ) 機物質後以二氣甲烷(3 X 2毫升)萃取水溶液部分u將有機 物質合併後,脱水(MgS04)再減壓濃縮。殘渣以快速層析 法(Si02,己烷至2:1乙酸乙酯/己烷之梯度溶離)純化可得 1,3,5-三-[3-(3-甲氧羰基甲基苯基)-4-(2-(H4,6-四-g-乙醯 基)-a -D-吡喃甘露糖氧基)蓼基甲基丨策(0.9克,67%)。 NMR (400 MHl CDC13): 6-98-7.50 (m, 21 ⑴,6.86 (私,3Η), 5.26 (m; 3H): 3.90-3.93 (m, 6H), 6H); 3.71 (Sf 6H); 3.66 (s. 9H), 1,94-2, Π (m. 36H) ppm ΰ IR (NaCl): 1745 cm'1 3 步驟5 :先前步骤所得之乙醯酯(¢).88克,〇_48毫莫耳)溶 於乙腈(2毫升)後以氫氧化鉀(0.4克,毫莫耳)於水(2毫 升)之溶液處理。反應經室溫攪拌隔夜後以濃鹽酸酸化至 pH 2。將反應物減壓後將殘渣以HPT,C (C-丨8逆相,以20-K0%乙腈於水進行梯度溶離,以254 nm監測)純化可得 1,3,5-三-1>(3·羧甲基苯基)-4-(2- π -D·咄喃甘露糖氡基)笨 基甲基]苯(0J5 克,57%),tn.p,: 155-biTC。hNMRGOU MHz, DMSG-d6): 7,27-7.34 (m, 9H), 7.17-7.22 (m, 9H), 7.08^7.10 (dd, J-K.44, 1,70 Hz, 3H), 7.01 (h, 3H)f 5.24 3H); 3.85 (s, 6H)f 3.33-3.64 (m, 24H) ppm ° IR (KBr): 343 1, 1710 cnr1。分奸:<:69Η72024·1.ϋ TFA之計萆值:60-+94% C, 5.26% Η。實驗値:60.85% C, 5.23% Π。 實例9 1,3,5-三-[4-[3-(3-羧甲基笨基)-4-(沈-〇-喊喃甘露糖基氧) 苯基]_4_氧代硫代丁基]幂 步驟1 : 3-(2-(2,3,4,6-四-g-乙醯基& 毗喃甘露糖基氧) -54- (^允聞请背面之注意事項再填寫本瓦> 訂 本紙氓尺度通用中固固家棵CNS ) 2!0Χ297公鳆) 457246 A7 B7 五 '發明説明(52 ) 笨基)苯乙酸乙基酯(0.32克,(K547毫莫耳)及溴基乙醯基澳 化物(0.06毫升,0.6&9毫莫耳)溶入二氣乙烷(3毫升)内再置 入乾冰/两嗣浴中冷卻。混合物以氯化鋁(丨.45克,1 0.9毫莫 -年)處理後將乾冰浴以冰水浴取代=15分鐘之後,加入冰 水(25毫弁)混合再攪掉1 5分鐘6分離有機物質後以二氣甲 虼(3 X 2毫升)萃取水溶液部分。將有機物質合併後,脱水 (MgS〇4)再減壓;農縮可得0,387克之A物,該農物可直接使 用而不須道一步純化"4 NMR (400 MHz, CDCl# S.〇3 (d, J=2,5 Il7, 1IT)5 7.95 (dd: J-8.8, 2.5 Hz, 1H), 7.41-7.47 (m, 3H): 7.35 (m, 1H), 7.3 1 (d, J=8,8 Hz, 1H), 5.62 (d, J=1.8 H?.r ΠΪ), 5.21-5.34 (m, 3H), 4.42 (s, 2H), 4.10-4.25 (m, 5TT), 3.99 (dd, J=12.1f 2.2 Hz, 1H), 3.80-3.85 (m, 1H), 3,74 (s, 2H), 2.18 (s, 3H), 2,03 (s, 3H), 2.02 (s; 3H)f 1.98 (s7 3H)f 1.26 (t3 J=8.0 Hz, 3IT) 〇 IR (NaCl): 1746, 1220 cm.1。 步驟2 : 1Λ3,5-三-(疏醇基T基)笨(102毫克,0,47毫莫耳) 於THF (丨亳升)中β氬化鈉(59.8毫克,1_49毫莫耳)處理後 將混合物於室溫下榄拌30分鐘。骑步驟1所得之溴基_ (1.02克,1.44毫莫耳)於THF (2-0毫升)之溶液緩緩加人1 將該混合物於室溫下攪拌隔夜3反應物與水混合後再以乙 酸乙酯(3 X 5毫升)萃取。將有機物質合併後’脱水(Μθ()4) 再減壓濃縮^殘渣以快速層析法(Si〇2,3:丨己烷/乙酸乙酿 至1:1己虼/乙酸乙酯之梯度溶離)純化可得丨,3,5-三-[4'[3一 (3-乙氧羰基甲基笨基)-4-〇(2,3,4,0-四匕酿基_D_l!比 喃甘露糖氣基)苯基甲基J笨(0.59克,60%” NMR (4㈨ 55- 本紙氓尺度通用中阒闻家梯準(CNS ) .Μ規格(2U以糾公瘦) 聲- -β r 趄濟部中央標串扃貝工消f合#杜印取 457246 A7 B7_ 五、發明説明(53)The scale of this paper is generally in accordance with China ’s sample rate (CNS) A4 specification (210X2W male gage) 457246 A? B7 M. Qing _ Zhongdezhenglu Bureau Shellfish Consumer Cooperative Co., Ltd. V. Description of the invention (51) The aqueous solution was extracted with two gaseous methane (3 × 2 ml) to combine the organic substances, and then dehydrated (MgS04) and concentrated under reduced pressure. The residue was purified by flash chromatography (Si02, gradient separation of hexane to 2: 1 ethyl acetate / hexane) to obtain 1,3,5-tri- [3- (3-methoxycarbonylmethylphenyl). 4- (2- (H4,6-tetra-g-ethylfluorenyl) -a-D-pyranosyloxy) fluorenylmethyl (0.9 g, 67%). NMR (400 MHl CDC13): 6-98-7.50 (m, 21 ⑴, 6.86 (Private, 3Η), 5.26 (m; 3H): 3.90-3.93 (m, 6H), 6H); 3.71 (Sf 6H); 3.66 (s. 9H), 1,94-2, Π (m. 36H) ppm ΰ IR (NaCl): 1745 cm'1 3 Step 5: Acetyl ester (¢) obtained in the previous step. 88 g, 〇_ 48 mmol) was dissolved in acetonitrile (2 ml) and treated with a solution of potassium hydroxide (0.4 g, mmol) in water (2 ml). The reaction was stirred overnight at room temperature and acidified to pH 2 with concentrated hydrochloric acid. After depressurizing the reaction, the residue was purified by HPT, C (C- 丨 8 reverse phase, gradient gradient dissociation with 20-K0% acetonitrile in water, and monitoring at 254 nm) to obtain 1,3,5-tri-1 > (3 · carboxymethylphenyl) -4- (2-π-D · mannanylfluorenyl) benzylmethyl] benzene (0J5 g, 57%), tn.p .: 155-biTC. hNMRGOU MHz, DMSG-d6): 7,27-7.34 (m, 9H), 7.17-7.22 (m, 9H), 7.08 ^ 7.10 (dd, JK.44, 1,70 Hz, 3H), 7.01 (h, 3H) f 5.24 3H); 3.85 (s, 6H) f 3.33-3.64 (m, 24H) ppm ° IR (KBr): 343 1, 1710 cnr1. Separation: <: 69Η72024 · 1.ϋ TFA value: 60- + 94% C, 5.26% Η. Experiment 値: 60.85% C, 5.23% Π. Example 9 1,3,5-tri- [4- [3- (3-carboxymethylbenzyl) -4- (shen-o-mannosyloxy) phenyl] -4_oxothiobutane Base] Power Step 1: 3- (2- (2,3,4,6-tetra-g-ethylamyl & pyranosyloxy) -54- (^ Yunwen Please fill in the notes on the back Benwa > Bindings, Paper Scales, Universal, Gugo Family, CNS) 2! 0 × 297 Gong) 457246 A7 B7 Five 'Invention Description (52) Benzy) Ethyl Phenylacetate (0.32 g, (K547 mmol) And bromoacetamidine (0.06 ml, 0.6 & 9 mmol) were dissolved in digas ethane (3 ml) and then placed in a dry ice / two-bath bath to cool. The mixture was cooled with aluminum chloride (丨. 45 g, 1 0.9 mmol-year) After treatment, replace the dry ice bath with an ice-water bath = 15 minutes, add ice water (25 m 弁), mix and stir away for 15 minutes. 3 X 2 ml) to extract the aqueous solution. After combining the organic substances, dehydration (MgS04) and decompression; 0,387 g of substance A can be obtained by agricultural shrinkage, which can be used directly without further purification. "4 NMR (400 MHz, CDCl # S.〇3 (d, J = 2, 5 Il7, 1IT) 5 7.95 (dd: J-8.8, 2.5 Hz, 1H), 7.41-7.47 (m, 3H): 7.35 (m, 1H), 7.3 1 (d, J = 8,8 Hz, 1H), 5.62 (d, J = 1.8 H? .R ΠΪ), 5.21-5.34 (m , 3H), 4.42 (s, 2H), 4.10-4.25 (m, 5TT), 3.99 (dd, J = 12.1f 2.2 Hz, 1H), 3.80-3.85 (m, 1H), 3,74 (s, 2H ), 2.18 (s, 3H), 2,03 (s, 3H), 2.02 (s; 3H) f 1.98 (s7 3H) f 1.26 (t3 J = 8.0 Hz, 3IT) 〇IR (NaCl): 1746, 1220 cm.1. Step 2: 1Λ3,5-tris- (thiol-T-group) benzyl (102 mg, 0,47 mmol) in sodium THF (59.8 mg, 1_49 mmol) After the treatment, the mixture was stirred at room temperature for 30 minutes. The bromo group (1.02 g, 1.44 mmol) obtained in step 1 was added to a solution of THF (2-0 ml) and added slowly. The mixture was stirred overnight at room temperature. The reaction mixture was mixed with water and extracted with ethyl acetate (3 X 5 ml). The organic materials were combined and dehydrated (Mθ () 4) and concentrated under reduced pressure. The residue was subjected to flash chromatography. Purification by method (Sio2, 3: hexane / ethyl acetate to 1: 1 hexane / ethyl acetate gradient separation) purification can be obtained 丨, 3,5-tri- [4 '[3' (3-ethyl Oxycarbonylmethylbenzyl) -4-〇 (2,3,4,0-tetramethylamino_D_l! Phenylmethyl J-benzyl (0.59 g, 60% "NMR (4㈨ 55- this paper is a universal standard for CNS) .M specifications (2U to correct the weight) Acoustic--β r Ministry of Economy Standard string 扃 贝 工 消 f 合 # 杜 印 取 457457 A7 B7_ V. Description of the invention (53)
Mllz, CDClj): 7,98 (d, J=2,5 Η/, 3H), 7.89 (dd, J=8,8, 2.5 Hz, 3H). 7.40-7.46 (m, 611), 7.25-7.35 (m, 12H), 5.61 (s, 3ΪΙ), 5.22-5.33 (m, 9H), 4.10-4,25 (m, l〇H), 3-97 (dd, J=12.1, 2,2 Hz, 3H). 3-78-3.R4 (m. 3ΙΓ), 3.72 (s, 6II)? 3.69 (s; 3H)f 3.64 (s, 311), 2.16 (s, 9H), 2,02 (s, 9H)f 2.01 (s; 9H); 1.97 (s, 9H); 1.25 (i, .1-8.0 Hz, 9H); IR (NaCl); 1747, 1219 cnr1 ^ 步驟3 :由歩驟2所得之乙m酯三酯(0.59克,0.28毫莫耳) 於THF(3毫升}中以一種新鮮製備之甲氧化鈉ΐ容液(93毫克 ,4 0 4毫莫耳於3毫升之甲醇)處理再將混合物於室溫下機 掉濁夜。將结果形成之沉澉物以眞空過濾收集再以2:丨 THF..__甲醇洗數次,然後於眞空下乾燥可得白色固體克 *將固體溶於水(12毫升),加入2 N氣氣化鈉使成pH 14, 再於室溫下攪拌4小時。反應物以酸性Dowex 50W離子交 換樹脂酸化,過濾,再減壓除去揮發性物質e將一部价水 溶性殘渣以逆钿層析法純化可得白色固體之1,3,5-三-[4-[3-(3-羧甲基苯基)-4-( & -D-吡喃甘露糖基氧)苯基]-‘氧代-2-硫代 丁基]苯,m.p : 140-143rC = 1M NMR (400 Μ[ί/.: DMSO-d6): 7.95 (dd: J = S.8, 2.5 Hz, 3TT): 7.89 (d: J-2.2 Hz, 罐濟部中失標隼扃貝工f合作社印製 ^^1· ^—Ε. - - -I P^E ^^^1 ^^^1 ^^^1 ^^^1 ^^^1 ^^^1」ffJ (请先閩讀背16之ϊί,,δ事項再靖鸿本π) 3H), 7.32-7.45 (ra? 12H), 7.26 (d; J=7.3 Hz, 3H), 7.16-7.20 (m, 3H). 5.54 (s, 3H), 5,05 (br s, 3H), 4.85 (br s, 3Ή), 4.70 (br s, 3ΤΓ), 4.50 (br s, 3H), 3.8K-3.92 (m, 6H), 3-58-3.73 (m. 18H)f 3.40-3,49 (m, 6H), 3-30-3.40 (m, 加 H20) <= IR (KBr): 3429, Π08,1669 cm·1。分析:C75H78027S3_1.8 TTA 之計算値:55.12% C,4.79% H。實驗値:55.14% C,5「20% H。 表紙張尺度違用中固®家梂华{ CNS ) Λ4*ί格(耵公緹) 經濟部t夾楳举扃貝工消资合作杜印货 457246 A7 B7 五、發明説明(54 ) 實例1 0 結合檢測分析 各個化合物經檢測分柄其對抑制Π-,"P·,及/或I,·選擇素 與唾液基-路易士 χ结合之能力π Ε-選擇素結合檢測分析包 含了評估以會表現唾液基-路易士 ^及唾液基-路易士 3之 HL60細胞純化Γ,_選擇素,Ρ-選擇素及L-選擇素重组蛋白質 之能力(細胞蛋白質撿測分析)3另一個類似之結合檢測 分析利用純化之_脂肪及純化之L-選擇素童组蛋白質(_ 腊肪-蛋白皙)則用來評估L-選擇素之結合。 細胞-要白質檢測分析 Η-選擇素,Ρ-選擇素,及選擇素係昱重組之可溶型式 表現成融合蛋白質,核蛋白質具有融合至小白鼠IgG2A cDNA之樞紐與恆定重鏠區域I及2 cDNA之胺基束瑞外源凝 集素,ECiF,及類似補體調節性重複段(CR)丨及2。所有選 擇素之融合匣(fusion cassettes)係以PCR由勝自R&D系統 (Minneapolis,MN)之E-選擇素eDNA,及利用PCR自人體胎 盤萃取所得之全部RNA所選殖之P_選擇素與L-選擇素之 cDNAs產生。小白鼠igG2A cUNA則選殖自以PCR放大之 cU>NA,而該cDN A則係產自融合瘤細胞系402C 1 ϋ Ψ萃驭所 得之RN A =所有融合匣均由捍病毒載體利用購自Clonetech 之SF21細胞與BakPAK表現。 重组之融合蛋白質則由經桿病毒感染之培養澄明液中利 用Dy⑽丨以經綿羊坑小白鼠IgG塗覆之磁性粒予藉免疫沉澱 纯化a對照組粒予(Moc.k beads)則由未經感染之SF2 1培養 本紙張疋度逍用中阄闳家擇率(CNS ) A4现格UI0XM7分釐) (请九閲讀背面之注意亨項再峨耗本頁) 訂 • I-C - - - · Λ7 _____ B7 五、發明説明(55) ----^--!i 装! (婧也閲請背面之注意事項4¾¾本頁) 澄明液產生。經過免疫沉澱後,與對照組埼養澄明液培育 之粒子無法和會表現唾液基-路易士 κ之HT,60細胞結合作爲 陰性對照組。經過與產生Η-,L-或Ρ-選擇素之培養澄明液 培育之粒子則會與HL60細胞結合c HL60細胞(10?細胞)在含有10%胎牛血清之RPMI 1640中 以巧營素(Calcein) AMC-3099(分予探針 Molecular Probes) 作螢光標記。將磁性粒子(7 ju 1,4 x 1 06粒子毫升)與7 1各 種濃度之化合物及7 μΐ經鈣螢素標記之HL60細胞複製培育 於兩偶廣用之96小槽微量標定皿内。將培f皿於宣溫下培 f 1 0分鐘「然後將培育皿置於磁性分離器上再培育2分鐘 。當檢測分析m依舊置於分離器時將iIL6細胞自小槽中移 除並再用磷酸鹽緩缓鹽水清洗兩次以除去束結合之HL60細 胞3以顯微鏡檢視仍然結合在粒予上之HL60細胞,然後再 加入50毫升】% NP40於PBS之溶液使細胞分解。利用螢光 定量技術使用Millipore Cytofluor 2350螢光儀定量結合量 "由此定出劑量反應曲線並測定抑制50%細胞結合之化合 物濃度(〗C5(})。 下表中所提起之化合物係彼在此所指較佳之化合物c 該等檢測分析之結果列示於下表: 杖濟郎中央樣半灼另工消背合作杜印« -58- 本紙涞尺及边用中囯囷家標來' < CNS ) A4规格(以加公* ) Λ57246 Λ7 Π7 五、發明説明(55 ) 體外選擇素檢測分析數據表 化合物 n = 或 m/p subst 卜選擇素〗c5t) (mM ) 或% inhib」/ (mM ) i]-選擇素〗c5a (mM ) 或% inliib·/ (mM ) L-選# WC_S() (mM ) 或% inhib" (mM ) A-4 4 5,0 2.5 2,0 A-5 5 0.4 0.3 0.3 A-6 6 0-5 0.07 0.56 A-7 7 0.5 0.4 0.75 Λ-9 9 1.0 1,0 1.0 B-m m 0/1 0.22 3.0 B-p P 2,0 2.0 3.0 c 2.5 0.7 0/2 D 29/2 0.5 5.0 Η 6 3.27 0.54 1.4 l·. 4 KO 1.0 3-0 G L5 i.O 0/3 H 0.7 0.2 0.5 J 4.0 0/3 2.0 凊先閑續背而之;IJ.Ail·项办咕衿本貝> 袈 59- 卷紙乐尺度4;?]中Ιϋϋΐ家梂涟.;CNS )八4坑樁(noxw?公梦)Mllz, CDClj): 7,98 (d, J = 2,5 Η /, 3H), 7.89 (dd, J = 8,8, 2.5 Hz, 3H). 7.40-7.46 (m, 611), 7.25-7.35 (m, 12H), 5.61 (s, 3ΪΙ), 5.22-5.33 (m, 9H), 4.10-4, 25 (m, l〇H), 3-97 (dd, J = 12.1, 2, 2 Hz, 3H). 3-78-3.R4 (m. 3ΙΓ), 3.72 (s, 6II)? 3.69 (s; 3H) f 3.64 (s, 311), 2.16 (s, 9H), 2,02 (s, 9H) f 2.01 (s; 9H); 1.97 (s, 9H); 1.25 (i, .1-8.0 Hz, 9H); IR (NaCl); 1747, 1219 cnr1 ^ Step 3: The acetylene obtained from step 2 m-ester triester (0.59 g, 0.28 mmol) in THF (3 ml) with a freshly prepared sodium methoxide solution (93 mg, 400 mmol in 3 ml methanol) and then The mixture was turbid at room temperature overnight. The resulting precipitate was collected by vacuum filtration and washed with 2: 丨 THF ..__ methanol several times, and then dried under vacuum to obtain a white solid. In water (12 ml), add 2 N sodium gasified to pH 14 and stir at room temperature for 4 hours. The reaction was acidified with acid Dowex 50W ion exchange resin, filtered, and the volatile substances were removed under reduced pressure. E A fraction of the water-soluble residue was purified by reversed-phase chromatography to obtain white 1,3,5-tri- [4- [3- (3-carboxymethylphenyl) -4- (& -D-pyranosyloxy) phenyl]-'oxo- 2-thiobutyl] benzene, mp: 140-143rC = 1M NMR (400 Μ [ί / .: DMSO-d6): 7.95 (dd: J = S.8, 2.5 Hz, 3TT): 7.89 (d: J-2.2 Hz, printed out of standard in the Ministry of Tanks. Printed by Fang Cooperative ^^ 1 · ^ —Ε.---IP ^ E ^^^ 1 ^^^ 1 ^^^ 1 ^^^ 1 ^ ^^ 1 ^^^ 1 '' ffJ (Please read the 16th of Min, δ, and then Jinghong π) 3H), 7.32-7.45 (ra? 12H), 7.26 (d; J = 7.3 Hz, 3H ), 7.16-7.20 (m, 3H). 5.54 (s, 3H), 5,05 (br s, 3H), 4.85 (br s, 3Ή), 4.70 (br s, 3ΤΓ), 4.50 (br s, 3H ), 3.8K-3.92 (m, 6H), 3-58-3.73 (m. 18H) f 3.40-3,49 (m, 6H), 3-30-3.40 (m, plus H20) < = IR ( KBr): 3429, Π08, 1669 cm · 1. Analysis: Calculation of C75H78027S3_1.8 TTA 値: 55.12% C, 4.79% H. Experiment 値: 55.14% C, 5 ¡20% H. The scale of the paper is in violation of Zhonggu ® Jiahuahua (CNS) Λ4 * ί (缇 公 蒂) Ministry of Economic Affairs, Ministry of Economic Affairs, cooperation, and investment Cargo 457246 A7 B7 V. Description of the invention (54) Example 1 0 Combined detection and analysis of each compound detected by detection of its inhibition Π-, " P ·, and / or I, selectin combined with salivary-Louis χ Capability π E-selectin binding assay analysis includes evaluation of purified HL60 cells expressing salivary-louis ^ and salivary-louis 3 Γ, _selectin, p-selectin and L-selectin recombinant proteins Capability (Cell Protein Pickup Assay) 3 Another similar binding assay uses purified _ fat and purified L-selectin toxin (_ wax-protein) to evaluate L-selectin binding Cell-to-white matter detection and analysis Η-selectin, P-selectin, and selectin are reconstituted soluble forms of fusion proteins, nuclear proteins have a hub and constant weight region I fused to mouse IgG2A cDNA and 2 Amino ray lectin, ECiF, and similar supplements of cDNA Body regulatory repeats (CR) 丨 and 2. All selectin fusion cassettes are PCR-derived from E-selectin eDNA from the R & D system (Minneapolis, MN), and from human placenta using PCR P_selectin and L-selectin cDNAs were generated from all the RNA extracted. The mouse igG2A cUNA was cloned from cU> NA amplified by PCR, and the cDN A was produced from the fusion tumor cell line. 402C 1 Ψ RN A = all fusion cassettes are expressed by the defending virus vector using SF21 cells and BakPAK purchased from Clonetech. Recombinant fusion proteins are treated with baculovirus-infected culture clear solution using Dy⑽ 丨IgG-coated magnetic particles of sheep pit mice were purified by immunoprecipitation a. Control group particles (Moc.k beads) were cultured from uninfected SF2 1 and the paper was used at a moderate rate (CNS). A4 is now UI0XM7 centimeters) (Please read the note on the back to see the item on the back, and then consume this page) Order • IC---· Λ7 _____ B7 5. Invention Description (55) ---- ^-! I Install! (Jing also read the note on the back of this page 4¾¾ page) Clear solution is produced. After immunoprecipitation, The granules cultivated in the culture clear solution could not be combined with HT, 60 cells that showed salivary-Lewis κ as a negative control group. The particles cultivated with the culture clear solution that produced Η-, L- or P-selectin were Will bind to HL60 cells. HL60 cells (10? Cells) will be fluorescently labeled with Calcein AMC-3099 (Molecular Probes) in RPMI 1640 containing 10% fetal bovine serum. Magnetic particles (7 ju 1, 4 x 1 06 particle ml), 7 1 compounds of various concentrations, and 7 μΐ calcein-labeled HL60 cells were replicated and cultivated in 96-slot micro-calibration plates widely used by the two couples. Incubate the dish at 10 ° C for 10 minutes. Then place the incubator on the magnetic separator and incubate for another 2 minutes. When the assay is still in the separator, remove the iIL6 cells from the small tank and re- Wash twice with phosphate slowly saline to remove bundle-bound HL60 cells. 3 Examine the HL60 cells still bound to the granules with a microscope, and then add 50 ml]% NP40 in PBS solution to decompose the cells. Quantitate with fluorescence The technology uses a Millipore Cytofluor 2350 fluorometer to quantify the binding amount " from which a dose-response curve is determined and the concentration of the compound that inhibits 50% of cell binding is determined (C5 (}). The compounds mentioned in the table below are referred to here. The better compound c The results of these tests are shown in the following table: Zhang Jilang's central sample, half-burned, burn-in, and back-up cooperation. Du Yin «-58- The paper ruler and the side are printed with Chinese house mark '< CNS) A4 specifications (in Canadian *) Λ57246 Λ7 Π7 V. Description of the invention (55) In vitro selectin detection and analysis data table Compound n = or m / p subst [selectin] c5t) (mM) or% inhib "/ (mM) i] -selectin〗 c5a (mM) or% inliib · / ( mM) L-Select # WC_S () (mM) or% inhib " (mM) A-4 4 5,0 2.5 2,0 A-5 5 0.4 0.3 0.3 A-6 6 0-5 0.07 0.56 A-7 7 0.5 0.4 0.75 Λ-9 9 1.0 1,0 1.0 Bm m 0/1 0.22 3.0 Bp P 2,0 2.0 3.0 c 2.5 0.7 0/2 D 29/2 0.5 5.0 Η 6 3.27 0.54 1.4 l ·. 4 KO 1.0 3 -0 G L5 iO 0/3 H 0.7 0.2 0.5 J 4.0 0/3 2.0 凊 First, go back and forth; IJ.Ail · Item Office Guru Benbei > 袈 59- Roll paper music scale 4;?] Medium Ιϋϋΐ 家 梂 莲.; CNS) Eight 4 pit piles (noxw? Public dream)
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW85115658A TW457246B (en) | 1996-12-19 | 1996-12-19 | Dimeric small molecule selectin inhibitors comprising of (mannopyranosyloxy)biphenyl-substituted carboxylic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW85115658A TW457246B (en) | 1996-12-19 | 1996-12-19 | Dimeric small molecule selectin inhibitors comprising of (mannopyranosyloxy)biphenyl-substituted carboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW457246B true TW457246B (en) | 2001-10-01 |
Family
ID=21625617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW85115658A TW457246B (en) | 1996-12-19 | 1996-12-19 | Dimeric small molecule selectin inhibitors comprising of (mannopyranosyloxy)biphenyl-substituted carboxylic acid |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW457246B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI626247B (en) * | 2012-12-18 | 2018-06-11 | 維泰克斯製藥公司 | Mannose derivative for the treatment of bacterial infections |
-
1996
- 1996-12-19 TW TW85115658A patent/TW457246B/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI626247B (en) * | 2012-12-18 | 2018-06-11 | 維泰克斯製藥公司 | Mannose derivative for the treatment of bacterial infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2165931C2 (en) | Small di- and trivalent molecules of selectin inhibitors, pharmaceutical composition, method of selecting inhibition | |
| US5919768A (en) | Di- and trivalent small molecule selectin inhibitors | |
| TW453995B (en) | Certain alpha-substituted arylsulfonamido acetohydroxamic acids | |
| JPH09512560A (en) | Binding of E-selectin, P-selectin or L-selectin to sialyl-Lewis top x or sialyl-Lewis top a. | |
| PT95855B (en) | PROCESS FOR THE ENZYMATIC RESOLUTION OF ENDO-BICYCLE {2.2.1} HEPTAN-2-OL AND DERIVATIVE PHARMACEUTICAL AGENTS | |
| HU197735B (en) | Process for producing ascorbinic acid derivatives and pharmaceutical compositions containing them | |
| WO2011091710A1 (en) | Phenyl c-glucoside derivatives, preparation methods and uses thereof | |
| KR0135723B1 (en) | Pharmaceutical composition containing aesculetin derivatives | |
| TW457246B (en) | Dimeric small molecule selectin inhibitors comprising of (mannopyranosyloxy)biphenyl-substituted carboxylic acid | |
| JPS6360748B2 (en) | ||
| JPS61152696A (en) | Bile acid derivative, its production and pharmaceutical composition containing the same | |
| EP0109225B1 (en) | Arachidonic acid analogues, processes for their preparation and their use in medicine | |
| CN103270033B (en) | C-aryl glucoside derivatives and their preparation methods and applications | |
| CN102040517A (en) | Resveratrol derivative and application thereof to medicament | |
| JPH02223A (en) | Furyl, phenylene, and thienyl leukotriene b4 analogue | |
| JPS5993041A (en) | Organic compounds and their pharmaceutical uses | |
| JP5898768B2 (en) | Indene derivatives for use in the treatment of inflammatory bowel disease | |
| JPH0859646A (en) | Enopyranose derivative or its salt and inhibitor of alpha-glucosidase containing the same | |
| CN115057856B (en) | 3,5-disubstituted-7 azaindole derivatives and their synthesis methods and applications | |
| TWI852728B (en) | Application of 10'(z), 13'(e), 15'(e)- heptadeca trienyl hydroquinone(hq17(3)) in treating coronavirus infection | |
| JPH05221901A (en) | Secosterol derivative | |
| CA1192543A (en) | Nicotinic derivatives of glucosamine, process for their preparation and related pharmaceutical compositions | |
| JPH08151341A (en) | Inhibitor of superoxide production and 1-naphthol derivative | |
| JPH07504176A (en) | New and known disulfides and their uses | |
| TW212180B (en) | Imidazo pyridine derivatives and the medicines containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |